WO2021191888A1 - Cannabis sativa (hemp and cannabis) products for viral disease prevention and management - Google Patents
Cannabis sativa (hemp and cannabis) products for viral disease prevention and management Download PDFInfo
- Publication number
- WO2021191888A1 WO2021191888A1 PCT/IL2021/050265 IL2021050265W WO2021191888A1 WO 2021191888 A1 WO2021191888 A1 WO 2021191888A1 IL 2021050265 W IL2021050265 W IL 2021050265W WO 2021191888 A1 WO2021191888 A1 WO 2021191888A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extracts
- cbd
- cells
- extract
- ace2
- Prior art date
Links
- 240000004308 marijuana Species 0.000 title claims abstract description 109
- 244000025254 Cannabis sativa Species 0.000 title claims abstract description 52
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 title claims abstract description 30
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 title claims abstract description 30
- 235000009120 camo Nutrition 0.000 title claims abstract description 20
- 235000005607 chanvre indien Nutrition 0.000 title claims abstract description 20
- 239000011487 hemp Substances 0.000 title claims abstract description 20
- 235000008697 Cannabis sativa Nutrition 0.000 title claims abstract description 17
- 230000003612 virological effect Effects 0.000 title claims description 52
- 230000006806 disease prevention Effects 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 353
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims abstract description 145
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 131
- 201000010099 disease Diseases 0.000 claims abstract description 95
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims abstract description 52
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 35
- 206010052015 cytokine release syndrome Diseases 0.000 claims abstract description 24
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 17
- 241000700605 Viruses Species 0.000 claims abstract description 17
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 203
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 170
- 229950011318 cannabidiol Drugs 0.000 claims description 170
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 170
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 166
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 claims description 55
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 claims description 48
- 150000003505 terpenes Chemical class 0.000 claims description 42
- 235000007586 terpenes Nutrition 0.000 claims description 42
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 229960003453 cannabinol Drugs 0.000 claims description 33
- QEBNYNLSCGVZOH-NFAWXSAZSA-N (+)-valencene Chemical compound C1C[C@@H](C(C)=C)C[C@@]2(C)[C@H](C)CCC=C21 QEBNYNLSCGVZOH-NFAWXSAZSA-N 0.000 claims description 29
- 239000001890 (2R)-8,8,8a-trimethyl-2-prop-1-en-2-yl-1,2,3,4,6,7-hexahydronaphthalene Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 29
- WCTNXGFHEZQHDR-UHFFFAOYSA-N valencene Natural products C1CC(C)(C)C2(C)CC(C(=C)C)CCC2=C1 WCTNXGFHEZQHDR-UHFFFAOYSA-N 0.000 claims description 29
- 229940036350 bisabolol Drugs 0.000 claims description 28
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 claims description 20
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 claims description 20
- 206010050685 Cytokine storm Diseases 0.000 claims description 19
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 claims description 19
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 18
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 18
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 18
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 18
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 14
- 241000196324 Embryophyta Species 0.000 claims description 13
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 208000025157 Oral disease Diseases 0.000 claims description 10
- 208000030194 mouth disease Diseases 0.000 claims description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 9
- 235000008397 ginger Nutrition 0.000 claims description 9
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 8
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 8
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 7
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 7
- 240000006927 Foeniculum vulgare Species 0.000 claims description 7
- 235000003373 curcuma longa Nutrition 0.000 claims description 7
- 239000006041 probiotic Substances 0.000 claims description 7
- 235000018291 probiotics Nutrition 0.000 claims description 7
- 235000002020 sage Nutrition 0.000 claims description 7
- 235000013976 turmeric Nutrition 0.000 claims description 7
- 241000711573 Coronaviridae Species 0.000 claims description 6
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 claims description 5
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 claims description 5
- 238000010397 one-hybrid screening Methods 0.000 claims description 4
- 238000002648 combination therapy Methods 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 244000273928 Zingiber officinale Species 0.000 claims description 2
- 208000037765 diseases and disorders Diseases 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 244000163122 Curcuma domestica Species 0.000 claims 1
- 244000042664 Matricaria chamomilla Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 136
- 230000000968 intestinal effect Effects 0.000 abstract description 29
- 210000004072 lung Anatomy 0.000 abstract description 27
- 241001678559 COVID-19 virus Species 0.000 abstract description 18
- 210000000981 epithelium Anatomy 0.000 abstract description 15
- 230000027281 viral reproductive process Effects 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 177
- 210000004027 cell Anatomy 0.000 description 174
- 230000014509 gene expression Effects 0.000 description 157
- 210000001519 tissue Anatomy 0.000 description 130
- 230000004044 response Effects 0.000 description 126
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 124
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 124
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 106
- 239000000203 mixture Substances 0.000 description 95
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 92
- 108700012920 TNF Proteins 0.000 description 78
- 238000001262 western blot Methods 0.000 description 63
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 56
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 56
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 53
- 230000000694 effects Effects 0.000 description 53
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 44
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 44
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 42
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 39
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 108090001005 Interleukin-6 Proteins 0.000 description 38
- -1 IL- 4 Proteins 0.000 description 36
- 108090001007 Interleukin-8 Proteins 0.000 description 34
- 102000004890 Interleukin-8 Human genes 0.000 description 33
- 206010061218 Inflammation Diseases 0.000 description 32
- 230000004054 inflammatory process Effects 0.000 description 32
- 102000004889 Interleukin-6 Human genes 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 30
- 239000003557 cannabinoid Substances 0.000 description 25
- 229930003827 cannabinoid Natural products 0.000 description 25
- 229940065144 cannabinoids Drugs 0.000 description 25
- 238000009472 formulation Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 239000007910 chewable tablet Substances 0.000 description 23
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 22
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 22
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 22
- 229940068682 chewable tablet Drugs 0.000 description 22
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 22
- 229960004242 dronabinol Drugs 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 230000003110 anti-inflammatory effect Effects 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 238000011529 RT qPCR Methods 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 108091058560 IL8 Proteins 0.000 description 17
- 101150054399 ace2 gene Proteins 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 16
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 16
- 229940117948 caryophyllene Drugs 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 230000000770 proinflammatory effect Effects 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000003247 decreasing effect Effects 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 239000002775 capsule Substances 0.000 description 12
- 231100000673 dose–response relationship Toxicity 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- 239000005792 Geraniol Substances 0.000 description 11
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 11
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 11
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 11
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 11
- 101150043341 Socs3 gene Proteins 0.000 description 11
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 11
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 11
- 229940113087 geraniol Drugs 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 239000006186 oral dosage form Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 238000013334 tissue model Methods 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 230000003828 downregulation Effects 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000002222 downregulating effect Effects 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 230000002757 inflammatory effect Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 230000036962 time dependent Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000007469 Actins Human genes 0.000 description 8
- 108010085238 Actins Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 229920000159 gelatin Polymers 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 240000003538 Chamaemelum nobile Species 0.000 description 7
- 239000001828 Gelatine Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 102000026633 IL6 Human genes 0.000 description 7
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 7
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 7
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 7
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 7
- 241000234314 Zingiber Species 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 239000000287 crude extract Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 244000008991 Curcuma longa Species 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 235000015218 chewing gum Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229940096437 Protein S Drugs 0.000 description 5
- 101710198474 Spike protein Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940112822 chewing gum Drugs 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 210000003953 foreskin Anatomy 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 4
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 4
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 4
- 102100031788 E3 ubiquitin-protein ligase MYLIP Human genes 0.000 description 4
- 101710190174 E3 ubiquitin-protein ligase MYLIP Proteins 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 3
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000003766 bioinformatics method Methods 0.000 description 3
- 230000008236 biological pathway Effects 0.000 description 3
- 239000004067 bulking agent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000000420 mucociliary effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 230000017613 viral reproduction Effects 0.000 description 3
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 2
- XMXLVNVGGJBUPF-UHFFFAOYSA-N 2-amino-n,n-diethyl-1,3-benzothiazole-6-carboxamide Chemical compound CCN(CC)C(=O)C1=CC=C2N=C(N)SC2=C1 XMXLVNVGGJBUPF-UHFFFAOYSA-N 0.000 description 2
- 102100021834 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 2
- KFVINGKPXQSPNP-UHFFFAOYSA-N 4-amino-2-[2-(diethylamino)ethyl]-n-propanoylbenzamide Chemical compound CCN(CC)CCC1=CC(N)=CC=C1C(=O)NC(=O)CC KFVINGKPXQSPNP-UHFFFAOYSA-N 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- 102000000872 ATM Human genes 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- 102100036664 Adenosine deaminase Human genes 0.000 description 2
- 102100033346 Adenosine receptor A1 Human genes 0.000 description 2
- 102100035990 Adenosine receptor A2a Human genes 0.000 description 2
- 102100035984 Adenosine receptor A2b Human genes 0.000 description 2
- 102100020925 Adenosylhomocysteinase Human genes 0.000 description 2
- 102100031793 Adipolin Human genes 0.000 description 2
- 102100022977 Antithrombin-III Human genes 0.000 description 2
- 102100030942 Apolipoprotein A-II Human genes 0.000 description 2
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 2
- 102100020999 Argininosuccinate synthase Human genes 0.000 description 2
- 102100029361 Aromatase Human genes 0.000 description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 2
- 102000017916 BDKRB1 Human genes 0.000 description 2
- 108060003359 BDKRB1 Proteins 0.000 description 2
- 102100026349 Beta-1,4-galactosyltransferase 1 Human genes 0.000 description 2
- 102100021277 Beta-secretase 2 Human genes 0.000 description 2
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 2
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 2
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 2
- 101710098191 C-4 methylsterol oxidase ERG25 Proteins 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 2
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 2
- 102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 description 2
- 108010052500 Calgranulin A Proteins 0.000 description 2
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 2
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 2
- 102100035959 Cationic amino acid transporter 2 Human genes 0.000 description 2
- 102100035371 Chymotrypsin-like elastase family member 1 Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 description 2
- 101150081028 Cysltr1 gene Proteins 0.000 description 2
- 102100038496 Cysteinyl leukotriene receptor 1 Human genes 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100022302 DNA polymerase beta Human genes 0.000 description 2
- 102100024360 Dual oxidase maturation factor 1 Human genes 0.000 description 2
- 102100024391 Dual oxidase maturation factor 2 Human genes 0.000 description 2
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 2
- 102100037569 Dual specificity protein phosphatase 10 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000017930 EDNRB Human genes 0.000 description 2
- 101150076616 EPHA2 gene Proteins 0.000 description 2
- 239000001692 EU approved anti-caking agent Substances 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 2
- 102100038595 Estrogen receptor Human genes 0.000 description 2
- 102100034169 Eukaryotic translation initiation factor 2-alpha kinase 1 Human genes 0.000 description 2
- 102100031758 Extracellular matrix protein 1 Human genes 0.000 description 2
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 description 2
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 description 2
- 108010026653 Fanconi Anemia Complementation Group D2 protein Proteins 0.000 description 2
- 102000013601 Fanconi Anemia Complementation Group D2 protein Human genes 0.000 description 2
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 2
- 102100020856 Forkhead box protein F1 Human genes 0.000 description 2
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 2
- 102100030479 Germinal center-associated signaling and motility protein Human genes 0.000 description 2
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 description 2
- 102000048988 Hemochromatosis Human genes 0.000 description 2
- 108700022944 Hemochromatosis Proteins 0.000 description 2
- 102100036284 Hepcidin Human genes 0.000 description 2
- 101150065637 Hfe gene Proteins 0.000 description 2
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 description 2
- 102100030688 Histone H2B type 1-A Human genes 0.000 description 2
- 102100026265 Histone-lysine N-methyltransferase ASH1L Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 2
- 101000964363 Homo sapiens Active breakpoint cluster region-related protein Proteins 0.000 description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 2
- 101000799712 Homo sapiens Adenosine receptor A1 Proteins 0.000 description 2
- 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 description 2
- 101000783756 Homo sapiens Adenosine receptor A2b Proteins 0.000 description 2
- 101000716952 Homo sapiens Adenosylhomocysteinase Proteins 0.000 description 2
- 101000775461 Homo sapiens Adipolin Proteins 0.000 description 2
- 101000757319 Homo sapiens Antithrombin-III Proteins 0.000 description 2
- 101000793406 Homo sapiens Apolipoprotein A-II Proteins 0.000 description 2
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 2
- 101000784014 Homo sapiens Argininosuccinate synthase Proteins 0.000 description 2
- 101000919395 Homo sapiens Aromatase Proteins 0.000 description 2
- 101000766145 Homo sapiens Beta-1,4-galactosyltransferase 1 Proteins 0.000 description 2
- 101000894883 Homo sapiens Beta-secretase 2 Proteins 0.000 description 2
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 description 2
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 2
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 2
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 2
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 2
- 101000932890 Homo sapiens Calcitonin gene-related peptide 1 Proteins 0.000 description 2
- 101000760563 Homo sapiens Calcitonin gene-related peptide type 1 receptor Proteins 0.000 description 2
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 2
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 2
- 101000737684 Homo sapiens Chymotrypsin-like elastase family member 1 Proteins 0.000 description 2
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 description 2
- 101000902539 Homo sapiens DNA polymerase beta Proteins 0.000 description 2
- 101001052938 Homo sapiens Dual oxidase maturation factor 1 Proteins 0.000 description 2
- 101001053276 Homo sapiens Dual oxidase maturation factor 2 Proteins 0.000 description 2
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 2
- 101000881127 Homo sapiens Dual specificity protein phosphatase 10 Proteins 0.000 description 2
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 description 2
- 101000967299 Homo sapiens Endothelin receptor type B Proteins 0.000 description 2
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 2
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 2
- 101000926530 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 description 2
- 101000866526 Homo sapiens Extracellular matrix protein 1 Proteins 0.000 description 2
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 2
- 101000931494 Homo sapiens Forkhead box protein F1 Proteins 0.000 description 2
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 2
- 101000860415 Homo sapiens Galanin peptides Proteins 0.000 description 2
- 101001014936 Homo sapiens Glutathione peroxidase 1 Proteins 0.000 description 2
- 101001021253 Homo sapiens Hepcidin Proteins 0.000 description 2
- 101000824104 Homo sapiens High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 description 2
- 101001084688 Homo sapiens Histone H2B type 1-A Proteins 0.000 description 2
- 101000785963 Homo sapiens Histone-lysine N-methyltransferase ASH1L Proteins 0.000 description 2
- 101000840572 Homo sapiens Insulin-like growth factor-binding protein 4 Proteins 0.000 description 2
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 2
- 101001015064 Homo sapiens Integrin beta-6 Proteins 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 description 2
- 101000852965 Homo sapiens Interleukin-1 receptor-like 2 Proteins 0.000 description 2
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 description 2
- 101001019598 Homo sapiens Interleukin-17 receptor A Proteins 0.000 description 2
- 101001019600 Homo sapiens Interleukin-17 receptor B Proteins 0.000 description 2
- 101001019602 Homo sapiens Interleukin-17 receptor C Proteins 0.000 description 2
- 101000998181 Homo sapiens Interleukin-17B Proteins 0.000 description 2
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001044895 Homo sapiens Interleukin-20 receptor subunit beta Proteins 0.000 description 2
- 101001044887 Homo sapiens Interleukin-22 receptor subunit alpha-2 Proteins 0.000 description 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 description 2
- 101001043817 Homo sapiens Interleukin-31 receptor subunit alpha Proteins 0.000 description 2
- 101000960936 Homo sapiens Interleukin-5 receptor subunit alpha Proteins 0.000 description 2
- 101001050321 Homo sapiens Junctional adhesion molecule C Proteins 0.000 description 2
- 101001046960 Homo sapiens Keratin, type II cytoskeletal 1 Proteins 0.000 description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 2
- 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 description 2
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 2
- 101001025971 Homo sapiens Lysine-specific demethylase 6B Proteins 0.000 description 2
- 101001004953 Homo sapiens Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 description 2
- 101000578928 Homo sapiens Macrophage immunometabolism regulator Proteins 0.000 description 2
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 101000581289 Homo sapiens Microcephalin Proteins 0.000 description 2
- 101001122476 Homo sapiens Mu-type opioid receptor Proteins 0.000 description 2
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 description 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 description 2
- 101001126836 Homo sapiens N-acetylmuramoyl-L-alanine amidase Proteins 0.000 description 2
- 101001109455 Homo sapiens NACHT, LRR and PYD domains-containing protein 6 Proteins 0.000 description 2
- 101001076431 Homo sapiens NF-kappa-B inhibitor zeta Proteins 0.000 description 2
- 101001109452 Homo sapiens NLR family member X1 Proteins 0.000 description 2
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 2
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 description 2
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
- 101000969031 Homo sapiens Nuclear protein 1 Proteins 0.000 description 2
- 101000683898 Homo sapiens Nucleoporin SEH1 Proteins 0.000 description 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- 101000614405 Homo sapiens P2X purinoceptor 1 Proteins 0.000 description 2
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 2
- 101000731015 Homo sapiens Peptidoglycan recognition protein 1 Proteins 0.000 description 2
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 2
- 101000702718 Homo sapiens Phosphatidylcholine:ceramide cholinephosphotransferase 1 Proteins 0.000 description 2
- 101000595751 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Proteins 0.000 description 2
- 101000730648 Homo sapiens Phospholipase A-2-activating protein Proteins 0.000 description 2
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 2
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 description 2
- 101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 2
- 101001135391 Homo sapiens Prostaglandin E synthase Proteins 0.000 description 2
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
- 101000592466 Homo sapiens Proteasome subunit beta type-4 Proteins 0.000 description 2
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 2
- 101000644045 Homo sapiens Protein unc-13 homolog D Proteins 0.000 description 2
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 description 2
- 101001116937 Homo sapiens Protocadherin alpha-4 Proteins 0.000 description 2
- 101001116931 Homo sapiens Protocadherin alpha-6 Proteins 0.000 description 2
- 101001069891 Homo sapiens RAS guanyl-releasing protein 1 Proteins 0.000 description 2
- 101100087590 Homo sapiens RICTOR gene Proteins 0.000 description 2
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 2
- 101001096578 Homo sapiens Rhomboid domain-containing protein 3 Proteins 0.000 description 2
- 101000854388 Homo sapiens Ribonuclease 3 Proteins 0.000 description 2
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 description 2
- 101000836983 Homo sapiens Secretoglobin family 1D member 1 Proteins 0.000 description 2
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 2
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 2
- 101000663635 Homo sapiens Sphingosine kinase 1 Proteins 0.000 description 2
- 101000879116 Homo sapiens Succinate receptor 1 Proteins 0.000 description 2
- 101000652224 Homo sapiens Suppressor of cytokine signaling 5 Proteins 0.000 description 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 2
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000653597 Homo sapiens TBC1 domain family member 23 Proteins 0.000 description 2
- 101000620880 Homo sapiens Tartrate-resistant acid phosphatase type 5 Proteins 0.000 description 2
- 101000658739 Homo sapiens Tetraspanin-2 Proteins 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 2
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 101000659267 Homo sapiens Tumor suppressor candidate 2 Proteins 0.000 description 2
- 101000890951 Homo sapiens Type-2 angiotensin II receptor Proteins 0.000 description 2
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 2
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 2
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 description 2
- 101000829770 Homo sapiens Uracil nucleotide/cysteinyl leukotriene receptor Proteins 0.000 description 2
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 2
- 101000955064 Homo sapiens WAP four-disulfide core domain protein 1 Proteins 0.000 description 2
- 101000976393 Homo sapiens Zyxin Proteins 0.000 description 2
- 102100029224 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 2
- 102100025305 Integrin alpha-2 Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102100033011 Integrin beta-6 Human genes 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 2
- 102100039065 Interleukin-1 beta Human genes 0.000 description 2
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 description 2
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 2
- 102100036697 Interleukin-1 receptor-like 2 Human genes 0.000 description 2
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 102100035018 Interleukin-17 receptor A Human genes 0.000 description 2
- 102100035014 Interleukin-17 receptor B Human genes 0.000 description 2
- 102100035012 Interleukin-17 receptor C Human genes 0.000 description 2
- 102100033101 Interleukin-17B Human genes 0.000 description 2
- 102100033454 Interleukin-17F Human genes 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 102100022705 Interleukin-20 receptor subunit beta Human genes 0.000 description 2
- 102100022703 Interleukin-22 receptor subunit alpha-2 Human genes 0.000 description 2
- 102100036680 Interleukin-25 Human genes 0.000 description 2
- 102100021594 Interleukin-31 receptor subunit alpha Human genes 0.000 description 2
- 108010067003 Interleukin-33 Proteins 0.000 description 2
- 102000017761 Interleukin-33 Human genes 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102100039881 Interleukin-5 receptor subunit alpha Human genes 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 102100023429 Junctional adhesion molecule C Human genes 0.000 description 2
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 2
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 description 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 2
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 2
- 101710089435 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 101001089108 Lotus tetragonolobus Anti-H(O) lectin Proteins 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 description 2
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 2
- 102100037461 Lysine-specific demethylase 6B Human genes 0.000 description 2
- 102100033320 Lysosomal Pro-X carboxypeptidase Human genes 0.000 description 2
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100028329 Macrophage immunometabolism regulator Human genes 0.000 description 2
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 description 2
- 102100027632 Microcephalin Human genes 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102100025298 Mitochondrial-processing peptidase subunit beta Human genes 0.000 description 2
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 102100028647 Mu-type opioid receptor Human genes 0.000 description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 2
- 102100030397 N-acetylmuramoyl-L-alanine amidase Human genes 0.000 description 2
- 102100022696 NACHT, LRR and PYD domains-containing protein 6 Human genes 0.000 description 2
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 2
- 102100026009 NF-kappa-B inhibitor zeta Human genes 0.000 description 2
- 102100022697 NLR family member X1 Human genes 0.000 description 2
- 102100034296 Natriuretic peptides A Human genes 0.000 description 2
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 2
- 102400001095 Neuropeptide FF Human genes 0.000 description 2
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 description 2
- 102100033174 Neutrophil elastase Human genes 0.000 description 2
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 2
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 2
- 108010029755 Notch1 Receptor Proteins 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 2
- 102100021133 Nuclear protein 1 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100023782 Nucleoporin SEH1 Human genes 0.000 description 2
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 description 2
- 102100040557 Osteopontin Human genes 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 102100040444 P2X purinoceptor 1 Human genes 0.000 description 2
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 2
- 101150084398 PTAFR gene Proteins 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 102100032393 Peptidoglycan recognition protein 1 Human genes 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 102100030919 Phosphatidylcholine:ceramide cholinephosphotransferase 1 Human genes 0.000 description 2
- 102100036052 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Human genes 0.000 description 2
- 102100032572 Phospholipase A-2-activating protein Human genes 0.000 description 2
- 102100023410 Phospholipid hydroperoxide glutathione peroxidase Human genes 0.000 description 2
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 2
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 102100033076 Prostaglandin E synthase Human genes 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 102100033190 Proteasome subunit beta type-4 Human genes 0.000 description 2
- 102100035251 Protein C-ets-1 Human genes 0.000 description 2
- 102100032442 Protein S100-A8 Human genes 0.000 description 2
- 102100020988 Protein unc-13 homolog D Human genes 0.000 description 2
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 2
- 108050004181 Proto-oncogene Mas Proteins 0.000 description 2
- 102100034220 RAS guanyl-releasing protein 1 Human genes 0.000 description 2
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 description 2
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 description 2
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 2
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 2
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 2
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 description 2
- 102000012211 Retinoic Acid 4-Hydroxylase Human genes 0.000 description 2
- 102100037471 Rhomboid domain-containing protein 3 Human genes 0.000 description 2
- 108091006231 SLC7A2 Proteins 0.000 description 2
- 101700032040 SMAD1 Proteins 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 101150063267 STAT5B gene Proteins 0.000 description 2
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 102100024474 Signal transducer and activator of transcription 5B Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101000873420 Simian virus 40 SV40 early leader protein Proteins 0.000 description 2
- 102000013380 Smoothened Receptor Human genes 0.000 description 2
- 101710090597 Smoothened homolog Proteins 0.000 description 2
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 2
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 2
- 102100039024 Sphingosine kinase 1 Human genes 0.000 description 2
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 2
- 102100037464 Succinate receptor 1 Human genes 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 102100030523 Suppressor of cytokine signaling 5 Human genes 0.000 description 2
- 102100035721 Syndecan-1 Human genes 0.000 description 2
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100029850 TBC1 domain family member 23 Human genes 0.000 description 2
- 102000003566 TRPV1 Human genes 0.000 description 2
- 102000003567 TRPV4 Human genes 0.000 description 2
- 101150098315 TRPV4 gene Proteins 0.000 description 2
- 102100022919 Tartrate-resistant acid phosphatase type 5 Human genes 0.000 description 2
- 102100035873 Tetraspanin-2 Human genes 0.000 description 2
- 101150050472 Tfr2 gene Proteins 0.000 description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 description 2
- 240000002657 Thymus vulgaris Species 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 2
- 102100026143 Transferrin receptor protein 2 Human genes 0.000 description 2
- 101150016206 Trpv1 gene Proteins 0.000 description 2
- 108010047933 Tumor Necrosis Factor alpha-Induced Protein 3 Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100024596 Tumor necrosis factor alpha-induced protein 3 Human genes 0.000 description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 102100036129 Tumor suppressor candidate 2 Human genes 0.000 description 2
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 2
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 2
- 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 2
- 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 2
- 102100023407 Uracil nucleotide/cysteinyl leukotriene receptor Human genes 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 2
- 102100023895 Zyxin Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 210000005058 airway cell Anatomy 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 210000000594 epithelial cell of lung Anatomy 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 108010057284 lysosomal Pro-X carboxypeptidase Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108010055752 phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide Proteins 0.000 description 2
- 102000030769 platelet activating factor receptor Human genes 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000001585 thymus vulgaris Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000007502 viral entry Effects 0.000 description 2
- FAMPSKZZVDUYOS-HRGUGZIWSA-N (1E,4E,8E)-alpha-humulene Chemical compound C\C1=C/CC(C)(C)\C=C\C\C(C)=C\CC1 FAMPSKZZVDUYOS-HRGUGZIWSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 102100040430 Active breakpoint cluster region-related protein Human genes 0.000 description 1
- 244000198134 Agave sisalana Species 0.000 description 1
- 235000011624 Agave sisalana Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 101100457310 Arabidopsis thaliana MIP1A gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N Arsenious Acid Chemical compound O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 101150116911 CCL3 gene Proteins 0.000 description 1
- 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000284152 Carapichea ipecacuanha Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
- 206010067671 Disease complication Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100022629 Fructose-2,6-bisphosphatase Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000823463 Homo sapiens Fructose-2,6-bisphosphatase Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- 101000829761 Homo sapiens N-arachidonyl glycine receptor Proteins 0.000 description 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 101150109636 Inos gene Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 239000009471 Ipecac Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 102100023414 N-arachidonyl glycine receptor Human genes 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710195703 Oxygen-dependent coproporphyrinogen-III oxidase Proteins 0.000 description 1
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 1
- 101710200437 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000107975 Strychnos nux-vomica Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101150033527 TNF gene Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000019752 Wheat Middilings Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000254 ciliated cell Anatomy 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000003224 coccidiostatic agent Substances 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FVCOIAYSJZGECG-UHFFFAOYSA-N diethylhydroxylamine Chemical compound CCN(O)CC FVCOIAYSJZGECG-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 150000005165 hydroxybenzoic acids Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000006197 inhalational dosage form Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940029408 ipecac Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000005351 kimble Substances 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 101150063226 parp-1 gene Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 239000006217 urethral suppository Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
Definitions
- the present invention relates generally to cannabis and hemp plant products and methods of their production, as well as in production of medicaments for preventing and treating viral diseases, such as COVID-19.
- the basic replication number, Ro, of SARS-CoV-2 is thought to be around 2-6 [Zhao, S., et al, 2020], meaning that each infected individual, some of whom are asymptomatic infect 2-6 other people, if no interventions are taken.
- SARS-CoV-2 shares 82% sequence identity with severe acute respiratory syndrome -related coronavirus (SARS-CoV). SARS-CoV relies on its spike protein to bind a host cell surface receptor for entry. For the SARS-CoV-2, research has shown that this receptor is the angiotensin-converting enzyme 2 (ACE2).
- ACE2 angiotensin-converting enzyme 2
- Both SARS-CoV-2 and SARS-CoV encode a large spike protein (2019-nCoV: 1253 aa; SARS-CoV: 1273 aa).
- the sequence identity of this protein between the two viruses is 76%.
- the spike protein has three regions, SI, S2, and S3.
- Receptor binding domain (RBD) of spike protein in SARS-CoV is majorly in SI and S2.
- SI region in the RBD from the two viral origins shows 73.5% sequence identity but S2 RBD is almost complete different in SARS-CoV-2 and SARS-CoV. This might affect binding of SARS-CoV-2 to ACE2 as compared to SARS-CoV.
- ACE2 is expressed in upper respiratory tract, lung, liver, intestine and kidney tissues in humans. Once SARS-CoV-2 enters the host via suggested major routes above, it further increases ACE2 expression.
- ACE2 ACE2-induced inflammatory response
- IL1B, IL1RA, IL7, IL8, IL9, IL10 levels were very high as well.
- Wuhan pointed that the levels of IL-1B, IL-10 and IL-8 were significantly increased in critically ill patients with new coronavims SARS-CoV-2 infection, indicating that there were cytokine-mediated inflammatory responses in patients with new coronavims infection.
- cytokine storm' and acute respiratory distress syndrome ARDS
- High concentrations of cytokines were recorded in plasma of critically ill patients infected with SARS-CoV-2 [Huang, et ah, 2019, Guo et al, 2019].
- ICU patients In the severe patients, levels of IL-6, IL-10, and TNF-a further increased[ Guo, et al., 2019]. ICU patients also had high plasma levels of IL-2, IL-7, granulocyte colony- stimulating factor (GCSF). Furthermore, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, IL-6, IL-10, TNFa and other cytokines than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity [Huang, et al., 2019, Guo et al, 2019].
- GCSF granulocyte colony- stimulating factor
- TNFa is one of the key cytokines in the cytokine storm and is likely to responsible for the escalation in severity [Liu et al., 2016].
- IL-6 [Tanaka et al., 2016]
- IL-1 and others are key mediators of the cytokine storm [Tisoncik et al., 2012].
- a cytokine storm manifests before the ARDS in COVID-19 patients and the cytokine storm constitutes one of the ARDS underlying mechanisms. There thus remains an unmet need to provide a product or pharmaceutical composition effective in treating viral diseases in mammals, including humans and non-human mammals, which spread the disease.
- anti-inflammatory therapies either prophylactically or to prevent a worsening of the underlying disease progression.
- anti-IL-6 receptor antibody tocilizumab
- tocilizumab anti-IL-6 receptor antibody
- compositions for improving wellness in a human or non-human mammalian organism It is an object of some aspects of the present invention to provide compositions for improving wellness in a human or non-human mammalian organism.
- the present invention provides products and compositions used in reducing levels of an ACE2 receptor in oral, lung and intestinal epithelial tissues in COVID-19 patients to prevent entry thereto of the SARS-CoV-2 RNA virus and related viruses.
- Products of the present invention are used further to treat a cytokine storm that precedes and underlies acute respiratory distress syndrome (ARDS), seen in the COVID-19 patients.
- ARDS acute respiratory distress syndrome
- the method includes generation of unique lines, whole plant extract preparation, treating normal EpiOral, Epilntestinal and EpiAirway human 3D tissues and human cell lines with tumor necrosis factor alpha (TNF) to induce inflammation, and then with extracts in an amount sufficient to profoundly down-regulate ACE2 expression, inflammation and molecular pathways involved in ACE2 regulation, vims entry and inflammation in the oral, intestinal and airway tissues.
- TNF tumor necrosis factor alpha
- Extracts of novel cannabis and hemp lines can be combined with anti-viral agents and anti inflammatory extracts of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics to increase their efficacy.
- the present invention provides methods of production of pharmaceutical compositions, suitable for treating viral diseases in mammalian subjects.
- the present invention provides pharmaceutical compositions, suitable for treating viral diseases in mammalian subjects.
- the present invention provides methods for preventing, mitigating and treating cytokine storms in in COVID-19 patients by administration of C. sativa extracts, which exhibit profound cytokine inhibition patterns.
- the present invention further provides methods and products for ACE2 inhibition in target tissues - lung, oral and intestinal epithelia, thereby decreasing or inhibiting a SARS-CoV-2 infection in a mammalian patient.
- the present invention further provides combination therapies including a combination of anti- viral (anti-SARS-CoV-2) and anti-cytokine agents will be an effective regimen targeting both etiology and pathogenesis of COVID-19.
- combination therapies including a combination of anti- viral (anti-SARS-CoV-2) and anti-cytokine agents will be an effective regimen targeting both etiology and pathogenesis of COVID-19.
- the present invention provides new Cannabis sativa lines and extracts as well as combination of single cannabinoids and terpenes and method of using them as a means to modulate ACE2 expression in oral, lung or intestinal tissues.
- the present invention also provides methods of modulating ACE2 expression through the application cannabis extracts to the oral, lung and intestinal tissues to prevent or treat COVID-19 and other SARS-CoV virus-caused diseases.
- the present invention provides a method for modulating ACE2 expression on mRNA and protein levels (e.g., in oral, lung and intestinal tissues and cells) by providing a source of new Cannabis sativa (hemp and cannabis) extracts, exposing oral cells or oral epithelial tissue, lung cell or lung epithelial tissue, intestinal cells of intestinal epithelial tissue to those in an amount sufficient to modulate gene expression where modulation of ACE2 expression results in a prevention of disease via decreased opportunity of virus entry into the cells.
- mRNA and protein levels e.g., in oral, lung and intestinal tissues and cells
- the present invention also provides new Cannabis sativa lines and extracts and as well as combinations of single cannabinoids and terpenes, and methods of using them as a means to modulate cytokine levels and cytokine storm in lung tissues.
- Extracts of novel cannabis and hemp lines or single cannabinoids and terpenes are combined with anti-viral agents and anti-inflammatory, such as, but not limited to, extracts of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics, to increase their efficacy.
- anti-viral agents and anti-inflammatory such as, but not limited to, extracts of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics, to increase their efficacy.
- the disclosure provides a means for modulating gene expression and protein levels (e.g., in oral, lung and intestinal tissues and cells) by providing a source of new Cannabis sativa (hemp and cannabis) extracts, exposing oral cells or oral epithelial tissue, lung cell or lung epithelial tissue, intestinal cells of intestinal epithelial tissue to those in an amount sufficient to modulate gene expression where modulation of gene expression results in a prevention of disease or reduction of a disease state in the aforementioned tissues.
- a source of new Cannabis sativa hemp and cannabis
- the present invention provides extracts of twenty nine new C. sativa lines (#1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114, #115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317).
- the present invention further combines use of extracts of these lines, as well as combination of single cannabinoids and terpenes.
- the aforementioned extracts, single cannabinoids and terpenes have been tested for anti-inflammatory properties and/or ACE2 inhibition properties using human cells lines and 3D EpiOral, Epilntestinal and EpiAirway tissue models. This is performed by detecting the expression of genes that are associated with molecular etiology and pathogenesis of COVID-19 and ARDS and cytokine storms.
- the present invention provides compositions having potent therapeutic ACE2 inhibitory effects in oral, intestinal and airway tissues and thus for treatment and prevention of COVID-19 and ARDS and cytokine storm.
- the present invention provides new Cannabis sativa lines and extracts as well as combination of single cannabinoids and terpenes and method of using them as a means to modulate ACE2 gene expression in oral, lung and intestinal tissues.
- the present invention also provides methods of modulating gene expression through the application of cannabis extracts to the mouth, airways and intestine affected by SARS-CoV-2 and other diseases and viruses.
- the present invention further provides extracts for treating and preventing viral diseases, including SARS-CoV-2 virus and resultant COVID-19, as well as other viral diseases and ARDS.
- the Cannabis sativa extract efficacy can further be increased by adding thereto additional Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), terpenes or combinations thereof.
- the extract efficacy can be further potentiated and increased by adding anti inflammatory herbs such as but not limited to chamomile, sage, turmeric, thyme, ginger, rosehip, as well as probiotics and their components, or combinations thereof.
- anti inflammatory herbs such as but not limited to chamomile, sage, turmeric, thyme, ginger, rosehip, as well as probiotics and their components, or combinations thereof.
- the present invention provided the methods of preparation of Cannabis extracts, cannabinoids, such as but not limited to, Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), D 9 - 1 c t a h y d o c a n n a b i n o 1 (THC), and terpenes.
- CBD Cannabidiol
- CBG Cannabigerol
- CBN Cannabinol
- THC terpenes
- the present invention provides new unique cannabis lines, extracts and methods for oral, lung and intestinal improvement and healing and reduction in virus entry into the cells and inflammation.
- the method includes generation of unique lines, whole plant extract preparation, exposing human oral, lung and intestinal tissues to the extracts in amount sufficient to modulate gene expression in them. The modulation of gene expression then results in a reduction of the disease state- associated changes or aspects thereof in the cannabis -treated tissues.
- improved methods and products are provided for oral application and treatment to prevent viral infection.
- improved methods and products are provided for oral treatment.
- improved methods and products are provided for airway application and treatment to prevent viral infection, COVID-19 and acute respiratory distress syndrome.
- improved methods and products are provided for treatment of viral infection and/or associated diseases.
- improved methods and products are provided for intestinal application and treatment to prevent SARS-CoV- 2 viral infection and/or COVID-19 disease.
- new Cannabis sativa lines are provided.
- new extracts from new Cannabis sativa lines are provided.
- the present invention provides a method for modulating gene expression on mRNA and protein levels (e.g., in oral cells, in oral tissue, in lung cells, in lung tissue, in intestinal cells, in intestinal tissue) by providing a source of new extracts, exposing cells or tissue to those in an amount sufficient to modulate gene expression where modulation of gene expression results in a prevention and reduction of a disease state in the in oral, lung and intestinal cells and tissue.
- mRNA and protein levels e.g., in oral cells, in oral tissue, in lung cells, in lung tissue, in intestinal cells, in intestinal tissue
- the present invention provides new unique cannabis lines, extracts, dried powders from the extracts, compositions comprising the powders or parts thereof, compounds derived therefrom, pharmaceutical compositions comprising the compound(s), and methods for the treatment of COVID-19, viral diseases, ARDS, cytokine storms, others and combinations thereof.
- the method includes generation of unique lines, whole plant extract preparation, treating human 3D oral, airway and intestinal tissues with extracts in amount sufficient to modulate gene expression in the said tissues.
- the modulation of Angiotensin-converting enzyme 2 gene (ACE2) expression and inflammatory gene expression then results in a reduction of the disease state-associated changes or aspects thereof in the treated tissues.
- ACE2 Angiotensin-converting enzyme 2 gene
- compositions and dosage forms of the present invention are useful in promoting health and preventing or treating a large number of disorders in human patients and other mammalian subjects.
- compositions and methods are provided for treating and/or preventing viral disorders.
- the invention provides methods and compositions for preventing ARDS and other diseases that harbor an inflammatory component.
- the invention provides methods and compositions for preventing systemic diseases and complications related to virus-caused pathologies.
- compositions of the present invention may be used for improving wellness of a human or mammalian subject. Additionally, the compositions of the present invention may be used to treat any disorder or ailment in a human patient or mammalian subject. Furthermore, the compositions of the present invention may be conveniently used in conjunction with a drug to treat any disorder or ailment in a human patient or mammalian subject.
- Some embodiments of the present invention provide compounds, compositions and formulations from at least one of hemp and cannabis.
- compositions and methods are provided for treating and/or preventing viral, inflammatory and fibrosis-related disorders.
- compositions and methods are provided for treating and/or preventing pneumonia and ARDS, and other disorders.
- compositions and methods are provided for inhibiting viral life cycle processes thereby treating and/or preventing viral disorders.
- Some embodiments of the present invention provide compounds, compositions and formulations from at least one of hemp and cannabis.
- Some further embodiments of the present invention provide methods for downregulating expression of ACE2 gene.
- Some further embodiments of the present invention provide methods for downregulating expression of at least one inflammatory pathway gene.
- Some further embodiments of the present invention provide methods for downregulating expression of at least TNF gene.
- Some further embodiments of the present invention provide methods for downregulating expression of at least IL gene.
- Some further embodiments of the present invention provide methods for downregulating expression of at least PARP-1 gene.
- Some further embodiments of the present invention provide methods for downregulating expression of at least iNOS gene.
- Some further embodiments of the present invention provide methods for downregulating at least one inflammatory pathway gene product.
- compositions, compounds, formulations and extracts for preventing viral diseases in a human patient there are described methods for preparing compositions, compounds, formulations and extracts for preventing viral diseases in a human patient.
- compositions, compounds, formulations and extracts for treating viral diseases in a human patient there are described methods for preparing compositions, compounds, formulations and extracts for treating viral diseases in a human patient.
- a use of a solvent extract from at least one of hemp and cannabis, according to some embodiments of the present invention, is for the manufacture of a pharmaceutical composition for the prevention and treatment of ARDS.
- Some embodiments of the present invention are directed to a method for preventing and treating a viral disease or disorder in a human patient comprising administering to said patient a pharmaceutically effective amount of the cannabis extract composition as described herein.
- some further embodiments of the present invention are directed to a method for preventing and treating a viral disorder or disease or complication of those in a human patient comprising administering to said patient the oral, inhalation or topical dosage form as described herein.
- liquid cannabis extracts of the present invention are suitable for oral administration, and appear to be well absorbed through the intestine by the blood and thus exhibit the potential to heal a wide range of viral and inflammatory conditions, such as, but not limited to those mentioned by Chattopadhyay et al. Current Science 87(1) July 2004, 44-53.
- the composition or formulation further comprises at least one solvent or hydrant.
- the hydrant is water, such as double-distilled water. In some cases, it may be at least one organic solvent, such as alcohol.
- the at least one solvent or hydrant is present in the composition or formulation in a concentration of 10-90%, 15-80%, 20-70%, 25-50%, 30-40%, or 10-18% by weight percent.
- the solvent or hydrant may further comprise a pH regulator, such as an acid or base.
- a pH regulator such as an acid or base.
- the base comprises sodium hydroxide.
- Suitable products or compositions of the present invention may be in the form of ointments or salves, creams, emulsions, gels, foams, sprays or medicated dressings or bandages, which must be directly applied on the affected zone and must be kept in contact with the oral.
- the compositions further comprise up to 10% of water.
- the composition is substantially non-aqueous and/or substantially alcohol-free.
- the present invention provides a method for inhibiting a disease in a subject comprising administering a subject a composition of the invention.
- the present invention provides a method for inhibiting a viral disease in a subject comprising administering a subject a composition of the present invention.
- the present invention provides a method for inhibiting a disease in a subject comprising orally administering a product of the present invention to the subject.
- the present invention provides a method for inhibiting a disease in a subject comprising inhalation-based administering a product of the present invention to the subject.
- the composition of the present invention is in a chewable oral dosage form.
- the chewable oral dosage form is a chewable tablet.
- the chewable tablet of the invention is taken slowly by chewing or sucking in the mouth.
- the chewable tablet of the invention enables the dried cannabis extracts contained therein to be orally administered without drinking.
- the composition further comprises a therapeutically effective concentration of one or more active agents.
- composition of the present invention further contains a surface-active agent.
- Surface- active agents include any agent linking oil and water in the composition, in the form of emulsion.
- a composition of the present invention includes one or more additional components.
- additional components include but are not limited to anti-static agents, buffering agents, bulking agents, chelating agents, cleansers, colorants, conditioners, diluents, dyes, emollients, fragrances, humectants, permeation enhancers, pH-adjusting agents, preservatives, protectants, oral penetration enhancers, softeners, solubilizers, sunscreens, sun blocking agents, sunless tanning agents, viscosity modifiers and vitamins.
- a specific additional component may have more than one activity, function or effect.
- a pharmaceutical composition for treating a viral disease or disorder in a mammalian subject including at least one of: a) an extract as described herein; b) at least one of Cannabigerol (CBG), Cannabinol (CBN) and Cannabidiol (CBD); and c) at least one terpene or terpene alcohol; wherein the pharmaceutical composition is suitable for treating the viral disease or the viral disorder in the mammalian subject.
- the at least one terpene is selected from the group consisting of myrcene, humulene, pinene carophyllene and valencene.
- the terpene alcohol includes bisabolol.
- the at least one of Cannabigerol (CBG), Cannabinol (CBN) and Cannabidiol (CBD) includes only Cannabidiol (CBD).
- the viral disease or disorder is caused by a corona virus, a mutant or variant thereof.
- the viral disease is COVID 19.
- the pharmaceutical composition is effective in treating a cytokine storm associated with the COVID 19.
- the pharmaceutical composition is suitable for reducing a level of an ACE2 protein in the mammalian subject.
- a method for treating a viral disease or disorder in a mammalian subject including administering a pharmaceutical composition including at least one of; an extract as described herein; at least one of Cannabigerol (CBG), Cannabinol (CBN) and
- Cannabidiol CBD
- terpene or terpene alcohol at least one terpene or terpene alcohol
- the method is effective in treating a cytokine storm associated with the COVID 19.
- the method is effective in reducing a level of an ACE2 protein in the mammalian subject.
- a method for preventing and treating corona virus-caused disease or disorder comprising: a) combining at least one marijuana strain and at least one hemp strain to form at least one Cannabis line; b) extracting at least one compound from said at least one Cannabis line to form an extract or combining an isolated cannabidiol and adding set of terpenes; and c) treating said disease or disorder with at least one of said extract and said at least one compound in an effective amount to treat said disease or disorder.
- said at least one Cannabis line is selected from the group consisting of a marijuana/marijuana hybrid line, hemp/hemp hybrid line and hemp/marijuana hybrid line.
- a method according to embodiment 5, wherein said at least one line is selected from the group consisting of designated lines (#1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114, #115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317) and combinations thereof.
- the disease state is selected from the group consisting of a virus-caused disease, virus-caused disease complications, environmental factor-induced inflammation and combinations thereof.
- An organic extract of at least one plant line said at least one plant line formed from combining at least one of: a) at least one marijuana strain; and b) at least one hemp strain, wherein said organic extract comprises at least one compound suitable for treating a mammalian oral disease or disorder.
- An organic extract according to embodiment 19, wherein said mammalian oral disease or disorder is selected from the group consisting of a viral disease, an oral disease, a lung disease, an intestinal disease and combinations thereof.
- a combination therapy isolated from an organic extract of at least one hybrid line, said at least one hybrid line formed from combining at least one of: a) at least one marijuana strain; and b) at least one hemp strain; and wherein said organic extract comprises a plurality of compounds suitable for treating a mammalian viral disease and disorder.
- a Cannabis extract for treating and preventing a viral disease or disorder, wherein said extract efficacy can be further increased by adding CBD, CBG, CBN, terpenes or combinations thereof.
- a Cannabis extract for treating and preventing viral disease or disorder wherein said extract efficacy can be further increased by adding extracts of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics or combinations thereof.
- a line of Cannabis sativa formed by combining at least one marijuana strain and at least one hemp strain said line will be deposited at public culture collection, currently under designation numbers (#1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114, #115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317, #CD10.
- a method for treating a disease state in oral epithelial cells or oral tissue comprising the steps of: a) providing a source of unique extract from at least one line of Cannabis sativa; and b) preventing and treating the COVID-19 and virus-caused disorders with aforementioned extract(s) in an effective amount to induce modulation of ACE 2 and inflammatory gene expression in the oral, airway and intestinal tissue; wherein the modulation of gene expression results in a reduction of the disease state in the aforementioned tissues.
- Fig. 1A is a simplified image of an EpiOral tissue experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention
- Fig. IB is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-i induced inflammation using the set-up in Fig.lA, in accordance with an embodiment of the present invention
- Fig. 2A is a graph showing the effects of cannabis extract 81 on the levels of ACE2 gene expression and expression of inflammation-related genes in EpiOral tissues, in accordance with an embodiment of the present invention
- Fig. 2B is a graph showing the effects of cannabis extract 130 on the levels of ACE2 gene expression and expression of inflammation-related genes in EpiOral tissues, in accordance with an embodiment of the present invention
- Fig. 2C is a graph showing the effects of several pro-inflammatory gene changes in a single bar for each condition (TNF vs DMSO, and extracts vs DMSO) for several different extracts, in accordance with an embodiment of the present invention
- Fig. 2D is an image showing the effects of different cannabis extracts on ACE2 protein and GAPDH protein levels in EpiOral tissues, in accordance with an embodiment of the present invention
- Fig. 2E is a graph showing the ratio of ACE2 protein to GAPDH protein after treatment with TNF/IFN and application of different cannabis extracts to EpiOral cells, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment;
- Fig. 3A is a simplified image of Epilntestinal tissues experimental set-up for testing candidate treatments for anti inflammatory properties, in accordance with an embodiment of the present invention;
- Fig. 3B is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-induccd inflammation using the set-up in Fig.3A, in accordance with an embodiment of the present invention
- Fig. 4 A is a graph showing the effects of different cannabis extracts on the levels of ACE2 gene expression in Epilntestinal tissues, in accordance with an embodiment of the present invention
- Fig. 4B is a graph showing the effects of extract of Cannabis Line 45 effectively decreasing levels of ACE2 gene expression in human 3D Epilntestinal tissues, in accordance with an embodiment of the present invention
- Fig. 5A is an image showing the effects of different cannabis extracts on ACE2 protein and GAPDH protein levels in Epilntestinal tissues, in accordance with an embodiment of the present invention
- Fig. 5B is a graph showing the ratio of ACE2 protein to GAPDH protein after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment;
- Fig. 5C is a graph showing the effects of different cannabis extracts on down- regulation of inflammation-related PARP-1 and iNOS proteins in Epilntestinal cells, in accordance with an embodiment of the present invention
- Fig. 5D is a graph showing the ratio of PARP-1 to actin after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention.
- Fig. 5E is a graph showing the ratio of iNOS to actin after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention.
- Fig. 6A is a simplified image of an EpiAirway tissue model tissue experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention
- Fig. 6B is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-i induced inflammation using the set-up in Fig.6A, in accordance with an embodiment of the present invention.
- Fig. 7 A is a graph showing the effects of cannabis extracts of novel cannabis lines in reducing levels of the ACE2 protein in human 3D EpiAirway tissue, in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment;
- Fig. 7B is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and GAPDH protein in human 3D EpiAirway tissue, in accordance with an embodiment of the present invention
- Fig. 7C is a graph showing the ratio of ACE2 protein to GAPDH protein after different cannabis extracts were applied to EpiAirway tissues, in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment;
- Fig. 7D is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and Actin protein in human 3D EpiAirwayFT tissue after induction of inflammation with TNF/IFN and after application of cannabis extracts, in accordance with an embodiment of the present invention
- Fig. 7E is a graph showing the ratio of ACE2 protein to Actin protein after induction of inflammation with TNF/IFN and after application of different cannabis extracts were applied to EpiAirway tissues, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment;
- Fig. 7F is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and GAPDH protein in human 3D EpiAirway tissue after induction of inflammation with TNF/IFN and after application of cannabis extracts, in accordance with an embodiment of the present invention
- Fig. 7G is a graph showing the ratio of ACE2 protein to GAPDH protein after induction of inflammation with TNF/IFN and after application of different cannabis extracts were applied to human 3D EpiAirway tissues, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
- Figs. 8A-8F are a set of graphs showing that cannabinoids affect processes involved in a viral life cycle -
- Figs. 8A-8C show that different cannabinoids applied at different concentrations to an in vitro viral experiment inhibit reverse transcription- namely Fig. 8A, CBD, Fig. 8B, THC, Fig. 8B THC and Fig. 8C, CB and Figs. 8D-8F show that different cannabinoids applied at different concentrations to an in vitro viral experiment inhibit DNA replication- namely Fig. 8D, CBD, Fig. 8E, THC and Fig. 8F THC, in accordance with some embodiments of the present invention;
- Fig. 9 is a simplified pictorial illustration showing a schematic summary of the main effects of cannabis extracts on SARS-COV-2, in accordance with an embodiment of the present invention.
- Fig. 10A shows the dose-dependent increase in relative expression of COX2 as measured by qRT-PCR 24h after treatment with TNFa/IFNy in HSIEC cells; asterisks indicated significant (p ⁇ 0.01) difference;
- Fig. 10B shows the dose-dependent increase in relative expression of COX2 protein as measured by western blot 24h after treatment with TNFa/IFNy in HSIEC cells;
- Fig. IOC shows the time-dependent increase in relative expression of COX2 (as measured by western blot) in response to 10 ng/ml of TNFa/IFNy in HSIEC.
- Fig. 10D is a graph showing ImageJ measured (from Fig. IOC) time-dependent increase in relative expression of COX2 in response to 10 ng/ml of TNFa/IFNy in HSIEC.
- Fig. 11A shows the dose-dependent increase in relative expression of COX2 (as measured by qRT-PCR) in response to TNFa/IFNy in WI-38 human lung fibroblast cells;
- Fig. 11B shows the dose-dependent increase in relative expression of COX2 (as measured by western blot) in response to TNFa/IFNy in WI-38 cells;
- Fig. llC is a graph showing ImageJ measured dose-dependent increase in relative expression of COX2 (as measured by western blot) in response to 10 ng/ml of TNFa/IFNy in WI-38 cells;
- Fig. 11D shows the time-dependent increase in relative expression of COX2 (as measured by western blot) in response to TNFa/IFNy in WI-38 cells;
- Fig. 11E is a graph showing ImageJ measured time-dependent increase in relative expression of COX2 (done by western blot) in response to 10 ng/ml of TNFa/IFNy in WI-38 cells.
- Fig. 12A is a western blot image showing the expression of COX2, SOCS3 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in HSIEC cells;
- Fig. 12B is a graph showing ImageJ measured expression of COX2 relative to GAPDH in response to treatment with TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in HSIEC cells;
- Fig. 12C is a graph showing ImageJ measured expression of SOCS3 relative to GAPDH in response to treatment with TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in HSIEC cells;
- Fig. 12D is a western blot image showing the expression of COX2, SOCS3 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in WI-38 cells;
- Fig. 12E is a graph showing ImageJ measured expression of COX2 relative to GAPDH in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in WI-38 cells;
- Fig. 12F is a graph showing ImageJ measured expression of SOCS3 relative to GAPDH in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in WI-38 cells;
- Fig. 13A is a western blot image showing the expression of IL8 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells;
- Fig. 13B is a graph showing ImageJ measured expression of IL8 relative to GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells;
- Fig. 13C is a western blot image showing the expression of IL8 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells;
- Fig. 13D is a graph showing ImageJ measured expression of IL8 relative to GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells;
- Fig. 13E is a western blot image showing the expression of IL-6, pAktl/2/3, Aktl and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells;
- Fig. 13F is a graph showing ImageJ measured expression of IL-6 relative to GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells;
- Fig. 13G is a western blot image showing the expression of IL-6, pAktl/2/3, Aktl and GAPDH in response to treatment with 10 ng/ml TNFa/IRNg alone, or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells;
- Fig. 13H is a graph showing ImageJ measured expression of IL-6 relative to GAPDH in response to treatment with 10 ng/ml TNFa/IRNg alone or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells;
- Fig. 14A is a graph showing qRT-PCR analysis of IL-6 expression in WI-38 in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169;
- Fig. 14B is a graph showing qRT-PCR analysis of IL-8 expression in WI-38 in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169;
- Fig. 14C is a graph showing qRT-PCR analysis of COX-2 expression in WI- 38 in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169;
- Fig. 14D is a graph showing qRT-PCR analysis of IL-6 expression in HSIEC in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169;
- Fig. 14E is a graph showing qRT-PCR analysis of IL-8 expression in HSIEC in response to treatment with 10 ng/ml TNFa/IRNg alone, or followed by treatment with extracts #1, #5, #7 and #169;
- Fig. 14F is a graph showing qRT-PCR analysis of COX-2 expression in HSIEC in response to treatment with 10 ng/ml TNFa/IRNg alone or followed by treatment with extracts #1, #5, #7 and #169.
- Fig. 15A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 10 mM CBD or 0.015 pg of various extracts;
- Fig. 15B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 10 pM CBD or 0.015 pg of various extracts;
- Fig. 16A is a graph showing qRT-PCR analysis of IL-6 expression in WI-38 cells in response to 24, 48, 72 or 96 h of treatment with 10 ng/ml TNFa/IFNy alone or in combination with extract #1;
- Fig. 16B is a graph showing qRT-PCR analysis of IL-8 expression in WI-38 cells in response to 24, 48, 72 or 96 h of treatment with 10 ng/ml TNFa/IFNy alone or in combination with extract #1;
- Fig. 16C is a graph showing qRT-PCR analysis of IL-6 expression in WI-38 cells in response to 24, 48, 72 or 96 h of treatment with 10 ng/ml TNFa/IFNy alone or in combination with extract #5;
- Fig. 16D is a graph showing qRT-PCR analysis of IL-8 expression in WI-38 cells in response to 24, 48, 72 or 96 h of treatment with 10 ng/ml TNFa/IFNy alone or in combination with extract #5.
- Fig. 17A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with different concentrations of extracts #1 and #5;
- Fig. 17B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to different concentrations of extracts #1 and #5;
- Fig. 18A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with different concentrations of CBD, CBN and THC;
- Fig. 18B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with different concentrations of CBD, CBN and THC;
- Fig. 18C is a western blot image showing ACE2 and GAPDH protein levels in BJ-5ta immortalized foreskin fibroblast cells in response to 24 h treatment with different concentrations of CBD, CBN and THC;
- Fig. 18D is a graph showing the ratio of ACE2 protein to GAPDH protein in BJ-5ta immortalized foreskin fibroblast cells in response to 24 h treatment with different concentrations of CBD, CBN and THC;
- Fig. 19A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in BJ-5ta cells in response to 24 h treatment with 0.015 pg/pl concentration of CBD or various extracts CBN and THC;
- Fig. 19B is a graph showing the ratio of ACE2 protein to GAPDH protein in BJ-5ta cells in response to 24 h treatment with 0.015 pg/pl concentration of CBD or various extracts CBN and THC;
- Fig. 19C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in BJ-5ta cells in response to 24 h treatment with 0.015 pg/pl concentration of CBD or various extracts CBN and THC;
- Fig. 20A shows graphs of the fold change in the expression of selected pro- inflammatory genes in EpiDermFT human 3D tissues in response to UVC and treatment with extracts #4, #6, #8, #12, #13, #14 and #15;
- Fig. 20B shows a graph of the fold change in the expression of PTGS2 (COX2) gene in EpiDermFT human 3D tissues in response to UVC and treatment with extracts #4, #6, #8, #12, #13, #14 and #15;
- Fig. 20C is a western blot image showing IL-6 and COX-2 protein levels in EpiDermFT human 3D tissues in response to UVC and treatment with extracts #4, #6, #8, #12, #13, #14 and #15;
- Fig. 21 A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
- Fig. 2 IB is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
- Fig. 21C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
- Fig. 22A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
- Fig. 22B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
- Fig. 22C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
- Fig. 23A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
- Fig. 23B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
- Fig. 23C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
- Fig. 24A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
- Fig. 24B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
- Fig. 24C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
- Fig. 25A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
- Fig. 25B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
- Fig. 25C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
- Fig. 26A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
- Fig. 26B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
- Fig. 26C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
- Fig. 27A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
- Fig. 27B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
- Fig. 27C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
- Fig. 28A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
- Fig. 28B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
- Fig. 28C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
- Fig. 29A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
- Fig. 29B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
- Fig. 29C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
- Fig. 30A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
- Fig. 30B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
- Fig. 30C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
- Fig. 31A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
- Fig. 3 IB is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
- Fig. 31C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
- Fig. 32A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
- Fig. 32B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
- Fig. 32C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene.
- Fig. 33A shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in WI-38 cells exposed for 24h to CBD, THC, CBN, b-myrcene, b-caryophyllene, a-bisabolol, a- humulene, a combination of all these components or to the extract #1 itself.
- Fig. 33B shows the same for COX-2, IL-6, IL-8 and GAPDH.
- Fig. 33C and D show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 33A.
- Fig. 34A shows the western blot in HSIEC cells exposed for 24h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #1 or its individual components.
- Fig. 34B, C and D show ImageJ quantification of COX2, IL6 or IL8, respectively.
- Fig. 35A shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in WI-38 cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol, a combination of all these components or to the extract #7 itself.
- Fig. 35B and C show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 35A.
- Fig. 35D shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in Bj-5ta cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol, a combination of all these components or to the extract #7 itself.
- Fig. 35E and F show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 35D.
- Fig. 36A shows the western blot image of IL6, COX2 and GAPDH proteins in WI-38 cells exposed for 48h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #7 or its individual components - CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol or their combination.
- Fig. 36B and C show ImageJ quantification of IL6 and COX2 from Fig. 36A.
- Fig. 36D shows the western blot image of IL8 and GAPDH proteins in HSIEC cells exposed for 48h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #7 or its individual components - CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol or their combination.
- Fig. 36E shows ImageJ quantification of IL8 from Fig. 36D.
- Fig. 1A is a simplified image of an EpiOral tissue experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention.
- EpiOral tissues 110 consist of normal, human- derived oral epithelial cells that have been cultured to form multilayered, highly differentiated models of the human buccal phenotypes.
- Fig. IB is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNY-induced inflammation using the set-up in Fig.lA, in accordance with an embodiment of the present invention
- 3D EpiOral tissues 110 were inserted in a well with medium. Tissues were equilibrated in the medium for 24 h (overnight) and then culture medium was replaced and incubated for another 24 h. Tissues were then exposed for 24 h to TNFa (40 ng/ml) and IFNa (5 ng/ml) or to DMSO only.
- an extract treatment step 130 all crude extracts were diluted from a 60 mg/mL stock (the stock is prepared in DMSO). For this experiment, a final concentration of 0.01 ug/uL in 30% glycerol-PBS was used. 24 h after TNF/IFN exposure, 15 uL of 0.01 ug/uL extract solution or control (DMSO alone) were applied to the tissues.
- an analysis step 140 the samples were harvested and used for the analysis of mRNA by sequencing. Bioinformatics analysis of mRNA revealed changes in biological pathways associated with changes in ACE2 expression or inflammation.
- Fig. 2 A and 2B represent the graphs showing the relative expression of ACE2 gene in EpiOral 3D tissues in response in response to treatment with cannabis extract #81 (2A) and #130 (2B), in accordance with an embodiment of the present invention; Extracts #81 and #130 down-regulate the levels of ACE2 in EpiOral tissues.
- Fig. 2C is a graph showing the cumulative effect of several (as per Embodiment 11) pro-inflammatory gene changes in a single bar for each condition (TNF vs DMSO, and extracts vs DMSO) in EpiOral tissues treated with TNF/IFN followed by treatment with several different extracts (as per Fig. 1), in accordance with an embodiment of the present invention.
- Fig. 2D is an image showing the effects of different cannabis extracts on ACE2 protein and GAPDH protein levels using the same EpiOral tissues as per Fig. 1, in accordance with an embodiment of the present invention.
- Fig. 2E is a graph showing the ImageJ-based measurement of the band intensity from Fig.2D, representing the ratio of ACE2 protein to GAPDH protein after treatment with TNF/IFN and application of different cannabis extracts to EpiOral cells, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
- Fig. 3A is a simplified image of Epilntestinal tissues 310 experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention.
- Epilntestinal tissues are 3D highly differentiated tissue models produced from normal, human cell-derived small intestine epithelial and endothelial cells and fibroblasts.
- Fig. 3B is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-induccd inflammation using the set-up in Fig.3A, in accordance with an embodiment of the present invention.
- Fig. 3B is one simplified illustration of a scheme of a TNFa/IFNy-induccd inflammation experiment. 3D Epilntestinal tissues of oral epithelial cells 310 from Fig. 3A were used.
- 3D tissues 310 were inserted in a well with medium. Tissues were equilibrated in the medium for 24 h (overnight) and then culture medium was replaced and incubated for another 24 h. Tissues were then exposed for 24 h to TNFa (40 ng/ml) and IFNa (5 ng/ml) or to DMSO only.
- an extract treatment step 330 all crude extracts were diluted from a 60 mg/mF stock (the stock is prepared in DMSO). For this experiment, a final concentration of 0.01 ug/uF in 30% glycerol-PBS was used. 24 h after TNF/IFN exposure, 15 uF of 0.01 ug/uF extract solution or control (DMSO alone) were applied to the tissues.
- an analysis step 340 the samples were harvested and used for the analysis of mRNA by sequencing. Bioinformatics analysis of mRNA revealed changes in biological pathways associated with changes in ACE2 expression or inflammation.
- Fig. 4 A is a graph showing the relative expression of ACE2 gene in Epilntestinal tissues in response to treatment with different cannabis extracts, in accordance with an embodiment of the present invention.
- Fig. 4B is a graph showing the effects of extract of Cannabis Line 45 effectively decreasing levels of ACE2 gene expression in human 3D Epilntestinal tissues, in accordance with an embodiment of the present invention.
- Fig. 5A is an image showing the effects of different cannabis extracts on ACE2 protein and GAPDH protein in Epilntestinal tissues treated with TNF/IFN (as per Fig. 3), in accordance with an embodiment of the present invention.
- Fig. 5B is a graph showing the ImageJ-based measurement of the band intensity from Fig. 5A showing the ratio of ACE2 protein to GAPDH protein after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
- Fig. 5C is a graph showing the effects of different cannabis extracts on down- regulation of inflammation-related PARP-1 and iNOS proteins in Epilntestinal tissues treated with TNF/IFN, in accordance with an embodiment of the present invention.
- Fig. 5D is a graph showing the ratio of PARP-1 to actin after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention.
- Fig. 5E is a graph showing the ratio of iNOS to actin after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention.
- Fig. 6A is a simplified image of an EpiAirway tissue model tissue 610 experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention.
- Fig. 6B is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-i induced inflammation using the set-up in Fig.6A, in accordance with an embodiment of the present invention.
- 3D EpiAirway tissues of oral epithelial cells 610 were obtained (per Fig. 6A).
- 3D tissues were inserted in a well with medium. Tissues were equilibrated in the medium for 24 h (overnight) and then culture medium was replaced and incubated for another 24 h. Tissues were then exposed for 24 h to TNFa (40 ng/ml) and IFNa (5 ng/ml) or to DMSO only.
- extract treatment step 630 all crude extracts were diluted from a 60 mg/mF stock (the stock is prepared in DMSO). For this experiment, a final concentration of 0.01 ug/uF in 30% glycerol-PBS was used. 24 h after TNF/IFN exposure, 15 uF of 0.01 ug/uF extract solution or control (DMSO alone) were applied to the tissues.
- an analysis step 640 the samples were harvested and used for the analysis of mRNA by sequencing. Bioinformatics analysis of mRNA revealed changes in biological pathways associated with changes in ACE2 expression or inflammation.
- Fig. 7 A is a graph showing the effects of cannabis extracts of novel cannabis lines in reducing levels of the ACE2 protein in human 3D EpiAirway tissue (as described in Fig. 6), in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment.
- Fig. 7B is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and GAPDH protein in human 3D EpiAirway tissue (measured from Fig. 7A), in accordance with an embodiment of the present invention.
- Fig. 7C is a graph showing the ratio of ACE2 protein to GAPDH protein after different cannabis extracts were applied to EpiAirway tissues, in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment.
- Fig. 7D is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and Actin protein in human 3D EpiAirwayFT tissue after induction of inflammation with TNF/IFN and after application of cannabis extracts (as described in Fig. 6), in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment.
- Fig. 7E is a graph showing the ratio of ACE2 protein to Actin protein measured from the image in Fig. 7D, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
- Fig. 7F is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and GAPDH protein in human 3D EpiAirway tissue after induction of inflammation with TNF/IFN and after application of cannabis extracts (as described in Fig. 6), in accordance with an embodiment of the present invention.
- Fig. 7G is a graph showing the ratio of ACE2 protein to GAPDH protein measured from the image in Fig. 7F, in accordance with an embodiment of the present invention. asterisks show significant difference from TNF/IFN treatment.
- Figs. 8A-8F are a set of graphs showing that cannabinoids affect processes involved in a viral life cycle -
- Figs. 8A-8C show that different cannabinoids applied at different concentrations inhibit reverse transcription in vitro - namely Fig. 8A, CBD, Fig. 8B, THC, and Fig. 8C, CBN and Figs. 8D-8F show that different cannabinoids applied at different concentrations inhibit DNA replication- namely Fig. 8D, CBD, Fig. 8E, THC and Fig. 8F CBN, in accordance with some embodiments of the present invention.
- Fig. 9 is a simplified pictorial illustration showing a schematic summary 900 of the main effects of cannabis extracts on SARS-COV-2, in accordance with an embodiment of the present invention.
- Step 910 illustrates mechanism of entry of SARS-COV-2 virus through the recognition of ACE2 receptor.
- Step 920 illustrates the use of cannabis extract or single cannabinoids or single terpene molecules or their combination to block the viral entry by downregulating the expression of ACE2 receptor.
- Step 930 illustrates the use of cannabis extract or single cannabinoids or single terpene molecules or their combination to block the virus life cycle, including but not limited to blocking reverse transcription and replication.
- Step 940 illustrates mechanism of cytokine storm development in response to SARS-COV-2 vims.
- Step 950 illustrates the use of cannabis extract or single cannabinoids or single terpene molecules or their combination to decrease the expression of pro- inflammatory molecules and prevent the development of cytokine storm.
- Fig. 10A shows the dose-dependent increase in relative expression of COX2 as measured by qRT-PCR 24h after treatment with TNFa/IFNy in HSIEC cells; asterisks indicated significant (p ⁇ 0.01) difference.
- Fig. 10B shows the dose-dependent increase in relative expression of COX2 protein as measured by western blot 24h after treatment with TNFa/IFNy in HSIEC cells.
- Fig. IOC shows the time-dependent increase in relative expression of COX2 (as measured by western blot) in response to 10 ng/ml of TNFa/IFNy in HSIEC.
- Fig. 10D is a graph showing ImageJ measured (from Fig. IOC) time-dependent increase in relative expression of COX2 in response to 10 ng/ml of TNFa/IFNy in HSIEC.
- Fig. 11A shows the dose-dependent increase in relative expression of COX2 as measured by qRT-PCR 24h after treatment with TNFa/IFNy in WI-38 human lung fibroblast cells; asterisks indicated significant (p ⁇ 0.01) difference.
- Fig. 1 IB shows the dose-dependent increase in relative expression of COX2 as measured by western blot 24h after treatment with TNFa/IFNy in WI-38 cells.
- Fig. llC is a graph showing ImageJ-measured dose-dependent increase in relative expression of COX2 (from Fig. 11B) in response to TNFa/IFNy in WI-38 cells.
- Fig. 11D shows the time-dependent increase in relative expression of COX2 (as measured by western blot) in response to 10 ng/ml of TNFa/IFNy in WI-38 cells.
- Fig. 11E is a graph showing ImageJ measured time-dependent increase in relative expression of COX2 (from Fig. 11D) in response to 10 ng/ml of TNFa/IFNy in WI-38 cells.
- Fig. 12A is a western blot image showing the expression of COX2, SOCS3 and GAPDH in response to 24h treatment with 10 ng/ml TNFa/IFNy alone or followed by 24h treatment with 5mM CBD or 15 uF of 0.01 ug/uF of various cannabis extracts in HSIEC cells.
- Fig. 12B is a graph showing ImageJ measured expression of COX2 relative to GAPDH (from Fig. 12A) in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in HSIEC cells; asterisks show significant difference.
- Fig. 12C is a graph showing ImageJ measured expression of SOCS3 relative to GAPDH (from Fig. 12 A) in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in HSIEC cells; asterisks show significant difference.
- Fig. 12D is a western blot image showing the expression of COX2, SOCS3 and GAPDH in response to 24h treatment with 10 ng/ml TNFa/IFNy alone or followed by 24h treatment with 5mM CBD or 15 uL of 0.01 ug/uL of various cannabis extracts in WI-38 cells.
- Fig. 12E is a graph showing ImageJ measured expression of COX2 relative to GAPDH (from Fig.l2D) in response to treatment with TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in WI-38 cells; asterisks show significant difference.
- Fig. 12F is a graph showing ImageJ measured expression of SOCS3 relative to GAPDH (from Fig.l2D) in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in WI-38 cells; asterisks show significant difference.
- Fig. 13A is a western blot image showing the expression of IL8 and GAPDH in response to 24h treatment with 10 ng/ml TNFa/IFNy alone or followed by 24h treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in WI-38 cells.
- Fig. 13B is a graph showing ImageJ measured expression of IL8 relative to GAPDH (from Fig. 13A) in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in WI-38 cells; asterisks show significant difference.
- Fig. 13C is a western blot image showing the expression of IL8 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in HSIEC cells.
- Fig. 13D is a graph showing ImageJ measured expression of IL8 relative to GAPDH (from Fig. 13C) in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in HSIEC cells; asterisks show significant difference.
- Fig. 13E is a western blot image showing the expression of IL-6, pAktl/2/3, Aktl and GAPDH in response to 24h treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells.
- Fig. 13F is a graph showing ImageJ measured expression of IL-6 relative to GAPDH (from Fig. 13E) in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in WI-38 cells; asterisks show significant difference.
- Fig. 13G is a western blot image showing the expression of IL-6, pAktl/2/3, Aktl and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells.
- Fig. 13H is a graph showing ImageJ measured expression of IL-6 relative to GAPDH (from Fig. 13G) in response to 24h treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in HSIEC cells; asterisks show significant difference.
- Fig. 14 shows qRT-PCR of IL-6, IL-8 and COX-2 genes in WI-38 and HSIEC cells in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169; asterisks show significant difference.
- FIG. 14A shows IL-6 expression in WI-38
- Fig. 14B - IL-8 in WI-38
- Fig. 14C - COX-2 in WI-38
- Fig. 14D - IL-6 in HSIEC
- Fig.l4E - IL-8 in HSIEC
- Fig. 14F COX-2 in HSIEC.
- Fig. 15 A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 10 mM CBD or 0.015 pg of various extracts.
- Fig. 15B is a graph showing the ratio of ACE2 protein to GAPDH protein measured from Fig. 15A using ImageJ; asterisks show significant difference.
- Fig. 16 shows qRT-PCR of IL-6 and IL-8 genes in WI-38 cells treated for 24- 96h with 10 ng/ml TNFa/IFNy alone or in combination with 0.015 pg of extract #1 or #5; asterisks show significant difference.
- Fig. 16A shows IL-6 expression in response to extract #1
- Fig. 16B - IL-8 in response to extract #1
- Fig.l6C - IL-6 in response to ext #5
- Fig. 16D - IL-8 in response to ext #5.
- Fig. 17 A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with different concentrations of extracts #1 and #5.
- Fig. 17B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells (calculated from Fig. 17A) in response to different concentrations of extracts #1 and #5; asterisks show significant difference.
- Fig. 18A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with different concentrations of CBD, CBN and THC.
- Fig. 18B is a graph showing the ratio of ACE2 protein to GAPDH protein (calculated from Fig. 18A) in WI-38 cells in response to 24 h treatment with different concentrations of CBD, CBN and THC.
- Fig. 18C is a western blot image showing ACE2 and GAPDH protein levels in BJ-5ta immortalized foreskin fibroblast cells in response to 24 h treatment with different concentrations of CBD, CBN and THC.
- Fig. 18D is a graph showing the ratio of ACE2 protein to GAPDH protein (calculated from Fig. 18A) in BJ-5ta immortalized foreskin fibroblast cells in response to 24 h treatment with different concentrations of CBD, CBN and THC.
- Fig. 19A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in BJ-5ta cells in response to 24h treatment with 0.015 pg/pl concentration of CBD or various extracts.
- Fig. 19B is a graph showing the ratio of ACE2 protein to GAPDH protein (calculated from Fig.l9A) in BJ-5ta cells in response to 24h treatment with 0.015 pg/pl concentration of CBD or various extracts.
- Fig. 19C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein (calculated from Fig.l9A) in BJ-5ta cells in response to 24 h treatment with 0.015 pg/pl concentration of CBD or various extracts CBN and THC.
- Fig. 20A shows graphs of the fold change in the expression of selected pro- inflammatory genes in EpiDermFT human 3D tissues in response to UVC followed by 24h treatment with 0.015 pg/pl concentration of extracts #4, #6, #8, #12, #13, #14 and #15.
- Fig. 20B shows a graph of the log2 fold change in the expression of PTGS2 (COX2) gene in EpiDermFT human 3D tissues in response to UVC f treatment with extracts #4, #6, #8, #12, #13, #14 and #15.
- COX2 PTGS2
- Fig. 20C is a western blot image showing IL-6 and COX-2 protein levels in EpiDermFT human 3D tissues in response to UVC or UVC followed by 24h treatment with 0.015 pg/pl concentration of extracts #4, #6, #8, #12, #13, #14 and #15; PBS and DMSO are controls; UV-PBS and UV-DMSO are samples treated with UV with PBS or DMSO added to them.
- Fig. 21 -Fig.32 show the set of experiments to compare the effect of CBD and terpenes on the expression of ACE2 and TMPRSS2 proteins in WI-38 and HSIEC cells.
- Cells were treated for 24h with 20 uM CBD alone, with 10-100 pg/ml of an isolated terpene or with combination of CBD and terpenes.
- Asterisks show significant difference, either between control and any individual treatment, or between CBD and CBD + terpene, or terpene and CBD + terpene.
- Fig. 21 A shows the western blot image of ACE2, TMPRSS2 and GAPDH protein levels
- Fig. 2 IB and C show the ImageJ calculated expression of ACE2 and TMPRSS2 relative to GAPDH in response to CBD and myrcene in WI- 38 cells
- Fig. 22 shows the same in HSIEC cells.
- Fig. 23 and 24 show the same for caryophyllene in WI-38 and HSIEC cells.
- Fig. 25 and 26 show the same for a-pinene in WI-38 and HSIEC cells.
- Fig. 27 and 28 show the same for bisabolol in WI-38 and HSIEC cells.
- Fig. 29 and 30 show the same for humulene in WI-38 and HSIEC cells.
- Fig. 31 and 32 show the same for valencene in WI-38 and HSIEC cells.
- CBD may be less efficient than whole extracts or isolated terpenes in downregulation of ACE2/TMPRSS2 and pro- inflammatory proteins COX, IL-6 and IL-8, it was attempted to check individual components of the extracts.
- Fig. 33-36 show the results of exposure of three different cell types, WI-38, HSIEC and Bj-5ta for 24h or 48h to 15 pg/ml of two best working extracts, #1 and #7.
- cells were exposed to the same concentrations found in the extract of three main cannabinoids, CBD, THC and CBN or 4-6 major terpenes or to a combination of all cannabinoids and major terpenes, attempting to reconstitute the effect of a whole extract.
- Asterisks show significant difference from DMSO control.
- Fig. 33A shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in WI-38 cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-bisabolol, a-humulene, a combination of all these components or to the extract #1 itself.
- Fig. 33B shows the same for COX-2, IL-6, IL-8 and GAPDH.
- Fig. 33C and D show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 33A.
- Fig. 34A shows the western blot in HSIEC cells exposed for 24h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #1 or its individual components.
- Fig. 34B, C and D show ImageJ quantification of COX2, IL6 or IL8, respectively.
- Fig. 35A shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in WI-38 cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol, a combination of all these components or to the extract #7 itself.
- Fig. 35B and C show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 35A.
- Fig. 35D shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in Bj-5ta cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol, a combination of all these components or to the extract #7 itself.
- Fig. 35E and F show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 35D.
- Fig. 36A shows the western blot image of IL6, COX2 and GAPDH proteins in WI-38 cells exposed for 48h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #7 or its individual components - CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol or their combination.
- Fig. 36B and C show ImageJ quantification of IL6 and COX2 from Fig. 36A.
- Fig. 36D shows the western blot image of IL8 and GAPDH proteins in HSIEC cells exposed for 48h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #7 or its individual components - CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol or their combination.
- Fig. 36E shows ImageJ quantification of IL8 from Fig. 36D.
- Described herein is a method for decreasing the expression of ACE2 and decreasing the levels of cytokine storm and inflammation, but is not limited to the steps of: 1) preparation of new cannabis extracts, 2) exposing normal and disease oral, lung and intestinal models to novel extracts and 3) modulating the gene expression and protein levels to cause a reduction of a disease state, or prevent an increase in the disease state in the body tissues, such as oral cavity tissues, lung tissues and intestinal tissues.
- the present invention provides extracts of twenty nine new C. sativa lines (#1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114, #115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317) ( see Table 1).
- the present invention further combines use of extracts of these lines, as well as combination of single cannabinoids and terpenes.
- ACE2- inhibitory potential of these lines in oral tissues may be used to develop modalities to prevent SARS-CoV2 entry via oral and nasopharyngeal epithelial cells.
- ACE2-inhibitory potential of these lines in lung epithelial tissues may be used to develop modalities to prevent SARS-CoV2 entry via airway cells as well as to treat COVID-19.
- ACE2 protein in the Epilntestinal tissues (Fig. 5A), and affected the levels of PARP-1 (Fig. 5C), iNOS, (Fig. 5C), as well as inhibited pro -inflammatory gene induction by TNFa/IFNy (Fig. 5B).
- ACE2-inhibitory and anti-inflammatory potential of these lines in intestinal epithelial tissues may be used to develop modalities to prevent SARS-CoV2 entry via intestinal cells as well as to treat COVID-19.
- a method for COVID-19 prevention and treatment via affecting the levels of SARS-CoV2 receptor ACE2 in the oral and nasopharyngeal, lung and intestinal epithelial tissues that includes the steps of exposing a patient to novel cannabis extracts, resulting in a reduction in the disease incidence and manifestation in the patient.
- extracts of new cannabis lines are applied to a human patient. In other embodiments, they may be applied to human oral tissue, artificial human oral tissue, or even animal oral tissue to modulate gene expression leading to a reduction, or at least prevent an increase in a disease state.
- ACE2 pro-inflammatory genes
- pro-inflammatory genes ABR, ACP5, ACVR1, ADA, ADORA1, ADORA2A, ADORA2B, AGER, AGTR2, AHCY, AKT1, ALOX5, APOA2, ASH1L, ASS1, ATM, AXL, B4GALT1, BACE2, BAP1, BCR, BDKRB1, BMP6, BMPR1B, BTK, C1QTNF12, C3, C5orf30, C6, CALCA, CALCRL, CCL11, CCL24, CCR4, CD28, CD40, CD96, CDK19, CELA1, CLOCK, CNR1, CNR2, CXCR2, CYP19A1, CYP26B1, CYSLTR1, DROSHA, DUOXA1, DUOXA2, DUSP10, ECM1, EDNRB, EGFR, EIF2AK1, ELANE, EPHA2, EPO, ESR1, ETS1, FABP4, F
- sequence identity or “identity” in the context of two nucleic acid or protein sequences makes reference to a specified percentage of residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window, as measured by sequence comparison algorithms or by visual inspection.
- percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule.
- sequences differ in conservative substitutions the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution.
- Sequences that differ by such conservative substitutions are said to have “sequence similarity” or “similarity.” Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif.).
- substantially identical of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 94%, or even at least 95%, 96%, 97%, 98%, or 99% sequence identity, compared to a reference sequence using one of the alignment programs described using standard parameters.
- nucleotide sequences are substantially identical if two molecules hybridize to each other under stringent conditions.
- stringent conditions are selected to be about 5° C lower than the thermal melting point (T m ) for the specific sequence at a defined ionic strength and pH.
- T m thermal melting point
- stringent conditions encompass temperatures in the range of about 1° C to about 20° C, depending upon the desired degree of stringency as otherwise qualified herein.
- Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.
- One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.
- substantially identical in the context of a peptide indicates that a peptide comprises a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 94%, or even 95%, 96%, 97%, 98% or 99%, sequence identity to the reference sequence over a specified comparison window.
- optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch (Needleman and Wunsch, JMB, 48, 443 (1970)).
- nucleic acid molecules and peptides that are substantially identical to the nucleic acid molecules and peptides presented herein.
- sequence comparison typically one sequence acts as a reference sequence to which test sequences are compared.
- test and reference sequences are input into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated.
- sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
- new extracts may modulate genes and proteins sharing a sequence identity or substantial sequence identity to those genes and proteins listed herein.
- cannabinoids and new extracts may affect key processes of the viral life cycle - reverse transcription, replication, and other ones (Figs. 8A-8F).
- cannabis extracts including but not limited to #1, #5, #7, #10, #169 and #317, are more potent than CBD alone in downregulation of COX2 and upregulation of SOCS3 in two different models, intestinal epithelial cells (HSIEC) and lung fibroblast cells (WI-38) (Fig. 12).
- HSIEC intestinal epithelial cells
- WI-38 lung fibroblast cells
- Top performing extracts such as #1, #5, #7 and #169 were further found to substantially downregulate the expression of IL-6, IL-8 and COX-2 on both mRNA and protein levels in both models, HSIEC and WI-38 (Fig. 13-14).
- Extracts #317, #129 and #98 also more substantially inhibited ACE2 expression as compared to CBD alone (Fig. 15).
- Extracts #1 and #5 demonstrated time-dependent decrease in TNF/IFN- induced expression of IL-6 and IL-8 (Fig. 16). Dose-dependent decrease in ACE2 expression in response to extracts #1 and #5 was also observed (Fig. 17).
- TMPRSS2 is a serine protease essential for activation of recognition of SARS-COV-2, namely by priming the viral spike protein to allow viral entry into the target cell.
- Top extracts (#1, #5 and #7) were common in the composition of cannabinoids (CBD-dominant) and terpenes and were enriched in caryophyllene, myrcene, pinene, bisabolol, humulene and valencene. Therefore, the contribution of each terpene on ACE2 and TMPRSS2 expression was tested (Fig. 23A-C). Caryophyllene demonstrated comparable to CBD effect on downregulation of ACE2 and TMPRSS2, with higher concentrations being more efficient. It was further found that combination of CBD with caryophyllene results in potentiation of the effect of CBD on ACE2 and TMPRSS2 in WI-38 cells (Fig.
- Fig. 24A-C Effect of a-pinene was less obvious, although synergistic effect of CBD and 10 pg/rnl pinene on ACE2 and TMPRSS2 expression was evident in WI-38 cells (Fig. 25A-C) and on TMPRSS2 in HSIEC cells (Fig. 26A-C). Bisabolol also downregulated ACE2 and TMPRSS2 expression in WI-38 cells, more prominent at lower concentration; no synergistic effect was observed (Fig. 27A-C). Bisbolol alone did not decrease the expression of ACE2 and TMPRSS2 expression in HSIEC cells, but synergistic effect on ACE2 expression was apparent (Fig.
- Humulene decreased the expression of ACE2 in WI-38 cells, but without synergistic effect; no effect on TMPRSS2 was observed (Fig. 29A-C). Humulene alone did not have any effect on ACE2 expression in HSIEC cells, but showed synergistic effect with CBD (Fig. 30A-C). Valencene decreased the expression of ACE2 in WI-38 cells, but without synergistic effect; no effect of valencene alone on TMPRSS2 was observed, but synergistic effect at low concentration was evident (Fig. 31A-C). In HSIEC cells, valencene decreased expression of ACE2 with synergistic effect with CBD (Fig. 32A-C).
- Extract Preparation 3 g of the powdered plant tissue were weighed using an analytical balance Plant material was placed inside a 250 mL Erlenmeyer flask (clean). 100 mL of Ethyl Acetate was poured into the flask containing the plant material. The flasks were then wrapped with tin foil and shaken continuously (120 rpm) in an incubator @ 21°C overnight and in the dark.
- the stocks were prepared weighing a 3-6 mg of crude extract into a micro centrifuge tube.
- the crude extract was dissolved in DMSO (Dimethyl sulfoxide anhydrous from Life technologies cat # D 12345) to reach 60 mg/mL final concentration and stored at -20°C.
- DMSO Dimethyl sulfoxide anhydrous from Life technologies cat # D 12345
- Appropriate cell culture media in our experiments RPMI 1640 medium supplemented with 10% FBS or EMEM medium supplemented with 10% FBS) were used to dilute the 60mg/mL stock. The stocks are allowed to thaw then added to the cell culture media, mixed thoroughly to ensure they are in solution and filtered through a 0.22 pm syringe filter. These filtrates were ready to be applied to cells and tested.
- Terpenes were purchased from True Terpenes (www.trueterpenes.com) and were diluted to the assay concentrations using DMSO or media.
- CBD, THC and CBN were purchased from MilliporeSigma (Sigma- Aldrich) and were diluted to the assay concentrations using DMSO or media.
- a 2 pL injection volume was used for all calibration standards (THC, CBD, THC-A, CBD-A, CBG, CBG-A, all Sigma- Aldrich) and sample analysis. The compound peaks were detected for 230 nm and 280 nm.
- Mobile phases consisted of 50 mM ammonium formate (pH 5.19) (Sigma - Aldrich) in HPLC grade water (Lisher Chemical) on the A side and 100% methanol (Lisher Chemical) on the B side, with a flow rate 0.3 ml/min. Two samples per cultivar were analyzed, with two technical repeats per each sample.
- EpiAirway (AIR-100) tissues Mattek’s Epi Airway tissue model is a human 3D mucociliary tissue model that consists of normal, human-derived tracheal/bronchial epithelial cells, is cultured at the air-liquid interface and fully recapitulates the barrier, mucociliary responses, infection, toxicity responses of human airway tissues in vivo.
- EpiAirwayFT (AFT-100) tissues EpiAirway FT is a ready-to-use, 3D mucociliary tissue model consisting of normal, human-derived tracheal/bronchial epithelial cells and normal human stromal fibroblasts (Mattek Life Sciences, MA). H&E-stained section of EpiAirwayFT tissue (courtesy of Mattek) exhibits a pseudostratified epithelium with ciliated cells and an extracellular matrix containing fibroblasts on a microporous membrane.
- EpiOral (ORL-20) tissues MatTek’s EpiOral tissues consist of normal, human-derived oral epithelial cells. The cells have been cultured to form multilayered, highly differentiated models of the human buccal (EpiOral) phenotypes. The tissues are cultured on specially prepared cell culture inserts using serum free medium and attain levels of differentiation on the cutting edge of in vitro cell culture technology. The EpiOral tissue models exhibit in vivo-like morphological and growth characteristics which are uniform and highly reproducible.
- Epilntestinal (SMI-100) tissues are 3D highly differentiated tissue models produced from normal, human cell-derived small intestine epithelial and endothelial cells and fibroblasts. Grown at the air-liquid interface, Epilntestinal tissue models are similar to in vivo human epithelial tissues and exhibit columnar shaped basal cells and Kerckring folds, as well as brush borders, functional tight junctions and mucous secreting granules.
- Human normal foreskin fibroblasts (BJ-5ta), purchased from American Type Culture Collection (ATCC, Manassas, USA), were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S).
- DMEM Modified Eagle’s Medium
- FBS fetal bovine serum
- P/S penicillin/streptomycin
- Human primary small intestinal epithelial cells (HSIEC), purchased from Cell Biologies, were cultured in Epithelial Cell Medium /w Kit supplemented with 1% P/S.
- Human lung fibroblasts (WI-38), purchased from ATCC, were cultured in EMEM supplemented with 10% FBS and 1% P/S. All cell lines were incubated at 37°C in a humidified atmosphere of 5% CO2.
- tissues or cells were equilibrated for 24 h, after equilibration tissues were treated with 10 ng/mL TNFa /IFNy alone or in combination with 5-30 mM CBD, 5-30 mM CBN, 5-30 mM THC, or different concentrations of extracts for various time.
- cells were treated either with CBD alone, terpenes alone or in combination of CBD with terpenes.
- HSIEC and WI-38 cells grown to 70% confluency were exposed to either 10 ng/ml TNFa/IFNy or in combination with extracts #1 or #5 or #7 or #169 for 48 h, 1% DMSO served as a control; HSIEC and WI-38 cells grown to 80% confluency were treated with either 10 ng/ml TNFa/IFNy or in combination with extracts #1 or #5 for an indicated time-course, 1% DMSO served as a control; HSIEC cells grown to 70% confluency were exposed to either 10 ng/ml TNFa/IFNy or in combination with a range of doses of extracts #1 or #5 for 48 h, 1% DMSO served as a control; at the indicated time-point after treatment, total RNA was isolated using TRIzol RNA isolation reagent (ThermoFisher Scientific) and subjected to qRT-PCR analysis with iScript Select cDNA Synthesis kit (Bio-Rad) and SsoF
- Tissues were harvested and solubilized in laboratory-prepared 1% sodium dodecyl sulfate (SDS) lysis buffer (BioUltraPure, Bioshop) by sonication using a Braunsonic model 1510 sonicator (B. Braun Germany) operating at 80% sonication intensity. Lysates were centrifuged at 15,000 rpm for 10 min and the supernatant was decanted for use. Protein concentrations were determined using the Bradford protein assay with bovine serum albumin as the standard protein using the Nanodrop 2000c spectrophotometer (v. 1.5). Total proteins were separated by electrophoresis on 10- 12% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE).
- SDS sodium dodecyl sulfate
- PVDF polyvinyl difluoride
- the membranes were incubated for one hour in a blocking solution (5% dry skimmed milk in PBS, 0.5% Tween 20) at room temperature, and incubated with specific primary antibodies at 4°C overnight with 1:200 to 1:1,000 dilution of polyclonal/monoclonal antibodies against cannabinoid receptor 1 (CB1), cannabinoid receptor 2 (CB2) (all from Abeam, Cambridge, UK) or GPR18 (from LSBio, Seattle, USA) or CDK2, cyclin El, E2F1, ERK1/2, pERKl/2, PFKFB3 (all from Cell Signaling, Danvers, USA) or AKT1, p53, pAKTl/2/3 (all from Santa Cruz Biotechnology, Dallas, USA), IL-6, IL-8, COX-2, ACE2, TMPRSS2 (Ab
- compositions of the present invention may be provided in any suitable dosage form.
- the dosage form is an oral dosage form.
- Oral dosage forms comprise liquids (solutions, suspensions, and emulsions), semi-solids (pastes), and solids (tablets, capsules, powders, granules, premixes, and medicated blocks).
- oral dosage forms in the art include, W090/04391, which discloses an oral dosage form of omega-3 polyunsaturated acids to overcome the problems of diseases. It is known to supply said acids in soft gelatine capsule shells.
- EP 2 240 581 B1 discloses a gelatine capsule for pharmaceutical use with a controlled release of active ingredients and a process for the preparation of said gelatine capsules. During said process xylose is added to the liquid gelatine from which afterwards gelatine capsules are formed. Gelatine capsules manufactured according to the process provide retarded release of active ingredients.
- US Patent No. 7,264,824 discloses and oral dosage form for food and food supplements, as well as dietetics comprising polyunsaturated acids in a xylose- hardened gelatine capsule with a retarded release time.
- compositions described herein may be in a suspension or emulsion.
- a suspension is a coarse dispersion of insoluble drug particles, generally with a diameter exceeding 1 pm, in a liquid (usually aqueous) medium.
- Suspensions are useful for administering insoluble or poorly soluble drugs/components or in situations when the presence of a finely divided form of the material in the GI tract is required.
- the taste of most drugs is less noticeable in suspension than in solution, due to the drug being less soluble in suspension.
- Particle size is an important determinant of the dissolution rate and bioavailability of drugs in suspension.
- suspensions include surfactants and thickening agents. Surfactants wet the solid particles, thereby ensuring the particles disperse readily throughout the liquid. Thickening agents reduce the rate at which particles settle to the bottom of the container. Some settling is acceptable, provided the sediment can be readily dispersed when the container is shaken. Because hard masses of sediment do not satisfy this criterion, caking of suspensions is not acceptable.
- An emulsion is a system consisting of 2 immiscible liquid phases, one of which is dispersed throughout the other in the form of fine droplets; droplet diameter generally ranges from 0.1-100 pm.
- the 2 phases of an emulsion are known as the dispersed phase and the continuous phase.
- Emulsions are inherently unstable and are stabilized through the use of an emulsifying agent, which prevents coalescence of the dispersed droplets. Creaming, as occurs with milk, also occurs with pharmaceutical emulsions. However, it is not a serious problem because a uniform dispersion returns upon shaking. Creaming is, nonetheless, undesirable because it is associated with an increased likelihood of the droplets coalescing and the emulsion breaking.
- Other additives include buffers, antioxidants, and preservatives.
- Emulsions for oral administration are usually oil (the active ingredient) in water, and facilitate the administration of oily substances such as castor oil or liquid paraffin in a more palatable form.
- a paste is a 2-component semi-solid in which drug is dispersed as a powder in an aqueous or fatty base.
- the particle size of the active ingredient in pastes can be as large as 100 pm.
- the vehicle containing the drug may be water; a polyhydroxy liquid such as glycerin, propylene glycol, or polyethylene glycol; a vegetable oil; or a mineral oil.
- Other formulation excipients include thickening agents, co solvents, adsorbents, humectants, and preservatives.
- the thickening agent may be a naturally occurring material such as acacia or tragacanth, or a synthetic or chemically modified derivative such as xanthum gum or hydroxypropylmethyl cellulose.
- the degree of cohesiveness, plasticity, and syringeability of pastes is attributed to the thickening agent. It may be necessary to include a cosolvent to increase the solubility of the drug. Syneresis of pastes is a form of instability in which the solid and liquid components of the formulation separate over time; it is prevented by including an adsorbent such as microcrystalline cellulose. A humectant (eg, glycerin or propylene glycol) is used to prevent the paste that collects at the nozzle of the dispenser from forming a hard crust. Microbial growth in the formulation is inhibited using a preservative. It is critical that pastes have a pleasant taste or are tasteless.
- a tablet consists of one or more active ingredients and numerous excipients and may be a conventional tablet that is swallowed whole, a chewable tablet, or a modified-release tablet (more commonly referred to as a modified-release bolus due to its large unit size).
- Conventional and chewable tablets are used to administer drugs to dogs and cats, whereas modified-release boluses are administered to cattle, sheep, and goats.
- the physical and chemical stability of tablets is generally better than that of liquid dosage forms.
- the main disadvantages of tablets are the bioavailability of poorly water-soluble drugs or poorly absorbed drugs, and the local irritation of the GI mucosa that some drugs may cause.
- a capsule is an oral dosage form usually made from gelatin and filled with an active ingredient and excipients.
- Two common capsule types are available: hard gelatin capsules for solid-fill formulations, and soft gelatin capsules for liquid-fill or semi-solid-fill formulations.
- Soft gelatin capsules are suitable for formulating poorly water-soluble drugs because they afford good drug release and absorption by the GI tract.
- Gelatin capsules are frequently more expensive than tablets but have some advantages. For example, particle size is rarely altered during capsule manufacture, and capsules mask the taste and odor of the active ingredient and protect photolabile ingredients.
- a powder is a formulation in which a drug powder is mixed with other powdered excipients to produce a final product for oral administration.
- Powders have better chemical stability than liquids and dissolve faster than tablets or capsules because disintegration is not an issue. This translates into faster absorption for those drugs characterized by dissolution rate-limited absorption. Unpleasant tastes can be more pronounced with powders than with other dosage forms and can be a particular concern with in-feed powders, in which it contributes to variable ingestion of the dose. Moreover, sick animals often eat less and are therefore not amenable to treatment with in-feed powder formulations.
- Drug powders are principally used prophylactically in feed, or formulated as a soluble powder for addition to drinking water or milk replacer. Powders have also been formulated with emulsifying agents to facilitate their administration as liquid drenches.
- a granule is a dosage form consisting of powder particles that have been aggregated to form a larger mass, usually 2-4 mm in diameter. Granulation overcomes segregation of the different particle sizes during storage and/or dose administration, the latter being a potential source of inaccurate dosing. Granules and powders generally behave similarly; however, granules must deaggregate prior to dissolution and absorption.
- a premix is a solid dosage form in which an active ingredient, such as a coccidiostat, production enhancer, or nutritional supplement, is formulated with excipients.
- Premix products are mixed homogeneously with feed at rates (when expressed on an active ingredient basis) that range from a few milligrams to -200 g/ton of food/beverage
- the density, particle size, and geometry of the premix particles should match as closely as possible those of the feed in which the premix will be incorporated to facilitate uniform mixing. Issues such as instability, electrostatic charge, and hygroscopicity must also be addressed.
- the excipients present in premix formulations include carriers, liquid binders, diluents, anti-caking agents, and anti dust agents.
- Carriers such as wheat middlings, soybean mill run, and rice hulls, bind active ingredients to their surfaces and are important in attaining uniform mixing of the active ingredient.
- a liquid binding agent such as a vegetable oil, should be included in the formulation whenever a carrier is used.
- Diluents increase the bulk of premix formulations, but unlike carriers, do not bind the active ingredients. Examples of diluents include ground limestone, dicalcium phosphate, dextrose, and kaolin.
- Caking in a premix formulation may be caused by hygroscopic ingredients and is addressed by adding small amounts of anti-caking agents such as calcium silicate, silicon dioxide, and hydrophobic starch.
- the dust associated with powdered premix formulations can have serious implications for both operator safety and economic losses, and is reduced by including a vegetable oil or light mineral oil in the formulation. An alternate approach to overcoming dust is to granulate the premix formulation.
- a medicated block is a compressed feed material that contains an active ingredient, such as a drug, anthelmintic, surfactant (for bloat prevention), or a nutritional supplement, and is commonly packaged in a cardboard box. Ruminants typically have free access to the medicated block over several days, and variable consumption may be problematic. This concern is addressed by ensuring the active ingredient is nontoxic, stable, palatable, and preferably of low solubility.
- excipients in the formulation modulate consumption by altering the palatability and/or the hardness of the medicated block. For example, molasses increases palatability and sodium chloride decreases it.
- a binder such as lignin sulfonate
- the hygroscopic nature of molasses in a formulation may also impact the hardness of medicated blocks and is addressed by using appropriate packaging.
- the composition of the present invention is in a chewable oral dosage form.
- the chewable oral dosage form is a chewable tablet.
- the chewable tablet of the invention is taken slowly by chewing or sucking in the mouth.
- the chewable tablet of the invention enables the dried cannabis extracts contained therein to be orally administered without drinking.
- the composition may comprise any suitable flavor or combination of flavors.
- composition may further comprise other additives, coloring, emulsifiers.
- flavors and additives may be of a natural, semi-synthetic, synthetic source or combinations thereof.
- the composition further comprises fructose, sorbitol, microcrystalline cellulose, magnesium stearate, or any combination thereof.
- the composition further comprises chamomile.
- the composition further comprises ginger.
- the composition further comprises peppermint.
- the composition further comprises anise.
- the composition further comprises fennel.
- the composition further comprises thyme.
- the composition further comprises Arsenicum album.
- the composition further comprises Carbo vegetabilis.
- the composition further comprises Ignatia, homeopathic ipecac.
- the composition further comprises Nux vomica.
- the composition further comprises Zingiber officinale.
- composition of the present invention is in the form of a chewing gum product.
- chewing gum compositions contemplated by the present invention comprise all types of sugar and sugarless chewing gums and chewing gum formulations known to those skilled in the art, including regular and bubble gum types.
- chewing gum compositions of the invention comprise a chewing gum base, a modifier, a bulking agent or sweetener, and one or more other additives such as, flavoring agents, colorants and antioxidants.
- the modifying agents are used to soften, plasticize and/or compatibilize one or more of the components of the gum base and/or of the formulation as a whole.
- the present invention provides a soft, chewable dosage form which is pliable and chewy, yet dissolves quickly in the mouth, has a long shelf life, contains little moisture which improves stability and decreases the tendency for the dosage form to dry out, does not require cooking or heating as part of the manufacturing process.
- the dosage form is used as a matrix for dried cannabis extracts.
- the chewable tablet of the invention comprises a metal salt such as calcium, magnesium, aluminum salt, or any mixture thereof.
- the chewable tablet of the invention comprises hydroxyalkyl cellulose.
- the chewable tablet of the invention comprises low viscosity hydroxyalkyl cellulose.
- the chewable tablet of the invention comprises high viscosity hydroxyalkyl cellulose.
- the chewable tablet of the invention comprises various additives. In another embodiment, the chewable tablet of the invention comprises sweeteners. In another embodiment, the chewable tablet of the invention comprises acidic ingredients. In another embodiment, the chewable tablet of the invention comprises taste correctives. In another embodiment, the chewable tablet of the invention comprises polymeric compounds. In another embodiment, the chewable tablet of the invention comprises essential oils.
- the chewable tablet of the invention is a soft tablet. In another embodiment, the chewable tablet of the invention is made in a state of soft candy. In another embodiment, the chewable tablet of the invention is made in a state of jelly.
- the chewable tablet of the invention comprises a core comprising the vitamins of the invention.
- the chewable tablet of the invention comprises an outer layer wrapping the core which is made up of chewable base such as a gum, a soft candy or a caramel.
- compositions of the present invention may be provided in any suitable food of a solid, semi- solid or liquid form.
- compositions that contain a dried cannabis extract for example by mixing, granulating, or tablet-forming processes, is well understood in the art.
- the dried cannabis extracts are often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient.
- the active ingredients of compositions of the present invention are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions.
- additional methods of administering the dried cannabis extracts, or compound(s) isolated therefrom, of the invention comprise injectable dosage forms.
- the injectable is administered intraperitoneally.
- the injectable is administered intramuscularly.
- the injectable is administered intra-dermally.
- the injectable is administered intravenously.
- the pharmaceutical compositions are administered by intravenous, intra-arterial, or intra-muscular injection of a liquid preparation.
- suitable liquid formulations include solutions, suspensions, dispersions, emulsions, oils and the like.
- the pharmaceutical compositions are administered intravenously and are thus formulated in a form suitable for intravenous administration.
- the pharmaceutical compositions are administered intra-arterially and are thus formulated in a form suitable for intra arterial administration.
- the pharmaceutical compositions are administered intra-muscularly and are thus formulated in a form suitable for intra muscular administration.
- additional methods of administering the dried cannabis extracts of the invention comprise dispersions, suspensions or emulsions.
- the dispersion, suspension or emulsion is administered orally.
- the solution is administered by infusion.
- the solution is a solution for inhalation.
- the pharmaceutical composition is administered as a suppository, for example a rectal suppository or a urethral suppository.
- the pharmaceutical composition is administered by subcutaneous implantation of a pellet.
- the pellet provides for controlled release of active compound agent over a period of time.
- pharmaceutically acceptable carriers for liquid formulations are aqueous or non-aqueous solutions, suspensions, emulsions or oils.
- non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- oils are those of animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil, another marine oil, or a lipid from milk or eggs. Each possibility represents a separate embodiment of the present invention.
- parenteral vehicles for subcutaneous, intravenous, intra-arterial, or intramuscular injection
- parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Examples are sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants.
- water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.
- oils are those of animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil, another marine oil, or a lipid from milk or eggs.
- the pharmaceutical compositions provided herein are controlled-release compositions, i.e. compositions in which the active compounds are released over a period of time after administration.
- Controlled- or sustained-release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils).
- the composition is an immediate -release composition, i.e. a composition in which all the active compound is released immediately after administration.
- each possibility represents a separate embodiment of the present invention.
- the pharmaceutical composition is delivered in a controlled release system.
- the agents are administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration.
- a pump is used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989).
- polymeric materials are used; e.g. in microspheres in or an implant.
- a controlled release system is placed in proximity to the therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984); and Langer R, Science 249: 1527-1533 (1990).
- a controlled release system is placed in proximity to the therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984); and Langer R, Science 249: 1527-1533 (1990).
- compositions also include, in another embodiment, incorporation of the active materials into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.)
- polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.
- particulate compositions coated with polymers e.g. poloxamers or poloxamines
- polymers e.g. poloxamers or poloxamines
- the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors are also included in the present invention.
- polymers e.g. poloxamers or poloxamines
- Also comprehended by the invention are compounds modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline.
- the modified compounds are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et ah, 1981; Newmark et ah, 1982; and Katre et ah, 1987).
- Such modifications also increase, in another embodiment, the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound.
- the desired in vivo biological activity is achieved by the administration of such polymer-compound abducts less frequently or in lower doses than with the unmodified compound.
- compositions of the present invention may comprise one or more additional components may further include an additional component selected from the group consisting of an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a diluent, a dye, an emollient, a fragrance, an occlusive agent, a pH- adjusting agent, a preservative, and a vitamin.
- an additional component selected from the group consisting of an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a diluent, a dye, an emollient, a fragrance, an occlusive agent, a pH- adjusting agent, a preservative, and a vitamin.
- compositions of the present invention may comprise one or more additional active agents, selected from the group consisting of active herbal extracts, analgesics, anti-allergic agents, anti-aging agents, anti-bacterials, antibiotic agents, anticancer agents, antidandruff agents, antidepressants, anti-dermatitis agents, anti- edemics, antihistamines, anti-helminths, anti-hyperkeratolyte agents, anti inflammatory agents, anti-irritants, anti-microbials, anti-mycotic s, anti-proliferative agents, antioxidants, anti-wrinkle agents, anti-pruritic s, antiseptic agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, keratolytic agents, lactams, metals, metal oxide
- the composition may comprise one or more anti-oxidants/radical scavengers.
- the anti-oxidant/radical scavenger may be selected from butylated hydroxy benzoic acids and their salts, coenzyme Q10, coenzyme A, gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N- diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and its salts, lycine pidolate, arginine pilolate, nordihydroguaiaretic acid, bioflavonoids, curcumin, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts, grape skin/seed extracts, melanin
- the term “treating” refers to curing a disease. In another embodiment, “treating” refers to preventing a disease. In another embodiment, “treating” refers to reducing the incidence of a disease. In another embodiment,
- treating refers to ameliorating symptoms of a disease.
- treating refers to ameliorating symptoms of a disease.
- treating refers to inducing remission. In another embodiment, “treating” refers to slowing the progression of a disease.
Abstract
The present invention provides Cannabis Sativa (hemp and cannabis) lines, extracts and methods of their use to reduce the levels of ACE2 receptors in oral, lung and intestinal epithelial tissues thereby preventing entry of SARS-CoV-2 and related viruses to mammalian subjects and further treating or preventing cytokine storms, which precede and underlie acute respiratory distress syndrome (ARDS) in COVID- 19 and other diseases and affect viral life cycle processes.
Description
CANNABIS SATIVA (HEMP AND CANNABIS) PRODUCTS FOR VIRAL DISEASE PREVENTION AND MANAGEMENT
FIELD OF THE INVENTION
The present invention relates generally to cannabis and hemp plant products and methods of their production, as well as in production of medicaments for preventing and treating viral diseases, such as COVID-19.
BACKGROUND OF THE INVENTION
There are many viral diseases for which there is no known or approved medicament. There is currently a Corona vims (SARS-CoV-2) pandemic causing the COVID-19 disease. Moreover, as the pandemic spreads around the world, new mutants are discovered. The limited published data on this virus suggests that it spreads easily and has human-human transmission, with a 2-5% death rate. Up to 20% of the COVID-19 disease cases are serious, requiring hospitalization and supplementary oxygen. Around 5% of COVID-19 patients require intensive care. The basic replication number, Ro, of SARS-CoV-2 is thought to be around 2-6 [Zhao, S., et al, 2020], meaning that each infected individual, some of whom are asymptomatic infect 2-6 other people, if no interventions are taken.
SARS-CoV-2 shares 82% sequence identity with severe acute respiratory syndrome -related coronavirus (SARS-CoV). SARS-CoV relies on its spike protein to bind a host cell surface receptor for entry. For the SARS-CoV-2, research has shown that this receptor is the angiotensin-converting enzyme 2 (ACE2).
Both SARS-CoV-2 and SARS-CoV encode a large spike protein (2019-nCoV: 1253 aa; SARS-CoV: 1273 aa). The sequence identity of this protein between the two viruses is 76%. The spike protein has three regions, SI, S2, and S3. Receptor binding domain (RBD) of spike protein in SARS-CoV is majorly in SI and S2. SI region in the RBD from the two viral origins shows 73.5% sequence identity but S2 RBD is almost complete different in SARS-CoV-2 and SARS-CoV. This might affect binding of SARS-CoV-2 to ACE2 as compared to SARS-CoV. Recent studies relating to SARS-CoV-2 RBD-ACE2 crystal structure concluded that changes in RBD of SARS- CoV-2 suggest evolution from SARS-CoV. Now it is well established that ACE2
binding of SARS-CoV-2 is significantly higher than SARS-CoV and it is the main route for receptor-mediated entry of the vims into the human host.
ACE2 is expressed in upper respiratory tract, lung, liver, intestine and kidney tissues in humans. Once SARS-CoV-2 enters the host via suggested major routes above, it further increases ACE2 expression.
Upon SARS-CoV-2 infection, lungs and upper respiratory tract showed very high ACE2 expression. High expression of ACE2 was related to innate and acquired immune response, cytokine secretion, and enhanced the inflammatory response. Neutrophils were significantly higher in infected patients as compared to healthy and IL1B, IL1RA, IL7, IL8, IL9, IL10 levels were very high as well. A clinical study in Wuhan pointed that the levels of IL-1B, IL-10 and IL-8 were significantly increased in critically ill patients with new coronavims SARS-CoV-2 infection, indicating that there were cytokine-mediated inflammatory responses in patients with new coronavims infection.
Higher ACE2 expression after SARS-CoV-2 infection is correlated with increased cytokine levels in the patients. Key aspects of the COVID-19 disease pathogenesis include hyperinduction of proinflammatory cytokine production, which is also known as ‘cytokine storm' and acute respiratory distress syndrome (ARDS) [Li, 2020, Channappanavar et ah, 2020]. High concentrations of cytokines were recorded in plasma of critically ill patients infected with SARS-CoV-2 [Huang, et ah, 2019, Guo et al, 2019]. It was noted that patients infected with SARS-CoV-2 had high amounts of interleukin (IL) IL-1, IL-2, IL- 4, IL-7, IL-10, IL-12, IL-13, IL-17, GCSF, macrophage colony-stimulating factor (MCSF), IP- 10, MCP-1, MIP-la, hepatocyte growth factor (HGF), IFN-g and TNF-a, probably leading to activated T- helper-1 (Thl) cell responses [Guo et al., 2019].
In the severe patients, levels of IL-6, IL-10, and TNF-a further increased[ Guo, et al., 2019]. ICU patients also had high plasma levels of IL-2, IL-7, granulocyte colony- stimulating factor (GCSF). Furthermore, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, IL-6, IL-10, TNFa and other cytokines than did those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity [Huang, et al., 2019, Guo et al, 2019].
Moreover, TNFa is one of the key cytokines in the cytokine storm and is likely to responsible for the escalation in severity [Liu et al., 2016]. Along with
TNFa, IL-6 [Tanaka et al., 2016], IL-1 and others are key mediators of the cytokine storm [Tisoncik et al., 2012]. As appearing chronologically, a cytokine storm manifests before the ARDS in COVID-19 patients and the cytokine storm constitutes one of the ARDS underlying mechanisms. There thus remains an unmet need to provide a product or pharmaceutical composition effective in treating viral diseases in mammals, including humans and non-human mammals, which spread the disease. Moreover, there is an urgent unmet need to provide a product or pharmaceutical composition effective in treating corona viral diseases. Additionally, there is an urgent unmet need to provide a product or pharmaceutical composition effective in treating SARS-CoV-2 (COVID-19) viral disease and mutants thereof in human subjects.
Additionally, it would be highly advantageous to provide anti-inflammatory therapies either prophylactically or to prevent a worsening of the underlying disease progression. Currently, anti-IL-6 receptor antibody, tocilizumab, is being evaluated as a potential cytokine storm therapy [Tanaka et al., 2016]. However, potentially effective, biologies have significant side effects and are extremely expensive. Thus, there is an urgent need for new, effective, minimally invasive, easy to use, and have no systemic side effects that can inhibit cytokine storm.
SUMMARY OF THE INVENTION
It is an object of some aspects of the present invention, to provide improved methods and products for preventing, treating, improving and curing viral diseases, including SARS-CoV2 as well as other corona virus-caused diseases in mammalian subjects.
It is an object of some aspects of the present invention to provide compositions for improving wellness in a human or non-human mammalian organism.
It is another object of some aspects of the present invention to provide compositions for preventing or treating diseases or disorders in a human or non human mammalian organism.
It is another object of some aspects of the present invention to provide compositions for preventing, mitigating or treating viral diseases or disorders in a human or non-human mammalian organism.
It is another object of some aspects of the present invention to provide compositions for preventing, mitigating or treating pathogenic coronavims diseases or disorders in a human or non-human mammalian organism.
The present invention provides products and compositions used in reducing levels of an ACE2 receptor in oral, lung and intestinal epithelial tissues in COVID-19 patients to prevent entry thereto of the SARS-CoV-2 RNA virus and related viruses. Products of the present invention are used further to treat a cytokine storm that precedes and underlies acute respiratory distress syndrome (ARDS), seen in the COVID-19 patients.
The method includes generation of unique lines, whole plant extract preparation, treating normal EpiOral, Epilntestinal and EpiAirway human 3D tissues and human cell lines with tumor necrosis factor alpha (TNF) to induce inflammation, and then with extracts in an amount sufficient to profoundly down-regulate ACE2 expression, inflammation and molecular pathways involved in ACE2 regulation, vims entry and inflammation in the oral, intestinal and airway tissues. The modulation of these pathways is a key to prevention and treatment success in COVID-19. Extracts of novel cannabis and hemp lines can be combined with anti-viral agents and anti inflammatory extracts of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics to increase their efficacy.
The present invention provides methods of production of pharmaceutical compositions, suitable for treating viral diseases in mammalian subjects.
The present invention provides pharmaceutical compositions, suitable for treating viral diseases in mammalian subjects.
The present invention provides methods for preventing, mitigating and treating cytokine storms in in COVID-19 patients by administration of C. sativa extracts, which exhibit profound cytokine inhibition patterns.
The present invention further provides methods and products for ACE2 inhibition in target tissues - lung, oral and intestinal epithelia, thereby decreasing or inhibiting a SARS-CoV-2 infection in a mammalian patient.
The present invention further provides combination therapies including a combination of anti- viral (anti-SARS-CoV-2) and anti-cytokine agents will be an effective regimen targeting both etiology and pathogenesis of COVID-19.
The present invention provides new Cannabis sativa lines and extracts as well as combination of single cannabinoids and terpenes and method of using them as a means to modulate ACE2 expression in oral, lung or intestinal tissues. The present invention also provides methods of modulating ACE2 expression through the application cannabis extracts to the oral, lung and intestinal tissues to prevent or treat COVID-19 and other SARS-CoV virus-caused diseases.
Accordingly, the present invention provides a method for modulating ACE2 expression on mRNA and protein levels (e.g., in oral, lung and intestinal tissues and cells) by providing a source of new Cannabis sativa (hemp and cannabis) extracts, exposing oral cells or oral epithelial tissue, lung cell or lung epithelial tissue, intestinal cells of intestinal epithelial tissue to those in an amount sufficient to modulate gene expression where modulation of ACE2 expression results in a prevention of disease via decreased opportunity of virus entry into the cells.
The present invention also provides new Cannabis sativa lines and extracts and as well as combinations of single cannabinoids and terpenes, and methods of using them as a means to modulate cytokine levels and cytokine storm in lung tissues.
Extracts of novel cannabis and hemp lines or single cannabinoids and terpenes are combined with anti-viral agents and anti-inflammatory, such as, but not limited to, extracts of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics, to increase their efficacy.
Accordingly, the disclosure provides a means for modulating gene expression and protein levels (e.g., in oral, lung and intestinal tissues and cells) by providing a source of new Cannabis sativa (hemp and cannabis) extracts, exposing oral cells or oral epithelial tissue, lung cell or lung epithelial tissue, intestinal cells of intestinal epithelial tissue to those in an amount sufficient to modulate gene expression where modulation of gene expression results in a prevention of disease or reduction of a disease state in the aforementioned tissues.
The present invention provides extracts of twenty nine new C. sativa lines (#1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114, #115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317). The present invention further combines use of extracts of these lines, as well as combination of single cannabinoids and terpenes. The aforementioned extracts, single cannabinoids and terpenes have been tested for anti-inflammatory properties and/or ACE2 inhibition properties using human cells lines and 3D EpiOral, Epilntestinal and EpiAirway tissue models. This is performed by detecting the expression of genes that are associated with molecular etiology and pathogenesis of COVID-19 and ARDS and cytokine storms.
The present invention provides compositions having potent therapeutic ACE2 inhibitory effects in oral, intestinal and airway tissues and thus for treatment and prevention of COVID-19 and ARDS and cytokine storm.
The present invention provides new Cannabis sativa lines and extracts as well as combination of single cannabinoids and terpenes and method of using them as a means to modulate ACE2 gene expression in oral, lung and intestinal tissues. The present invention also provides methods of modulating gene expression through the application of cannabis extracts to the mouth, airways and intestine affected by SARS-CoV-2 and other diseases and viruses.
The present invention further provides extracts for treating and preventing viral diseases, including SARS-CoV-2 virus and resultant COVID-19, as well as other viral diseases and ARDS. The Cannabis sativa extract efficacy can further be increased by adding thereto additional Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), terpenes or combinations thereof.
The extract efficacy can be further potentiated and increased by adding anti inflammatory herbs such as but not limited to chamomile, sage, turmeric, thyme,
ginger, rosehip, as well as probiotics and their components, or combinations thereof.
The present invention provided the methods of preparation of Cannabis extracts, cannabinoids, such as but not limited to, Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), D 9 - 1 c t a h y d o c a n n a b i n o 1 (THC), and terpenes. These extracts and products are adapted to affect key molecular processes required for a virus life cycle, such as reverse transcription, transcription, viral replication, and by doing so, these exhibit anti-viral activity.
The present invention provides new unique cannabis lines, extracts and methods for oral, lung and intestinal improvement and healing and reduction in virus entry into the cells and inflammation. The method includes generation of unique lines, whole plant extract preparation, exposing human oral, lung and intestinal tissues to the extracts in amount sufficient to modulate gene expression in them. The modulation of gene expression then results in a reduction of the disease state- associated changes or aspects thereof in the cannabis -treated tissues.
In some embodiments of the present invention, improved methods and products are provided for oral application and treatment to prevent viral infection.
In some embodiments of the present invention, improved methods and products are provided for oral treatment.
In other embodiments of the present invention, a method and product is described for improving oral health.
In some embodiments of the present invention, improved methods and products are provided for airway application and treatment to prevent viral infection, COVID-19 and acute respiratory distress syndrome.
In other embodiments of the present invention, a method and product is described for improving lung health.
In some embodiments of the present invention, improved methods and products are provided for treatment of viral infection and/or associated diseases.
In some embodiments of the present invention, improved methods and products are provided for intestinal application and treatment to prevent SARS-CoV- 2 viral infection and/or COVID-19 disease.
In other embodiments of the present invention, a method and product is described for improving intestinal health.
In additional embodiments for the present invention, new Cannabis sativa
lines are provided.
In additional embodiments for the present invention, new extracts from new Cannabis sativa lines are provided.
Accordingly, the present invention provides a method for modulating gene expression on mRNA and protein levels (e.g., in oral cells, in oral tissue, in lung cells, in lung tissue, in intestinal cells, in intestinal tissue) by providing a source of new extracts, exposing cells or tissue to those in an amount sufficient to modulate gene expression where modulation of gene expression results in a prevention and reduction of a disease state in the in oral, lung and intestinal cells and tissue.
The present invention provides new unique cannabis lines, extracts, dried powders from the extracts, compositions comprising the powders or parts thereof, compounds derived therefrom, pharmaceutical compositions comprising the compound(s), and methods for the treatment of COVID-19, viral diseases, ARDS, cytokine storms, others and combinations thereof.
The method includes generation of unique lines, whole plant extract preparation, treating human 3D oral, airway and intestinal tissues with extracts in amount sufficient to modulate gene expression in the said tissues. The modulation of Angiotensin-converting enzyme 2 gene (ACE2) expression and inflammatory gene expression then results in a reduction of the disease state-associated changes or aspects thereof in the treated tissues.
The compositions and dosage forms of the present invention are useful in promoting health and preventing or treating a large number of disorders in human patients and other mammalian subjects.
In additional embodiments of the present invention, compositions and methods are provided for treating and/or preventing viral disorders.
Further, the invention provides methods and compositions for preventing ARDS and other diseases that harbor an inflammatory component.
Further, the invention provides methods and compositions for preventing systemic diseases and complications related to virus-caused pathologies.
The compositions of the present invention may be used for improving wellness of a human or mammalian subject. Additionally, the compositions of the present invention may be used to treat any disorder or ailment in a human patient or mammalian subject. Furthermore, the compositions of the present invention may be
conveniently used in conjunction with a drug to treat any disorder or ailment in a human patient or mammalian subject.
Some embodiments of the present invention provide compounds, compositions and formulations from at least one of hemp and cannabis.
In additional embodiments of the present invention, compositions and methods are provided for treating and/or preventing viral, inflammatory and fibrosis-related disorders.
In additional embodiments of the present invention, compositions and methods are provided for treating and/or preventing pneumonia and ARDS, and other disorders.
In additional embodiments of the present invention, compositions and methods are provided for inhibiting viral life cycle processes thereby treating and/or preventing viral disorders.
Some embodiments of the present invention provide compounds, compositions and formulations from at least one of hemp and cannabis.
Some further embodiments of the present invention provide methods for downregulating expression of ACE2 gene.
Some further embodiments of the present invention provide methods for downregulating expression of at least one inflammatory pathway gene.
Some further embodiments of the present invention provide methods for downregulating expression of at least TNF gene.
Some further embodiments of the present invention provide methods for downregulating expression of at least IL gene.
Some further embodiments of the present invention provide methods for downregulating expression of at least PARP-1 gene.
Some further embodiments of the present invention provide methods for downregulating expression of at least iNOS gene.
Some further embodiments of the present invention provide methods for downregulating at least one inflammatory pathway gene product.
In particular, there are described methods for preparing compositions, compounds, formulations and extracts for preventing viral diseases in a human patient.
In particular, there are described methods for preparing compositions,
compounds, formulations and extracts for treating viral diseases in a human patient.
Further embodiments of the present invention provide use of a solvent extract from at least one of hemp and cannabis, for the manufacture of a pharmaceutical composition for the treatment of a viral disease or disorder.
A use of a solvent extract from at least one of hemp and cannabis, according to some embodiments of the present invention, is for the manufacture of a pharmaceutical composition for the prevention and treatment of ARDS.
Some embodiments of the present invention are directed to a method for preventing and treating a viral disease or disorder in a human patient comprising administering to said patient a pharmaceutically effective amount of the cannabis extract composition as described herein.
Additionally, some further embodiments of the present invention are directed to a method for preventing and treating a viral disorder or disease or complication of those in a human patient comprising administering to said patient the oral, inhalation or topical dosage form as described herein.
The liquid cannabis extracts of the present invention, and/or dry powders therefrom, are suitable for oral administration, and appear to be well absorbed through the intestine by the blood and thus exhibit the potential to heal a wide range of viral and inflammatory conditions, such as, but not limited to those mentioned by Chattopadhyay et al. Current Science 87(1) July 2004, 44-53.
According to some embodiments of the present invention, the composition or formulation further comprises at least one solvent or hydrant. In some cases, the hydrant is water, such as double-distilled water. In some cases, it may be at least one organic solvent, such as alcohol.
According to some embodiments of the present invention, the at least one solvent or hydrant is present in the composition or formulation in a concentration of 10-90%, 15-80%, 20-70%, 25-50%, 30-40%, or 10-18% by weight percent.
The solvent or hydrant may further comprise a pH regulator, such as an acid or base. In some embodiments, the base comprises sodium hydroxide.
Suitable products or compositions of the present invention may be in the form of ointments or salves, creams, emulsions, gels, foams, sprays or medicated dressings or bandages, which must be directly applied on the affected zone and must be kept in contact with the oral.
In one or more embodiments, the compositions further comprise up to 10% of water.
In one or more embodiments, the composition is substantially non-aqueous and/or substantially alcohol-free.
In another embodiment, the present invention provides a method for inhibiting a disease in a subject comprising administering a subject a composition of the invention.
In another embodiment, the present invention provides a method for inhibiting a viral disease in a subject comprising administering a subject a composition of the present invention.
In another embodiment, the present invention provides a method for inhibiting a disease in a subject comprising orally administering a product of the present invention to the subject.
In another embodiment, the present invention provides a method for inhibiting a disease in a subject comprising inhalation-based administering a product of the present invention to the subject.
In another embodiment, the composition of the present invention is in a chewable oral dosage form. In another embodiment, the chewable oral dosage form is a chewable tablet. In another embodiment, the chewable tablet of the invention is taken slowly by chewing or sucking in the mouth. In another embodiment, the chewable tablet of the invention enables the dried cannabis extracts contained therein to be orally administered without drinking.
In one or more embodiments, the composition further comprises a therapeutically effective concentration of one or more active agents.
The composition of the present invention further contains a surface-active agent. Surface- active agents (also termed "surfactants") include any agent linking oil and water in the composition, in the form of emulsion.
In an embodiment of the present invention, a composition of the present invention includes one or more additional components. Such additional components include but are not limited to anti-static agents, buffering agents, bulking agents, chelating agents, cleansers, colorants, conditioners, diluents, dyes, emollients, fragrances, humectants, permeation enhancers, pH-adjusting agents, preservatives, protectants, oral penetration enhancers, softeners, solubilizers, sunscreens, sun
blocking agents, sunless tanning agents, viscosity modifiers and vitamins. As is known to one skilled in the art, in some instances a specific additional component may have more than one activity, function or effect.
There is thus provided according to an embodiment of the present invention, a pharmaceutical composition for treating a viral disease or disorder in a mammalian subject, the pharmaceutical composition including at least one of: a) an extract as described herein; b) at least one of Cannabigerol (CBG), Cannabinol (CBN) and Cannabidiol (CBD); and c) at least one terpene or terpene alcohol; wherein the pharmaceutical composition is suitable for treating the viral disease or the viral disorder in the mammalian subject.
Additionally, according to an embodiment of the present invention, the at least one terpene is selected from the group consisting of myrcene, humulene, pinene carophyllene and valencene.
Further, according to an embodiment of the present invention, the terpene alcohol includes bisabolol.
Moreover, according to an embodiment of the present invention, the at least one of Cannabigerol (CBG), Cannabinol (CBN) and Cannabidiol (CBD) includes only Cannabidiol (CBD).
Importantly, according to an embodiment of the present invention, the viral disease or disorder is caused by a corona virus, a mutant or variant thereof.
Additionally, according to an embodiment of the present invention, the viral disease is COVID 19.
Furthermore, according to an embodiment of the present invention, the pharmaceutical composition is effective in treating a cytokine storm associated with the COVID 19.
Further, according to an embodiment of the present invention, the pharmaceutical composition is suitable for reducing a level of an ACE2 protein in the mammalian subject.
There is thus provided according to an embodiment of the present invention, a method for treating a viral disease or disorder in a mammalian subject, the method including administering a pharmaceutical composition including at least one of;
an extract as described herein; at least one of Cannabigerol (CBG), Cannabinol (CBN) and
Cannabidiol (CBD); and at least one terpene or terpene alcohol; to the mammalian subject thereby treating the viral disease or the viral disorder in the mammalian subject.
Additionally, according to an embodiment of the present invention, the method is effective in treating a cytokine storm associated with the COVID 19. Importantly, according to an embodiment of the present invention, the method is effective in reducing a level of an ACE2 protein in the mammalian subject.
EMBODIMENTS
1. A method for preventing and treating corona virus-caused disease or disorder, the method comprising: a) combining at least one marijuana strain and at least one hemp strain to form at least one Cannabis line; b) extracting at least one compound from said at least one Cannabis line to form an extract or combining an isolated cannabidiol and adding set of terpenes; and c) treating said disease or disorder with at least one of said extract and said at least one compound in an effective amount to treat said disease or disorder.
2. A method according to embodiment 1, wherein said preventing and treating step induces modulation of gene expression in at least one of oral cells and oral tissue; and wherein said modulation of ACE2 gene said expression results in a reduction of vims entry and virus disease, an inflammatory state, a disorder state and combinations thereof.
3. A method according to embodiment 1, wherein said preventing and treating step induces modulation of gene expression in at least one of airway cells and tissue; and wherein said modulation of ACE2 gene expression results in a reduction of virus entry and virus disease, an inflammatory state, a disorder state and combinations thereof.
4. A method according to embodiment 1, wherein said preventing and treating
step induces modulation of gene expression in at least one of intestinal cells and tissue; and wherein said modulation of ACE2 gene expression results in a reduction of virus entry and virus disease, an inflammatory state, a disorder state and combinations thereof.
5. A method according to embodiment 1, wherein said at least one Cannabis line is selected from the group consisting of a marijuana/marijuana hybrid line, hemp/hemp hybrid line and hemp/marijuana hybrid line.
6. A method according to embodiment 5, wherein said at least one line is selected from the group consisting of designated lines (#1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114, #115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317) and combinations thereof.
7. A method according to embodiment 1, wherein said extracting step comprises extracting flowers of said at least one Cannabis line.
8. A method according to embodiment 5, wherein said extracting step comprises extracting said at least one compound in at least one organic solvent.
9. A method according to embodiment 5, wherein said extracting step is performed at a temperature in the range of 15- to 60°C and at a pressure in a range of -0.5 to 1.5 bar and wherein said at least one organic solvent comprises ethyl acetate.
10. A method according to embodiment 2, wherein said modulation of ACE2 gene expression results in a reduction of a 0.1-3 log2 fold reduction.
11. A method according to embodiment 10, wherein said modulation of gene expression results in a reduction of a 0.1-3 log2 fold reduction in at least one of a gene selected from the group consisting of: ABR, ACP5, ACVR1, ADA, ADORA1, ADORA2A, ADORA2B, AGER, AGTR2, AHCY, AKT1, ALOX5, APOA2, ASH1L, ASS1, ATM, AXL, B4GALT1, BACE2, BAP1, BCR, BDKRB1, BMP6, BMPR1B, BTK, C1QTNF12, C3, C5orf30, C6, CALCA, CALCRL, CCL11, CCL24, CCR4, CD28, CD40, CD96, CDK19, CELA1, CLOCK, CNR1, CNR2, CXCR2, CYP19A1, CYP26B1, CYSLTR1, DROSHA, DUOXA1, DUOXA2, DUSP10, ECM1, EDNRB, EGFR, EIF2AK1, ELANE, EPHA2, EPO, ESR1, ETS1, FABP4, FANCA, FANCD2, FCER1G, FOXF1, FOXP3, GAL, GAT A3, GPR17, GPX1, GPX4, HAMP,
HFE, HGF, HIST1H2BA, HSPD1, ICAM1, IDOl, IDOl, IGFBP4, IL10, IL12B, IL13, IL15, IL17B, IL17F, IL17RA, IL17RB, IL17RC, ILIA, IL1R1, IL1R2, IL1RL1, IL1RL2, IL2, IL20RB, IL22RA2, IL25, IL2RA, IL31RA, IL33, IL5, IL5RA, iNOS, ITGA2, ITGB2, ITGB6, JAK2, JAM3, JUN, KDM6B, KRT1, LBP, LDLR, LIPA, LRRK2, LTA, LYN, MAP2K3, MAS1, MCPH1, NAMPT, NFE2L2, NFKB1, NFKBIZ, NLRP6, NLRX1, NOTCH1, NPFF, NPPA, NPY5R, NT5E, NUPR1, OGGI, OPRM1, PARP-1, P2RX1, P2RX7, PBK, PGLYRP1, PGLYRP2, PIK3CG, PLAA, PLP1, POLB, PPARG, PRCP, PSMB4, PTAFR, PTGES, PTGS2, PYCARD, RASGRP1, RBPJ, RHBDD3, RICTOR, S100A8, S1PR3, SCN9A, SDC1, SEH1L, SELP, SERPINC1, SERPINF1, SGMS1, SLC7A2, SMAD1, SMAD3, SMO, SOCS3, SOCS5, SPHK1, SPP1, STAT3, STAT5B, STK39, SUCNR1, TAC1, TBC1D23, TFR2, TGM2, TIMP1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, TNF, TNFAIP3, TNFRSF1B, TRPV1,TRPV4, TSPAN2, TUSC2, UCN, UGT1A1, UNC13D, VCAM1, WFDC1 and ZYX and combinations thereof.
12. A method according to embodiment 1, wherein said at least one compound is provided in a concentration in a range of 0.0001-0.05 pg/pl, 0.001-0.05 pg/pl, 0.001-0.005 pg/pl, 0.003-0.03 pg/pl or 0.007-0.015 pg/pl.
13. A method according to embodiment 1, wherein said at least one compound is provided in a solvent extract and said solvent extract exhibits viral disease or disorder healing properties.
14. A method according to embodiment 1, wherein said at least one compound is provided in a solvent extract and said solvent extract exhibits ARDS and other inflammatory conditions healing properties.
15. A method according to embodiment 10, wherein said solvent extract is at least 2-20, 3-15, 4-12, 5-10 or 6-9 times as effective as at least one of THC and CBD, administered at the same concentration in treating said disease or said disorder.
16. The method of embodiment 1, wherein the disease state is a viral disease, corona virus-cause disease and complications, inflammatory disease or combinations thereof.
17. The method of embodiment 16, wherein the disease state is selected from the group consisting of a virus-caused disease, virus-caused disease
complications, environmental factor-induced inflammation and combinations thereof.
18. A method according to embodiment 1, wherein said Cannabis line is a Cannabis sativa line.
19. An organic extract of at least one plant line, said at least one plant line formed from combining at least one of: a) at least one marijuana strain; and b) at least one hemp strain, wherein said organic extract comprises at least one compound suitable for treating a mammalian oral disease or disorder.
20. An organic extract according to embodiment 19, wherein said at least one plant line comprises a Cannabis sativa line.
21. An organic extract according to embodiment 19, wherein said mammalian oral disease or disorder is selected from the group consisting of a viral disease, an oral disease, a lung disease, an intestinal disease and combinations thereof.
22. An organic extract according to embodiment 19, wherein said extract is effective against corona virus disease.
23. An organic extract according to embodiment 19, wherein said extract is effective against other virus diseases.
24. An organic extract according to embodiment 19, wherein said extract is effective against ARDS and other cytokine-induced diseases and disorders.
25. An organic extract according to embodiment 19, wherein said organic extract is at least 2-20, 3-15, 4-12, 5-10 or 6-9 times as effective as at least one of THC and CBD, administered at the same concentration in treating said disease.
26. A combination therapy, isolated from an organic extract of at least one hybrid line, said at least one hybrid line formed from combining at least one of: a) at least one marijuana strain; and b) at least one hemp strain; and wherein said organic extract comprises a plurality of compounds suitable for treating a mammalian viral disease and disorder.
27. A Cannabis extract for treating and preventing a viral disease or disorder, wherein said extract efficacy can be further increased by adding CBD, CBG,
CBN, terpenes or combinations thereof.
28. A Cannabis extract for treating and preventing viral disease or disorder, wherein said extract efficacy can be further increased by adding extracts of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics or combinations thereof.
29. A line of Cannabis sativa formed by combining at least one marijuana strain and at least one hemp strain, said line will be deposited at public culture collection, currently under designation numbers (#1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114, #115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317, #CD10.
30. A method for treating a disease state in oral epithelial cells or oral tissue, the method comprising the steps of: a) providing a source of unique extract from at least one line of Cannabis sativa; and b) preventing and treating the COVID-19 and virus-caused disorders with aforementioned extract(s) in an effective amount to induce modulation of ACE 2 and inflammatory gene expression in the oral, airway and intestinal tissue; wherein the modulation of gene expression results in a reduction of the disease state in the aforementioned tissues.
31. The method of embodiment 30, wherein the extracts is extract #1.
32. The method of embodiment 30, wherein the extracts is extract #4.
33. The method of embodiment 30, wherein the extracts is extract #5.
34. The method of embodiment 30, wherein the extracts is extract #6.
35. The method of embodiment 30, wherein the extracts is extract #7.
36. The method of embodiment 30, wherein the extracts is extract #8.
37. The method of embodiment 30, wherein the extracts is extract #9.
38. The method of embodiment 30, wherein the extracts is extract #10.
39. The method of embodiment 30, wherein the extracts is extract #12.
40. The method of embodiment 30, wherein the extracts is extract #13.
41. The method of embodiment 30, wherein the extracts is extract #14.
42. The method of embodiment 30, wherein the extracts is extract #15.
43. The method of embodiment 30, wherein the extracts is extract #31
44. The method of embodiment 30, wherein the extracts is extract #45.
45. The method of embodiment 30, wherein the extracts is extract #49.
46. The method of embodiment 30, wherein the extracts is extract #81.
47. The method of embodiment 30, wherein the extracts is extract #90.
48. The method of embodiment 30, wherein the extracts is extract #98.
49. The method of embodiment 30, wherein the extracts is extract #114.
50. The method of embodiment 30, wherein the extracts is extract #115.
51. The method of embodiment 30, wherein the extracts is extract #129.
52. The method of embodiment 30, wherein the extracts is extract #130.
53. The method of embodiment 30, wherein the extracts is extract #131.
54. The method of embodiment 30, wherein the extracts is extract #132.
55. The method of embodiment 30, wherein the extracts is extract #155.
56. The method of embodiment 30, wherein the extracts is extract #157.
57. The method of embodiment 30, wherein the extracts is extract #166.
58. The method of embodiment 30, wherein the extracts is extract #167.
59. The method of embodiment 30, wherein the extracts is extract #169.
60. The method of embodiment 30, wherein the extracts is extract #207.
61. The method of embodiment 30, wherein the extracts is extract #274.
62. The method of embodiment 30, wherein the extracts is extract #317.
63. The method of embodiment 30, wherein the modulation of gene expression is a down-regulation of ACE2 gene expression.
64. The method of embodiment 30, wherein the modulation of gene expression is a down-regulation of proinflammatory gene expression and up-regulation of anti-inflammatory gene expression.
65. The method of embodiment 30, wherein the disease state is COVID-19.
66. The method of embodiment 30, wherein the disease state is corona virus disease.
67. The method of embodiment 30, wherein the disease state is viral disease.
68. The method of embodiment 30, wherein the disease state is Acute Respiratory Disease Syndrome
69. The method of embodiment 30, wherein the disease state is pneumonia.
70. Effects of extracts according to embodiments 19-25, wherein said effects are further extended by addition of CBD, CBG, CBN, terpenes or combinations thereof.
71. Effects of extracts in embodiments 19-25, wherein said effects are further extended by addition of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics or combinations thereof.
72. A method according to embodiments 30-62, wherein said reduction of the disease state is further extended by addition of CBD, CBG, CBN, terpenes or combinations thereof to said unique extract.
73. A method according to embodiments 30-62, wherein said reduction of the disease state is further extended by addition of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics or combinations thereof.
74. A method according to embodiment 1, wherein the cannabis extracts or components purified therefrom are adapted to inhibit processes critical for the vims life cycle.
The present invention will be more fully understood from the following detailed description of the preferred embodiments thereof, taken together with the drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will now be described in connection with certain preferred embodiments with reference to the following illustrative figures so that it may be more fully understood.
With specific reference now to the figures in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice. In the drawings:
Fig. 1A is a simplified image of an EpiOral tissue experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention;
Fig. IB is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-i induced inflammation using the set-up in Fig.lA, in accordance with an embodiment of the present invention;
Fig. 2A is a graph showing the effects of cannabis extract 81 on the levels of ACE2 gene expression and expression of inflammation-related genes in EpiOral tissues, in accordance with an embodiment of the present invention;
Fig. 2B is a graph showing the effects of cannabis extract 130 on the levels of ACE2 gene expression and expression of inflammation-related genes in EpiOral tissues, in accordance with an embodiment of the present invention;
Fig. 2C is a graph showing the effects of several pro-inflammatory gene changes in a single bar for each condition (TNF vs DMSO, and extracts vs DMSO) for several different extracts, in accordance with an embodiment of the present invention;
Fig. 2D is an image showing the effects of different cannabis extracts on ACE2 protein and GAPDH protein levels in EpiOral tissues, in accordance with an embodiment of the present invention;
Fig. 2E is a graph showing the ratio of ACE2 protein to GAPDH protein after
treatment with TNF/IFN and application of different cannabis extracts to EpiOral cells, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment; Fig. 3A is a simplified image of Epilntestinal tissues experimental set-up for testing candidate treatments for anti inflammatory properties, in accordance with an embodiment of the present invention;
Fig. 3B is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-induccd inflammation using the set-up in Fig.3A, in accordance with an embodiment of the present invention;
Fig. 4 A is a graph showing the effects of different cannabis extracts on the levels of ACE2 gene expression in Epilntestinal tissues, in accordance with an embodiment of the present invention;
Fig. 4B is a graph showing the effects of extract of Cannabis Line 45 effectively decreasing levels of ACE2 gene expression in human 3D Epilntestinal tissues, in accordance with an embodiment of the present invention;
Fig. 5A is an image showing the effects of different cannabis extracts on ACE2 protein and GAPDH protein levels in Epilntestinal tissues, in accordance with an embodiment of the present invention;
Fig. 5B is a graph showing the ratio of ACE2 protein to GAPDH protein after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment;
Fig. 5C is a graph showing the effects of different cannabis extracts on down- regulation of inflammation-related PARP-1 and iNOS proteins in Epilntestinal cells, in accordance with an embodiment of the present invention;
Fig. 5D is a graph showing the ratio of PARP-1 to actin after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention;
Fig. 5E is a graph showing the ratio of iNOS to actin after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention;
Fig. 6A is a simplified image of an EpiAirway tissue model tissue experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention;
Fig. 6B is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-i induced inflammation using the set-up in Fig.6A, in accordance with an embodiment of the present invention.
Fig. 7 A is a graph showing the effects of cannabis extracts of novel cannabis lines in reducing levels of the ACE2 protein in human 3D EpiAirway tissue, in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment;
Fig. 7B is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and GAPDH protein in human 3D EpiAirway tissue, in accordance with an embodiment of the present invention;
Fig. 7C is a graph showing the ratio of ACE2 protein to GAPDH protein after different cannabis extracts were applied to EpiAirway tissues, in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment;
Fig. 7D is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and Actin protein in human 3D EpiAirwayFT tissue after induction of inflammation with TNF/IFN and after application of cannabis extracts, in accordance with an embodiment of the present invention;
Fig. 7E is a graph showing the ratio of ACE2 protein to Actin protein after induction of inflammation with TNF/IFN and after application of different cannabis extracts were applied to EpiAirway tissues, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment;
Fig. 7F is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and GAPDH protein in human 3D EpiAirway tissue after induction of inflammation with TNF/IFN and after application of cannabis extracts, in accordance with an embodiment of the present invention;
Fig. 7G is a graph showing the ratio of ACE2 protein to GAPDH protein after induction of inflammation with TNF/IFN and after application of different cannabis extracts were applied to human 3D EpiAirway tissues, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
Figs. 8A-8F are a set of graphs showing that cannabinoids affect processes involved in a viral life cycle - Figs. 8A-8C show that different cannabinoids applied at
different concentrations to an in vitro viral experiment inhibit reverse transcription- namely Fig. 8A, CBD, Fig. 8B, THC, Fig. 8B THC and Fig. 8C, CB and Figs. 8D-8F show that different cannabinoids applied at different concentrations to an in vitro viral experiment inhibit DNA replication- namely Fig. 8D, CBD, Fig. 8E, THC and Fig. 8F THC, in accordance with some embodiments of the present invention;
Fig. 9 is a simplified pictorial illustration showing a schematic summary of the main effects of cannabis extracts on SARS-COV-2, in accordance with an embodiment of the present invention;
Fig. 10A shows the dose-dependent increase in relative expression of COX2 as measured by qRT-PCR 24h after treatment with TNFa/IFNy in HSIEC cells; asterisks indicated significant (p<0.01) difference;
Fig. 10B shows the dose-dependent increase in relative expression of COX2 protein as measured by western blot 24h after treatment with TNFa/IFNy in HSIEC cells;
Fig. IOC shows the time-dependent increase in relative expression of COX2 (as measured by western blot) in response to 10 ng/ml of TNFa/IFNy in HSIEC.
Fig. 10D is a graph showing ImageJ measured (from Fig. IOC) time-dependent increase in relative expression of COX2 in response to 10 ng/ml of TNFa/IFNy in HSIEC.
Fig. 11A shows the dose-dependent increase in relative expression of COX2 (as measured by qRT-PCR) in response to TNFa/IFNy in WI-38 human lung fibroblast cells;
Fig. 11B shows the dose-dependent increase in relative expression of COX2 (as measured by western blot) in response to TNFa/IFNy in WI-38 cells;
Fig. llC is a graph showing ImageJ measured dose-dependent increase in relative expression of COX2 (as measured by western blot) in response to 10 ng/ml of TNFa/IFNy in WI-38 cells;
Fig. 11D shows the time-dependent increase in relative expression of COX2 (as measured by western blot) in response to TNFa/IFNy in WI-38 cells;
Fig. 11E is a graph showing ImageJ measured time-dependent increase in relative expression of COX2 (done by western blot) in response to 10 ng/ml of TNFa/IFNy in WI-38 cells.
Fig. 12A is a western blot image showing the expression of COX2, SOCS3
and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in HSIEC cells;
Fig. 12B is a graph showing ImageJ measured expression of COX2 relative to GAPDH in response to treatment with TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in HSIEC cells;
Fig. 12C is a graph showing ImageJ measured expression of SOCS3 relative to GAPDH in response to treatment with TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in HSIEC cells;
Fig. 12D is a western blot image showing the expression of COX2, SOCS3 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in WI-38 cells;
Fig. 12E is a graph showing ImageJ measured expression of COX2 relative to GAPDH in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in WI-38 cells;
Fig. 12F is a graph showing ImageJ measured expression of SOCS3 relative to GAPDH in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in WI-38 cells;
Fig. 13A is a western blot image showing the expression of IL8 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells;
Fig. 13B is a graph showing ImageJ measured expression of IL8 relative to GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells;
Fig. 13C is a western blot image showing the expression of IL8 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells;
Fig. 13D is a graph showing ImageJ measured expression of IL8 relative to
GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells;
Fig. 13E is a western blot image showing the expression of IL-6, pAktl/2/3, Aktl and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells;
Fig. 13F is a graph showing ImageJ measured expression of IL-6 relative to GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells;
Fig. 13G is a western blot image showing the expression of IL-6, pAktl/2/3, Aktl and GAPDH in response to treatment with 10 ng/ml TNFa/IRNg alone, or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells;
Fig. 13H is a graph showing ImageJ measured expression of IL-6 relative to GAPDH in response to treatment with 10 ng/ml TNFa/IRNg alone or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells;
Fig. 14A is a graph showing qRT-PCR analysis of IL-6 expression in WI-38 in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169;
Fig. 14B is a graph showing qRT-PCR analysis of IL-8 expression in WI-38 in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169;
Fig. 14C is a graph showing qRT-PCR analysis of COX-2 expression in WI- 38 in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169;
Fig. 14D is a graph showing qRT-PCR analysis of IL-6 expression in HSIEC in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169;
Fig. 14E is a graph showing qRT-PCR analysis of IL-8 expression in HSIEC in response to treatment with 10 ng/ml TNFa/IRNg alone, or followed by treatment with extracts #1, #5, #7 and #169;
Fig. 14F is a graph showing qRT-PCR analysis of COX-2 expression in HSIEC in response to treatment with 10 ng/ml TNFa/IRNg alone or followed by treatment with extracts #1, #5, #7 and #169.
Fig. 15A is a western blot image showing ACE2 and GAPDH protein levels in
WI-38 cells in response to 10 mM CBD or 0.015 pg of various extracts;
Fig. 15B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 10 pM CBD or 0.015 pg of various extracts;
Fig. 16A is a graph showing qRT-PCR analysis of IL-6 expression in WI-38 cells in response to 24, 48, 72 or 96 h of treatment with 10 ng/ml TNFa/IFNy alone or in combination with extract #1;
Fig. 16B is a graph showing qRT-PCR analysis of IL-8 expression in WI-38 cells in response to 24, 48, 72 or 96 h of treatment with 10 ng/ml TNFa/IFNy alone or in combination with extract #1;
Fig. 16C is a graph showing qRT-PCR analysis of IL-6 expression in WI-38 cells in response to 24, 48, 72 or 96 h of treatment with 10 ng/ml TNFa/IFNy alone or in combination with extract #5;
Fig. 16D is a graph showing qRT-PCR analysis of IL-8 expression in WI-38 cells in response to 24, 48, 72 or 96 h of treatment with 10 ng/ml TNFa/IFNy alone or in combination with extract #5. Fig. 17A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with different concentrations of extracts #1 and #5;
Fig. 17B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to different concentrations of extracts #1 and #5;
Fig. 18A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with different concentrations of CBD, CBN and THC;
Fig. 18B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with different concentrations of CBD, CBN and THC;
Fig. 18C is a western blot image showing ACE2 and GAPDH protein levels in BJ-5ta immortalized foreskin fibroblast cells in response to 24 h treatment with different concentrations of CBD, CBN and THC;
Fig. 18D is a graph showing the ratio of ACE2 protein to GAPDH protein in BJ-5ta immortalized foreskin fibroblast cells in response to 24 h treatment with different concentrations of CBD, CBN and THC;
Fig. 19A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in BJ-5ta cells in response to 24 h treatment with 0.015 pg/pl
concentration of CBD or various extracts CBN and THC;
Fig. 19B is a graph showing the ratio of ACE2 protein to GAPDH protein in BJ-5ta cells in response to 24 h treatment with 0.015 pg/pl concentration of CBD or various extracts CBN and THC;
Fig. 19C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in BJ-5ta cells in response to 24 h treatment with 0.015 pg/pl concentration of CBD or various extracts CBN and THC;
Fig. 20A shows graphs of the fold change in the expression of selected pro- inflammatory genes in EpiDermFT human 3D tissues in response to UVC and treatment with extracts #4, #6, #8, #12, #13, #14 and #15;
Fig. 20B shows a graph of the fold change in the expression of PTGS2 (COX2) gene in EpiDermFT human 3D tissues in response to UVC and treatment with extracts #4, #6, #8, #12, #13, #14 and #15;
Fig. 20C is a western blot image showing IL-6 and COX-2 protein levels in EpiDermFT human 3D tissues in response to UVC and treatment with extracts #4, #6, #8, #12, #13, #14 and #15;
Fig. 21 A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
Fig. 2 IB is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
Fig. 21C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
Fig. 22A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
Fig. 22B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of myrcene or CBD with myrcene;
Fig. 22C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and
various concentrations of myrcene or CBD with myrcene;
Fig. 23A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
Fig. 23B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
Fig. 23C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
Fig. 24A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
Fig. 24B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
Fig. 24C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of caryophyllene or CBD with caryophyllene;
Fig. 25A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
Fig. 25B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
Fig. 25C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
Fig. 26A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
Fig. 26B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and
various concentrations of a-pinene or CBD with a-pinene;
Fig. 26C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of a-pinene or CBD with a-pinene;
Fig. 27A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
Fig. 27B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
Fig. 27C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
Fig. 28A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
Fig. 28B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
Fig. 28C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of bisabolol or CBD with bisabolol;
Fig. 29A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
Fig. 29B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
Fig. 29C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
Fig. 30A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration
of CBD and various concentrations of humulene or CBD with humulene;
Fig. 30B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
Fig. 30C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of humulene or CBD with humulene;
Fig. 31A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
Fig. 3 IB is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
Fig. 31C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in WI-38 cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
Fig. 32A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene;
Fig. 32B is a graph showing the ratio of ACE2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene; and
Fig. 32C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein in HSIEC cells in response to 24 h treatment with 20 uM concentration of CBD and various concentrations of valencene or CBD with valencene. Fig. 33A shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in WI-38 cells exposed for 24h to CBD, THC, CBN, b-myrcene, b-caryophyllene, a-bisabolol, a- humulene, a combination of all these components or to the extract #1 itself. Fig. 33B shows the same for COX-2, IL-6, IL-8 and GAPDH.
Fig. 33C and D show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 33A.
Fig. 34A shows the western blot in HSIEC cells exposed for 24h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #1 or its individual
components.
Fig. 34B, C and D show ImageJ quantification of COX2, IL6 or IL8, respectively.
Fig. 35A shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in WI-38 cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol, a combination of all these components or to the extract #7 itself.
Fig. 35B and C show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 35A. Fig. 35D shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in Bj-5ta cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol, a combination of all these components or to the extract #7 itself.
Fig. 35E and F show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 35D.
Fig. 36A shows the western blot image of IL6, COX2 and GAPDH proteins in WI-38 cells exposed for 48h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #7 or its individual components - CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol or their combination. Fig. 36B and C show ImageJ quantification of IL6 and COX2 from Fig. 36A.
Fig. 36D shows the western blot image of IL8 and GAPDH proteins in HSIEC cells exposed for 48h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #7 or its individual components - CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol or their combination. Fig. 36E shows ImageJ quantification of IL8 from Fig. 36D.
In all the figures similar reference numerals identify similar parts.
DETAILED DESCRIPTION OF THE EMBODIMENTS
In the detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those skilled in the art that these are specific embodiments and that the present invention may be practiced also in different ways that embody the characterizing features of the invention as described and claimed herein.
Fig. 1A is a simplified image of an EpiOral tissue experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention. EpiOral tissues 110 consist of normal, human- derived oral epithelial cells that have been cultured to form multilayered, highly differentiated models of the human buccal phenotypes.
Fig. IB is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNY-induced inflammation using the set-up in Fig.lA, in accordance with an embodiment of the present invention;
Scheme of the TNF-induced inflammation experiment.
In an induction step 120, 3D EpiOral tissues 110 were inserted in a well with medium. Tissues were equilibrated in the medium for 24 h (overnight) and then culture medium was replaced and incubated for another 24 h. Tissues were then exposed for 24 h to TNFa (40 ng/ml) and IFNa (5 ng/ml) or to DMSO only.
In an extract treatment step 130, all crude extracts were diluted from a 60 mg/mL stock (the stock is prepared in DMSO). For this experiment, a final concentration of 0.01 ug/uL in 30% glycerol-PBS was used. 24 h after TNF/IFN exposure, 15 uL of 0.01 ug/uL extract solution or control (DMSO alone) were applied to the tissues.
In an analysis step 140, the samples were harvested and used for the analysis of mRNA by sequencing. Bioinformatics analysis of mRNA revealed changes in biological pathways associated with changes in ACE2 expression or inflammation.
Fig. 2 A and 2B represent the graphs showing the relative expression of ACE2 gene in EpiOral 3D tissues in response in response to treatment with cannabis extract #81 (2A) and #130 (2B), in accordance with an embodiment of the present invention; Extracts #81 and #130 down-regulate the levels of ACE2 in EpiOral tissues.
Fig. 2C is a graph showing the cumulative effect of several (as per
Embodiment 11) pro-inflammatory gene changes in a single bar for each condition (TNF vs DMSO, and extracts vs DMSO) in EpiOral tissues treated with TNF/IFN followed by treatment with several different extracts (as per Fig. 1), in accordance with an embodiment of the present invention.
Fig. 2D is an image showing the effects of different cannabis extracts on ACE2 protein and GAPDH protein levels using the same EpiOral tissues as per Fig. 1, in accordance with an embodiment of the present invention.
Fig. 2E is a graph showing the ImageJ-based measurement of the band intensity from Fig.2D, representing the ratio of ACE2 protein to GAPDH protein after treatment with TNF/IFN and application of different cannabis extracts to EpiOral cells, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
Fig. 3A is a simplified image of Epilntestinal tissues 310 experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention.
Epilntestinal tissues are 3D highly differentiated tissue models produced from normal, human cell-derived small intestine epithelial and endothelial cells and fibroblasts.
Fig. 3B is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-induccd inflammation using the set-up in Fig.3A, in accordance with an embodiment of the present invention.
Fig. 3B is one simplified illustration of a scheme of a TNFa/IFNy-induccd inflammation experiment. 3D Epilntestinal tissues of oral epithelial cells 310 from Fig. 3A were used.
In an induction step 320, 3D tissues 310 were inserted in a well with medium. Tissues were equilibrated in the medium for 24 h (overnight) and then culture medium was replaced and incubated for another 24 h. Tissues were then exposed for 24 h to TNFa (40 ng/ml) and IFNa (5 ng/ml) or to DMSO only.
In an extract treatment step 330, all crude extracts were diluted from a 60 mg/mF stock (the stock is prepared in DMSO). For this experiment, a final concentration of 0.01 ug/uF in 30% glycerol-PBS was used. 24 h after TNF/IFN exposure, 15 uF of 0.01 ug/uF extract solution or control (DMSO alone) were applied
to the tissues.
In an analysis step 340, the samples were harvested and used for the analysis of mRNA by sequencing. Bioinformatics analysis of mRNA revealed changes in biological pathways associated with changes in ACE2 expression or inflammation.
Fig. 4 A is a graph showing the relative expression of ACE2 gene in Epilntestinal tissues in response to treatment with different cannabis extracts, in accordance with an embodiment of the present invention.
Fig. 4B is a graph showing the effects of extract of Cannabis Line 45 effectively decreasing levels of ACE2 gene expression in human 3D Epilntestinal tissues, in accordance with an embodiment of the present invention.
Fig. 5A is an image showing the effects of different cannabis extracts on ACE2 protein and GAPDH protein in Epilntestinal tissues treated with TNF/IFN (as per Fig. 3), in accordance with an embodiment of the present invention.
Fig. 5B is a graph showing the ImageJ-based measurement of the band intensity from Fig. 5A showing the ratio of ACE2 protein to GAPDH protein after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
Fig. 5C is a graph showing the effects of different cannabis extracts on down- regulation of inflammation-related PARP-1 and iNOS proteins in Epilntestinal tissues treated with TNF/IFN, in accordance with an embodiment of the present invention.
Fig. 5D is a graph showing the ratio of PARP-1 to actin after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention.
Fig. 5E is a graph showing the ratio of iNOS to actin after different cannabis extracts were applied to Epilntestinal cells, in accordance with an embodiment of the present invention.
Fig. 6A is a simplified image of an EpiAirway tissue model tissue 610 experimental set-up for testing candidate treatments for anti-inflammatory properties, in accordance with an embodiment of the present invention.
Fig. 6B is a simplified flowchart of a method for testing candidates for anti inflammatory properties after TNFa/IFNy-i induced inflammation using the set-up in Fig.6A, in accordance with an embodiment of the present invention.
3D EpiAirway tissues of oral epithelial cells 610 were obtained (per Fig. 6A).
In an induction step 620, 3D tissues were inserted in a well with medium. Tissues were equilibrated in the medium for 24 h (overnight) and then culture medium was replaced and incubated for another 24 h. Tissues were then exposed for 24 h to TNFa (40 ng/ml) and IFNa (5 ng/ml) or to DMSO only.
In extract treatment step 630, all crude extracts were diluted from a 60 mg/mF stock (the stock is prepared in DMSO). For this experiment, a final concentration of 0.01 ug/uF in 30% glycerol-PBS was used. 24 h after TNF/IFN exposure, 15 uF of 0.01 ug/uF extract solution or control (DMSO alone) were applied to the tissues.
In an analysis step 640, the samples were harvested and used for the analysis of mRNA by sequencing. Bioinformatics analysis of mRNA revealed changes in biological pathways associated with changes in ACE2 expression or inflammation.
Fig. 7 A is a graph showing the effects of cannabis extracts of novel cannabis lines in reducing levels of the ACE2 protein in human 3D EpiAirway tissue (as described in Fig. 6), in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment.
Fig. 7B is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and GAPDH protein in human 3D EpiAirway tissue (measured from Fig. 7A), in accordance with an embodiment of the present invention.
Fig. 7C is a graph showing the ratio of ACE2 protein to GAPDH protein after different cannabis extracts were applied to EpiAirway tissues, in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment.
Fig. 7D is an image showing the effects of different cannabis extracts of novel cannabis lines on ACE2 protein and Actin protein in human 3D EpiAirwayFT tissue after induction of inflammation with TNF/IFN and after application of cannabis extracts (as described in Fig. 6), in accordance with an embodiment of the present invention; asterisks show significant difference from DMSO treatment.
Fig. 7E is a graph showing the ratio of ACE2 protein to Actin protein measured from the image in Fig. 7D, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
Fig. 7F is an image showing the effects of different cannabis extracts of novel
cannabis lines on ACE2 protein and GAPDH protein in human 3D EpiAirway tissue after induction of inflammation with TNF/IFN and after application of cannabis extracts (as described in Fig. 6), in accordance with an embodiment of the present invention.
Fig. 7G is a graph showing the ratio of ACE2 protein to GAPDH protein measured from the image in Fig. 7F, in accordance with an embodiment of the present invention; asterisks show significant difference from TNF/IFN treatment.
Figs. 8A-8F are a set of graphs showing that cannabinoids affect processes involved in a viral life cycle - Figs. 8A-8C show that different cannabinoids applied at different concentrations inhibit reverse transcription in vitro - namely Fig. 8A, CBD, Fig. 8B, THC, and Fig. 8C, CBN and Figs. 8D-8F show that different cannabinoids applied at different concentrations inhibit DNA replication- namely Fig. 8D, CBD, Fig. 8E, THC and Fig. 8F CBN, in accordance with some embodiments of the present invention.
Fig. 9 is a simplified pictorial illustration showing a schematic summary 900 of the main effects of cannabis extracts on SARS-COV-2, in accordance with an embodiment of the present invention.
Step 910 illustrates mechanism of entry of SARS-COV-2 virus through the recognition of ACE2 receptor.
Step 920 illustrates the use of cannabis extract or single cannabinoids or single terpene molecules or their combination to block the viral entry by downregulating the expression of ACE2 receptor.
Step 930 illustrates the use of cannabis extract or single cannabinoids or single terpene molecules or their combination to block the virus life cycle, including but not limited to blocking reverse transcription and replication.
Step 940 illustrates mechanism of cytokine storm development in response to SARS-COV-2 vims.
Step 950 illustrates the use of cannabis extract or single cannabinoids or single terpene molecules or their combination to decrease the expression of pro- inflammatory molecules and prevent the development of cytokine storm.
Fig. 10A shows the dose-dependent increase in relative expression of COX2 as measured by qRT-PCR 24h after treatment with TNFa/IFNy in HSIEC cells; asterisks indicated significant (p<0.01) difference.
Fig. 10B shows the dose-dependent increase in relative expression of COX2 protein as measured by western blot 24h after treatment with TNFa/IFNy in HSIEC cells.
Fig. IOC shows the time-dependent increase in relative expression of COX2 (as measured by western blot) in response to 10 ng/ml of TNFa/IFNy in HSIEC.
Fig. 10D is a graph showing ImageJ measured (from Fig. IOC) time-dependent increase in relative expression of COX2 in response to 10 ng/ml of TNFa/IFNy in HSIEC.
Fig. 11A shows the dose-dependent increase in relative expression of COX2 as measured by qRT-PCR 24h after treatment with TNFa/IFNy in WI-38 human lung fibroblast cells; asterisks indicated significant (p<0.01) difference.
Fig. 1 IB shows the dose-dependent increase in relative expression of COX2 as measured by western blot 24h after treatment with TNFa/IFNy in WI-38 cells.
Fig. llC is a graph showing ImageJ-measured dose-dependent increase in relative expression of COX2 (from Fig. 11B) in response to TNFa/IFNy in WI-38 cells.
Fig. 11D shows the time-dependent increase in relative expression of COX2 (as measured by western blot) in response to 10 ng/ml of TNFa/IFNy in WI-38 cells.
Fig. 11E is a graph showing ImageJ measured time-dependent increase in relative expression of COX2 (from Fig. 11D) in response to 10 ng/ml of TNFa/IFNy in WI-38 cells.
Fig. 12A is a western blot image showing the expression of COX2, SOCS3 and GAPDH in response to 24h treatment with 10 ng/ml TNFa/IFNy alone or followed by 24h treatment with 5mM CBD or 15 uF of 0.01 ug/uF of various cannabis extracts in HSIEC cells.
Fig. 12B is a graph showing ImageJ measured expression of COX2 relative to GAPDH (from Fig. 12A) in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in HSIEC cells; asterisks show significant difference.
Fig. 12C is a graph showing ImageJ measured expression of SOCS3 relative to GAPDH (from Fig. 12 A) in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in HSIEC cells; asterisks show significant difference.
Fig. 12D is a western blot image showing the expression of COX2, SOCS3 and GAPDH in response to 24h treatment with 10 ng/ml TNFa/IFNy alone or followed by 24h treatment with 5mM CBD or 15 uL of 0.01 ug/uL of various cannabis extracts in WI-38 cells.
Fig. 12E is a graph showing ImageJ measured expression of COX2 relative to GAPDH (from Fig.l2D) in response to treatment with TNFa/IFNy alone, or with addition of CBD or various cannabis extracts in WI-38 cells; asterisks show significant difference.
Fig. 12F is a graph showing ImageJ measured expression of SOCS3 relative to GAPDH (from Fig.l2D) in response to treatment with TNFa/IFNy alone or with addition of CBD or various cannabis extracts in WI-38 cells; asterisks show significant difference.
Fig. 13A is a western blot image showing the expression of IL8 and GAPDH in response to 24h treatment with 10 ng/ml TNFa/IFNy alone or followed by 24h treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in WI-38 cells.
Fig. 13B is a graph showing ImageJ measured expression of IL8 relative to GAPDH (from Fig. 13A) in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in WI-38 cells; asterisks show significant difference.
Fig. 13C is a western blot image showing the expression of IL8 and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in HSIEC cells.
Fig. 13D is a graph showing ImageJ measured expression of IL8 relative to GAPDH (from Fig. 13C) in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in HSIEC cells; asterisks show significant difference.
Fig. 13E is a western blot image showing the expression of IL-6, pAktl/2/3, Aktl and GAPDH in response to 24h treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169 in WI-38 cells.
Fig. 13F is a graph showing ImageJ measured expression of IL-6 relative to GAPDH (from Fig. 13E) in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in WI-38 cells; asterisks show significant difference.
Fig. 13G is a western blot image showing the expression of IL-6, pAktl/2/3, Aktl and GAPDH in response to treatment with 10 ng/ml TNFa/IFNy alone, or followed by treatment with extracts #1, #5, #7 and #169 in HSIEC cells.
Fig. 13H is a graph showing ImageJ measured expression of IL-6 relative to GAPDH (from Fig. 13G) in response to 24h treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with 15 uL of 0.01 ug/uL of extracts #1, #5, #7 and #169 in HSIEC cells; asterisks show significant difference.
Fig. 14 shows qRT-PCR of IL-6, IL-8 and COX-2 genes in WI-38 and HSIEC cells in response to treatment with 10 ng/ml TNFa/IFNy alone or followed by treatment with extracts #1, #5, #7 and #169; asterisks show significant difference.
Specifically, Fig. 14A shows IL-6 expression in WI-38, Fig. 14B - IL-8 in WI-38, Fig. 14C - COX-2 in WI-38, Fig. 14D - IL-6 in HSIEC, Fig.l4E - IL-8 in HSIEC, Fig. 14F - COX-2 in HSIEC.
Fig. 15 A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 10 mM CBD or 0.015 pg of various extracts.
Fig. 15B is a graph showing the ratio of ACE2 protein to GAPDH protein measured from Fig. 15A using ImageJ; asterisks show significant difference.
Fig. 16 shows qRT-PCR of IL-6 and IL-8 genes in WI-38 cells treated for 24- 96h with 10 ng/ml TNFa/IFNy alone or in combination with 0.015 pg of extract #1 or #5; asterisks show significant difference. Specifically, Fig. 16A shows IL-6 expression in response to extract #1, Fig. 16B - IL-8 in response to extract #1, Fig.l6C - IL-6 in response to ext #5, Fig. 16D - IL-8 in response to ext #5.
Fig. 17 A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with different concentrations of extracts #1 and #5.
Fig. 17B is a graph showing the ratio of ACE2 protein to GAPDH protein in WI-38 cells (calculated from Fig. 17A) in response to different concentrations of extracts #1 and #5; asterisks show significant difference.
Fig. 18A is a western blot image showing ACE2 and GAPDH protein levels in WI-38 cells in response to 24 h treatment with different concentrations of CBD, CBN and THC.
Fig. 18B is a graph showing the ratio of ACE2 protein to GAPDH protein (calculated from Fig. 18A) in WI-38 cells in response to 24 h treatment with different
concentrations of CBD, CBN and THC.
Fig. 18C is a western blot image showing ACE2 and GAPDH protein levels in BJ-5ta immortalized foreskin fibroblast cells in response to 24 h treatment with different concentrations of CBD, CBN and THC.
Fig. 18D is a graph showing the ratio of ACE2 protein to GAPDH protein (calculated from Fig. 18A) in BJ-5ta immortalized foreskin fibroblast cells in response to 24 h treatment with different concentrations of CBD, CBN and THC.
Fig. 19A is a western blot image showing ACE2, TMPRSS2 and GAPDH protein levels in BJ-5ta cells in response to 24h treatment with 0.015 pg/pl concentration of CBD or various extracts.
Fig. 19B is a graph showing the ratio of ACE2 protein to GAPDH protein (calculated from Fig.l9A) in BJ-5ta cells in response to 24h treatment with 0.015 pg/pl concentration of CBD or various extracts.
Fig. 19C is a graph showing the ratio of TMPRSS2 protein to GAPDH protein (calculated from Fig.l9A) in BJ-5ta cells in response to 24 h treatment with 0.015 pg/pl concentration of CBD or various extracts CBN and THC.
Fig. 20A shows graphs of the fold change in the expression of selected pro- inflammatory genes in EpiDermFT human 3D tissues in response to UVC followed by 24h treatment with 0.015 pg/pl concentration of extracts #4, #6, #8, #12, #13, #14 and #15.
Fig. 20B shows a graph of the log2 fold change in the expression of PTGS2 (COX2) gene in EpiDermFT human 3D tissues in response to UVC f treatment with extracts #4, #6, #8, #12, #13, #14 and #15.
Fig. 20C is a western blot image showing IL-6 and COX-2 protein levels in EpiDermFT human 3D tissues in response to UVC or UVC followed by 24h treatment with 0.015 pg/pl concentration of extracts #4, #6, #8, #12, #13, #14 and #15; PBS and DMSO are controls; UV-PBS and UV-DMSO are samples treated with UV with PBS or DMSO added to them.
Fig. 21 -Fig.32 show the set of experiments to compare the effect of CBD and terpenes on the expression of ACE2 and TMPRSS2 proteins in WI-38 and HSIEC cells. Cells were treated for 24h with 20 uM CBD alone, with 10-100 pg/ml of an isolated terpene or with combination of CBD and terpenes. Asterisks show significant difference, either between control and any individual treatment, or between CBD and
CBD + terpene, or terpene and CBD + terpene.
Specifically, Fig. 21 A shows the western blot image of ACE2, TMPRSS2 and GAPDH protein levels, while Fig. 2 IB and C show the ImageJ calculated expression of ACE2 and TMPRSS2 relative to GAPDH in response to CBD and myrcene in WI- 38 cells. Fig. 22 shows the same in HSIEC cells.
Correspondingly, Fig. 23 and 24 show the same for caryophyllene in WI-38 and HSIEC cells.
Fig. 25 and 26 show the same for a-pinene in WI-38 and HSIEC cells.
Fig. 27 and 28 show the same for bisabolol in WI-38 and HSIEC cells.
Fig. 29 and 30 show the same for humulene in WI-38 and HSIEC cells.
Fig. 31 and 32 show the same for valencene in WI-38 and HSIEC cells.
Since previous experiments hinted that CBD may be less efficient than whole extracts or isolated terpenes in downregulation of ACE2/TMPRSS2 and pro- inflammatory proteins COX, IL-6 and IL-8, it was attempted to check individual components of the extracts.
Fig. 33-36 show the results of exposure of three different cell types, WI-38, HSIEC and Bj-5ta for 24h or 48h to 15 pg/ml of two best working extracts, #1 and #7. To compare the effect of individual components with the extract, cells were exposed to the same concentrations found in the extract of three main cannabinoids, CBD, THC and CBN or 4-6 major terpenes or to a combination of all cannabinoids and major terpenes, attempting to reconstitute the effect of a whole extract. Asterisks show significant difference from DMSO control.
Specifically, Fig. 33A shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in WI-38 cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-bisabolol, a-humulene, a combination of all these components or to the extract #1 itself. Fig. 33B shows the same for COX-2, IL-6, IL-8 and GAPDH.
Fig. 33C and D show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 33A.
Fig. 34A shows the western blot in HSIEC cells exposed for 24h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #1 or its individual components.
Fig. 34B, C and D show ImageJ quantification of COX2, IL6 or IL8, respectively.
Fig. 35A shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in WI-38 cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol, a combination of all these components or to the extract #7 itself.
Fig. 35B and C show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 35A.
Fig. 35D shows the western blot image of ACE2, TMPRSS2 and GAPDH proteins in Bj-5ta cells exposed for 24h to CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol, a combination of all these components or to the extract #7 itself.
Fig. 35E and F show ImageJ quantification of ACE2 and TMPRSS2 relative to GAPDH from Fig. 35D.
Fig. 36A shows the western blot image of IL6, COX2 and GAPDH proteins in WI-38 cells exposed for 48h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #7 or its individual components - CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol or their combination.
Fig. 36B and C show ImageJ quantification of IL6 and COX2 from Fig. 36A.
Fig. 36D shows the western blot image of IL8 and GAPDH proteins in HSIEC cells exposed for 48h to 10 ng/ml of TNF/IFN followed by another 24h exposure to extract #7 or its individual components - CBD, THC, CBN, b-myrcene, b- caryophyllene, a-pinene, a-bisabolol, valencene, geraniol or their combination.
Fig. 36E shows ImageJ quantification of IL8 from Fig. 36D.
RESULTS
Described herein is a method for decreasing the expression of ACE2 and decreasing the levels of cytokine storm and inflammation, but is not limited to the steps of: 1) preparation of new cannabis extracts, 2) exposing normal and disease oral, lung and intestinal models to novel extracts and 3) modulating the gene expression and protein levels to cause a reduction of a disease state, or prevent an increase in the disease state in the body tissues, such as oral cavity tissues, lung tissues and intestinal tissues.
The present invention provides extracts of twenty nine new C. sativa lines (#1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114,
#115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317) ( see Table 1). The present invention further combines use of extracts of these lines, as well as combination of single cannabinoids and terpenes. The aforementioned extracts, single cannabinoids and terpenes have been tested for anti-inflammatory properties and/or ACE2 inhibition properties using human cells lines and 3D EpiOral, Epilntestinal and EpiAirway tissue models. This is performed by detecting the expression of genes that are associated with molecular etiology and pathogenesis of COVID-19 and ARDS and cytokine storms. Table 1. Level of single and total cannabinoids in the extracts of selected C. sativa cultivars.
The effects of thirteen extracts of novel cannabis lines (#81, #90, #130, and #131, #1, #7, #9, #45, #115, #129, #151, #167, and #169) on inflammation provoked by TNFa/IFNy treatment in EpiOral tissues were analyzed. It was observed that extracts of 3 lines (#81, #130, and #45) significantly decreased the levels of expression of ACE2 gene in EpiOral tissues (Figs. 2A-2B).
Also, the anti-inflammatory effects of extracts #1, #7, #9, #45, #115, #129, #151, #167, and #169 were analysed (Fig. 2C), whereby the effect of all the pro- inflammatory gene changes was summed in a single bar for each condition (TNF vs DMSO, and vs each of the extracts #1, #7, #9, #45, #115, #129, #151, #167, and #169). This figure shows how TNFa/IFNy treatment produced a significant over expression pro-inflammatory signature that was completely abolished by extracts (Fig. 2C). Figure 2D,E further demonstrate, in an independent experiment, that extracts #7, #9, #115, #157, #167 and #169 inhibit the expression of ACE2 in EpiOral tissues.
The effects of extracts #1, #7, #9, #45, #115, #129, #130, #169, and #274 on Epilntestinal tissues were also analysed. Global gene expression analysis revealed that extract #45 decreased the levels of ACE2 gene expression in Epilntestinal tissues. Further analysis of the levels of ACE2 protein revealed that extract #45, as well as
extracts # 1, #7, #129, and #169 also suppressed the ACE2 levels in Epilntetsinal tissues. (Figs. 4A-4B). These data were supported by western blot analysis; extracts #1, #7, #45, #129 and #169 decreased the level of ACE2 protein (Figs. 5A-5B). Along with ACE2, some extracts also reduced the levels of PARP-1 and iNOS, as well as inhibited pro-inflammatory gene expression signatures induced by TNF (Figs. 5C- 5E).
The effects of extracts #81, #5, #31, #49, #114, #166, #10, #169, #155, and #207 on the levels of ACE2 in EpiAirway tissues were next evaluated. It was found that extracts #10, #31, #114, as well as #5 and #207 decreased the levels of ACE2 expression in EpiAirway tissues (Figs. 7A-7C). Induction of inflammation with TNF/IFN in EpiAirway and EpiAirwayFT 3D tissues, followed by treatment with extracts further revealed that extracts #1, #5, #7, #10, #45, #81 #129, #317 and #169 substantially decreased the expression of ACE2 (Figs. 7D-G).
In summary, treatments of oral tissues with extracts of new cannabis lines (#81, #130) significantly affected ACE2 gene expression in the oral tissues. ACE2- inhibitory potential of these lines in oral tissues may be used to develop modalities to prevent SARS-CoV2 entry via oral and nasopharyngeal epithelial cells.
Treatment of lung epithelial tissues with extracts of new cannabis lines (#10, #31, #114, as well as #5 and #207) significantly reduced the levels of ACE2 protein in the EpiAirway tissues (Figs. 7A-7C). ACE2-inhibitory potential of these lines in lung epithelial tissues may be used to develop modalities to prevent SARS-CoV2 entry via airway cells as well as to treat COVID-19.
Treatment of intestinal epithelial tissues with extracts of new cannabis lines (#45, # 1, #7, #129, and #169) significantly reduced the levels of ACE2 protein in the Epilntestinal tissues (Fig. 5A), and affected the levels of PARP-1 (Fig. 5C), iNOS, (Fig. 5C), as well as inhibited pro -inflammatory gene induction by TNFa/IFNy (Fig. 5B). ACE2-inhibitory and anti-inflammatory potential of these lines in intestinal epithelial tissues may be used to develop modalities to prevent SARS-CoV2 entry via intestinal cells as well as to treat COVID-19.
In a more specific embodiment, there is provided a method for COVID-19 prevention and treatment via affecting the levels of SARS-CoV2 receptor ACE2 in the oral and nasopharyngeal, lung and intestinal epithelial tissues that includes the steps of exposing a patient to novel cannabis extracts, resulting in a reduction in the
disease incidence and manifestation in the patient.
In some embodiments, extracts of new cannabis lines are applied to a human patient. In other embodiments, they may be applied to human oral tissue, artificial human oral tissue, or even animal oral tissue to modulate gene expression leading to a reduction, or at least prevent an increase in a disease state.
Among those genes down-regulated by new extracts are ACE2, and pro- inflammatory genes ABR, ACP5, ACVR1, ADA, ADORA1, ADORA2A, ADORA2B, AGER, AGTR2, AHCY, AKT1, ALOX5, APOA2, ASH1L, ASS1, ATM, AXL, B4GALT1, BACE2, BAP1, BCR, BDKRB1, BMP6, BMPR1B, BTK, C1QTNF12, C3, C5orf30, C6, CALCA, CALCRL, CCL11, CCL24, CCR4, CD28, CD40, CD96, CDK19, CELA1, CLOCK, CNR1, CNR2, CXCR2, CYP19A1, CYP26B1, CYSLTR1, DROSHA, DUOXA1, DUOXA2, DUSP10, ECM1, EDNRB, EGFR, EIF2AK1, ELANE, EPHA2, EPO, ESR1, ETS1, FABP4, FANCA, FANCD2, FCER1G, FOXF1, FOXP3, GAL, GAT A3, GPR17, GPX1, GPX4, HAMP, HFE, HGF, HIST1H2BA, HSPD1, ICAM1, IDOl, IDOl, IGFBP4, IL10, IL12B, IL13, IL15, IL17B, IL17F, IL17RA, IL17RB, IL17RC, ILIA, IL1R1, IL1R2, IL1RL1, IL1RL2, IL2, IL20RB, IL22RA2, IL25, IL2RA, IL31RA, IL33, IL5, IL5RA, ITGA2, ITGB2, ITGB6, JAK2, JAM3, JUN, KDM6B, KRT1, LBP, LDLR, LIPA, LRRK2, LTA, LYN, MAP2K3, MAS1, MCPH1, NAMPT, NFE2L2, NFKB1, NFKBIZ, NLRP6, NLRX1, NOTCH1, NPFF, NPPA, NPY5R, NT5E, NUPR1, OGGI, OPRM1, P2RX1, P2RX7, PBK, PGLYRP1, PGLYRP2, PIK3CG, PLAA, PLP1, POLB, PPARG, PRCP, PSMB4, PTAFR, PTGES, PTGS2, PYCARD, RASGRP1, RBPJ, RHBDD3, RICTOR, S100A8, S1PR3, SCN9A, SDC1, SEH1L, SELP, SERPINC1, SERPINF1, SGMS1, SLC7A2, SMAD1, SMAD3, SMO, SOCS3, SOCS5, SPHK1, SPP1, STAT3, STAT5B, STK39, SUCNR1, TAC1, TBC1D23, TFR2, TGM2, TIMP1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, TNF, TNFAIP3, TNFRSF1B, TRPV1,TRPV4, TSPAN2, TUSC2, UCN, UGT1A1, UNC13D, VCAM1, WFDC1, ZYX.
As used herein, “sequence identity” or “identity” in the context of two nucleic acid or protein sequences makes reference to a specified percentage of residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window, as measured by sequence comparison algorithms or by visual inspection. When percentage of sequence identity is used in reference to
proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have “sequence similarity” or “similarity.” Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif.).
The term “substantial identity” of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 94%, or even at least 95%, 96%, 97%, 98%, or 99% sequence identity, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 70%, 80%, 90%, or even at least 95%.
Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5° C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1° C to about 20° C, depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to each other under stringent conditions are still
substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.
The term “substantial identity” in the context of a peptide indicates that a peptide comprises a sequence with at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, or 94%, or even 95%, 96%, 97%, 98% or 99%, sequence identity to the reference sequence over a specified comparison window. In certain embodiments, optimal alignment is conducted using the homology alignment algorithm of Needleman and Wunsch (Needleman and Wunsch, JMB, 48, 443 (1970)). An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Thus, the invention also provides nucleic acid molecules and peptides that are substantially identical to the nucleic acid molecules and peptides presented herein.
For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
One skilled in the art will also readily recognize that where members are grouped together in a common manner, such as in a Markush group, the invention encompasses not only the entire group listed as a whole, but each member of the group individually and all possible subgroups of the main group. Additionally, for all purposes, the invention encompasses not only the main group, but also the main group absent one or more of the group members. The invention therefore envisages the explicit exclusion of any one or more of members of a recited group. Accordingly,
provisos may apply to any of the disclosed categories or embodiments whereby any one or more of the recited elements, species, or embodiments, may be excluded from such categories or embodiments, for example, for use in an explicit negative limitation.
In addition, new extracts may modulate genes and proteins sharing a sequence identity or substantial sequence identity to those genes and proteins listed herein.
In addition, cannabinoids and new extracts may affect key processes of the viral life cycle - reverse transcription, replication, and other ones (Figs. 8A-8F).
Further analysis demonstrates that many cannabis extracts, including but not limited to #1, #5, #7, #10, #169 and #317, are more potent than CBD alone in downregulation of COX2 and upregulation of SOCS3 in two different models, intestinal epithelial cells (HSIEC) and lung fibroblast cells (WI-38) (Fig. 12).
Top performing extracts, such as #1, #5, #7 and #169 were further found to substantially downregulate the expression of IL-6, IL-8 and COX-2 on both mRNA and protein levels in both models, HSIEC and WI-38 (Fig. 13-14).
Extracts #317, #129 and #98 also more substantially inhibited ACE2 expression as compared to CBD alone (Fig. 15).
Extracts #1 and #5 demonstrated time-dependent decrease in TNF/IFN- induced expression of IL-6 and IL-8 (Fig. 16). Dose-dependent decrease in ACE2 expression in response to extracts #1 and #5 was also observed (Fig. 17).
Exposure to CBD, THC or CBN demonstrated that dose-dependent decrease in ACE2 expression is only observed for certain cannabinoids and only in certain cell type (Fig. 18).
Western blot analysis showed the extracts #1, #5, #7, #10 and #317 are substantially more potent in the decrease of ACE2 expression as compared to CBD and extracts #5, #7, #10, #129, #132, #169 and #98 are more potent in downregulation of TMPRSS2 as compared to CBD (Fig. 19). TMPRSS2 is a serine protease essential for activation of recognition of SARS-COV-2, namely by priming the viral spike protein to allow viral entry into the target cell.
Analysis of the KEGG pathway regulation demonstrated significant downregulation of key pro-inflammatory genes by extracts #4, #6, #8, #13 and #14, while showing upregulation by extract #12 and lack of effect by extract #15 (Fig. 20). These data were substantiated by western blot analysis of COX2 and IL-6 (Fig.
20D,E).
Top extracts (#1, #5 and #7) were common in the composition of cannabinoids (CBD-dominant) and terpenes and were enriched in caryophyllene, myrcene, pinene, bisabolol, humulene and valencene. Therefore, the contribution of each terpene on ACE2 and TMPRSS2 expression was tested (Fig. 23A-C). Caryophyllene demonstrated comparable to CBD effect on downregulation of ACE2 and TMPRSS2, with higher concentrations being more efficient. It was further found that combination of CBD with caryophyllene results in potentiation of the effect of CBD on ACE2 and TMPRSS2 in WI-38 cells (Fig. 23A-C) and HSIEC cells (Fig. 24A-C). Effect of a-pinene was less obvious, although synergistic effect of CBD and 10 pg/rnl pinene on ACE2 and TMPRSS2 expression was evident in WI-38 cells (Fig. 25A-C) and on TMPRSS2 in HSIEC cells (Fig. 26A-C). Bisabolol also downregulated ACE2 and TMPRSS2 expression in WI-38 cells, more prominent at lower concentration; no synergistic effect was observed (Fig. 27A-C). Bisbolol alone did not decrease the expression of ACE2 and TMPRSS2 expression in HSIEC cells, but synergistic effect on ACE2 expression was apparent (Fig. 28A-C). Humulene decreased the expression of ACE2 in WI-38 cells, but without synergistic effect; no effect on TMPRSS2 was observed (Fig. 29A-C). Humulene alone did not have any effect on ACE2 expression in HSIEC cells, but showed synergistic effect with CBD (Fig. 30A-C). Valencene decreased the expression of ACE2 in WI-38 cells, but without synergistic effect; no effect of valencene alone on TMPRSS2 was observed, but synergistic effect at low concentration was evident (Fig. 31A-C). In HSIEC cells, valencene decreased expression of ACE2 with synergistic effect with CBD (Fig. 32A-C).
While analyzing the effect of whole extracts and comparing it to the effect of CBD alone and seeing the potentiation effect some of the terpenes had on the expression of ACE2 and pro-inflammatory genes, it was decided to analyze the effect of single components present in the extracts #1 and #7. WI-38, HSIEC and Bj-5ta cells were used either directly exposing them to the extracts, their individual components or their combination or first treating cells with TNF/IFN and then exposing them to the extracts and their components. It was found that combined components were as effective as extract #1 in downregulation of ACE2, while CBD and myrcene alone were also effective (Fig. 33). In HSIEC cells, combined components were effective in reducing the expression of IF6 and IF8, although not as
effective as extract #1; individual components were also effective, with humulene being the most effective (Fig. 34). Effect of combined components from extract #1 was more effective in reducing COX2 expression than extract #1 itself in HSIEC cells, and b-caryophyllene was also very effective (Fig. 34B).
Analysis of the components of extract #7 in Bj-5ta cells showed that several individual components, including b-caryophyllene, valencene and geraniol were more effective than extract #7 (Fig. 35E).
The effect of extract #7 on IL-6 in WI-38 revealed that it was the most effective, with combined components having statistically similar effect; individual components valencene, geraniol and bisabolol had very similar effect (Fig. 36B). The effect on COX2 was most prominent from combined components, followed by extract #7 and myrcene (Fig. 36C). Finally, similar analysis in HSIEC cells showed that extract #7 was the most efficient in downregulating IL8, while CBD, myrcene, pinene and geraniol were also very effective (Fig. 36E).
The presented Examples (Figures 2A-2C, 4A-4B, 5A-5E, 7A-7C, and 8A-8F, Fig. 12-36) are intended to illustrate the above invention and should not be construed as to narrow its scope. One skilled in the art will readily recognize that the Examples suggest many other ways in which the invention could be practiced. It should be understood that numerous variations and modifications may be made while remaining within the scope of the invention.
MATERIALS AND METHODS PLANT GROWTH
All cannabis plants were grown in the licensed facility at the University of Lethbridge (license number LIC-62AHHG0R77-2019). C. sativa cultivars #1, #4, #5, #6, #7, #8, #9, #10, #12, #13, #14, #15, #31, #45, #49, #81, #90, #98, #114, #115, #129, #130, #131, #132, #155, #157, #166, #167, #169, #207, #274, #317 were used for the experiments. Four plants per cultivar were grown at 22°C 18 h light 6 h dark for 4 weeks and then transferred to the chambers with 12 h light/ 12 h dark regime to promote flowering. Plants were grown to maturity and flowers were harvested and dried. Flower samples from four plants per cultivar were combined and used for extraction.
PLANT CRUDE EXTRACT PREPARATION:
Solvent used: Ethyl acetate ACS grade from Fisher cat# E145-4 (99.9% pure)
Extract Preparation: 3 g of the powdered plant tissue were weighed using an analytical balance Plant material was placed inside a 250 mL Erlenmeyer flask (clean). 100 mL of Ethyl Acetate was poured into the flask containing the plant material. The flasks were then wrapped with tin foil and shaken continuously (120 rpm) in an incubator @ 21°C overnight and in the dark.
After overnight solvent extraction the extracts were filtered through cotton into a lOOmL round bottom flask. The extracts were concentrated to around 2-3mL using a rotary vacuum evaporator. The extracts were then transferred to a tared 3 dram vial (cat# 60975L Kimble obtained from Fisher Scientific). The leftover solvent was evaporated to dryness in an oven overnight at 50°C to eliminate the solvent completely. Mass of each extract was recoded.
BIOASSAY PREPARATION:
Preparation of 60 mg/mL stocks.
The stocks were prepared weighing a 3-6 mg of crude extract into a micro centrifuge tube. The crude extract was dissolved in DMSO (Dimethyl sulfoxide anhydrous from Life technologies cat # D 12345) to reach 60 mg/mL final concentration and stored at -20°C.
Preparation of Crude Extracts for Bioassay.
Appropriate cell culture media (in our experiments RPMI 1640 medium supplemented with 10% FBS or EMEM medium supplemented with 10% FBS) were used to dilute the 60mg/mL stock. The stocks are allowed to thaw then added to the cell culture media, mixed thoroughly to ensure they are in solution and filtered through a 0.22 pm syringe filter. These filtrates were ready to be applied to cells and tested.
Preparation of terpene stocks.
Terpenes were purchased from True Terpenes (www.trueterpenes.com) and were diluted to the assay concentrations using DMSO or media.
Preparation of CBD, THC or CBN stock.
CBD, THC and CBN were purchased from MilliporeSigma (Sigma- Aldrich) and were diluted to the assay concentrations using DMSO or media.
Analysis of cannabinoids
Agilent Technologies 1200 Series HPLC system equipped with a G1315C DAD, G1316B column compartment, G1367D autosampler, and G1312B binary pump was used to analyse the acidic and neutral forms of phytocannabinoids. The separation was performed on a Phenomenex Kinetex EVO C18 column (5 pm, 100 x 2.1 mm id) with a Phenomenex SecurityGuard ULTRA guard column. Instrument control, data acquisition, and integration were done with ChemStation LC 3D Rev B.04.02 software (Agilent Technologies). A 2 pL injection volume was used for all calibration standards (THC, CBD, THC-A, CBD-A, CBG, CBG-A, all Sigma- Aldrich) and sample analysis. The compound peaks were detected for 230 nm and 280 nm. Mobile phases consisted of 50 mM ammonium formate (pH 5.19) (Sigma - Aldrich) in HPLC grade water (Lisher Chemical) on the A side and 100% methanol (Lisher Chemical) on the B side, with a flow rate 0.3 ml/min. Two samples per cultivar were analyzed, with two technical repeats per each sample.
Analysis of terpenes
Terpene analysis was performed on dry flowers using a 86 IOC GC coupled with a flame ionization detector (LID) from SRI Instruments at Canvas Labs (Vancouver, BC, Canada). Two samples per cultivar were analyzed.
MODELS:
EpiAirway (AIR-100) tissues: Mattek’s Epi Airway tissue model is a human 3D mucociliary tissue model that consists of normal, human-derived tracheal/bronchial epithelial cells, is cultured at the air-liquid interface and fully recapitulates the barrier, mucociliary responses, infection, toxicity responses of human airway tissues in vivo.
EpiAirwayFT (AFT-100) tissues: EpiAirway FT is a ready-to-use, 3D mucociliary tissue model consisting of normal, human-derived tracheal/bronchial epithelial cells and normal human stromal fibroblasts (Mattek Life Sciences, MA). H&E-stained section of EpiAirwayFT tissue (courtesy of Mattek) exhibits a pseudostratified epithelium with ciliated cells and an extracellular matrix containing fibroblasts on a microporous membrane.
EpiOral (ORL-20) tissues: MatTek’s EpiOral tissues consist of normal, human-derived oral epithelial cells. The cells have been cultured to form multilayered, highly differentiated models of the human buccal (EpiOral) phenotypes.
The tissues are cultured on specially prepared cell culture inserts using serum free medium and attain levels of differentiation on the cutting edge of in vitro cell culture technology. The EpiOral tissue models exhibit in vivo-like morphological and growth characteristics which are uniform and highly reproducible.
Epilntestinal (SMI-100) tissues: Epilntestinal tissues are 3D highly differentiated tissue models produced from normal, human cell-derived small intestine epithelial and endothelial cells and fibroblasts. Grown at the air-liquid interface, Epilntestinal tissue models are similar to in vivo human epithelial tissues and exhibit columnar shaped basal cells and Kerckring folds, as well as brush borders, functional tight junctions and mucous secreting granules.
Cell cultures: Human normal foreskin fibroblasts (BJ-5ta), purchased from American Type Culture Collection (ATCC, Manassas, USA), were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). Human primary small intestinal epithelial cells (HSIEC), purchased from Cell Biologies, were cultured in Epithelial Cell Medium /w Kit supplemented with 1% P/S. Human lung fibroblasts (WI-38), purchased from ATCC, were cultured in EMEM supplemented with 10% FBS and 1% P/S. All cell lines were incubated at 37°C in a humidified atmosphere of 5% CO2.
INDUCTION OF INFLAMMATION
To induce inflammation, tissues were either exposed to UVC (Figure 20) or TNF/IFN (all other experiments).
UVC was applied for 2 min, with tissues receiving 7000 erg. Distance from the light source was set to 10 cm. Upon exposure, tissues were treated with extracts. Specifically, right after the UVC treatment, the cannabis extracts (15 pi per sample) or vehicle (DMSO) were dissolved in media and applied to the media surrounding the tissues (n=3 for each condition). Control samples (PBS and DMSO) were sham treated - carried to the UVC source etc. but no UVC was given. The following experimental groups were set up: “UNT” - untreated tissues; “PBS” - 15 mΐ of 30% glycerol in PBS was applied to the tissues and no exposure was done; “DMSO” - 15 mΐ of DMSO (0.017% in 30% glycerolPBS) was applied to the tissues and no exposure was done; “UV-PBS” - tissues were exposed to UV and 15 mΐ of 30% glycerol-PBS was applied to them; “UV-DMSO” - tissues were exposed to UV and
15 mΐ of DMSO (0.017% in 30% glycerol-PBS) was applied to them; “#4” through “#15” - tissues were exposed to UV and 15 mΐ of extracts in DMSO was applied to them. Tissues were incubated with extracts for 24 h and flash frozen for RNA and protein analysis.
To induce inflammation using TNF/IFN, tissues or cells were equilibrated for 24 h, after equilibration tissues were treated with 10 ng/mL TNFa /IFNy alone or in combination with 5-30 mM CBD, 5-30 mM CBN, 5-30 mM THC, or different concentrations of extracts for various time. In yet another experiment, cells were treated either with CBD alone, terpenes alone or in combination of CBD with terpenes.
GENE EXPRESSION PROFILING:
Three tissues per group were used for the analysis of gene expression profiles. RNA was extracted from tissues using TRIzol® Reagent (Invitrogen, Carlsbad, CA), further purified using an RNAesy kit (Qiagen), and quantified using Nanodrop2000c (ThermoScientific). Afterwards, RNA integrity and concentration were established using 2100 BioAnalyzer (Agilent). Sequencing libraries were prepared using Illumina’s TruSeq RNA library preparation kits, and global gene expression profiles were determined using the Next 500 Illumina deep-sequencing platform at the University of Lethbridge Facility. Statistical comparisons between the control and treatment groups were performed using the DESeq Bioconductor package (version 1.8.3) and the baySeq Bioconductor package (version 1.10.0). Clustering of the samples was assessed with multidimensional scaling (MDS) plots built using the plotMDS function from the edgeR Bioconductor package. Features with a false discovery rate (FDR) < 0.1 (10% false positive rate) were considered differentially expressed between conditions.
The functional annotations of differentially expressed genes were performed using David, GO (Gene Ontology) Elite, and GO-TermFinder. Pathways were visualized using Pathview/KEGG and DAVID bioinformatics platforms DAVID Bioinformatics Resources 6.7 KEGG Pathway platforms. mRNA qRT-PCR
HSIEC and WI-38 cells grown to 70% confluency were exposed to either 10 ng/ml TNFa/IFNy or in combination with extracts #1 or #5 or #7 or #169 for 48 h, 1%
DMSO served as a control; HSIEC and WI-38 cells grown to 80% confluency were treated with either 10 ng/ml TNFa/IFNy or in combination with extracts #1 or #5 for an indicated time-course, 1% DMSO served as a control; HSIEC cells grown to 70% confluency were exposed to either 10 ng/ml TNFa/IFNy or in combination with a range of doses of extracts #1 or #5 for 48 h, 1% DMSO served as a control; at the indicated time-point after treatment, total RNA was isolated using TRIzol RNA isolation reagent (ThermoFisher Scientific) and subjected to qRT-PCR analysis with iScript Select cDNA Synthesis kit (Bio-Rad) and SsoFast Evagreen SYBR Supermix (Bio-Rad) using primers specific for IL6, IL8, and COX2 according to the manufacturer’s instructions. Real-time quantitative RT-PCR analysis was carried out with CFX96 Real-Time System (Bio-Rad). Glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) was used as the internal control to standardize the expression. All experiments for real-time RT-PCR were performed in triplicate and data was analysed using the comparative Ct method. Results are shown as fold induction of mRNA.
WESTERN BLOTTING
Tissues were harvested and solubilized in laboratory-prepared 1% sodium dodecyl sulfate (SDS) lysis buffer (BioUltraPure, Bioshop) by sonication using a Braunsonic model 1510 sonicator (B. Braun Germany) operating at 80% sonication intensity. Lysates were centrifuged at 15,000 rpm for 10 min and the supernatant was decanted for use. Protein concentrations were determined using the Bradford protein assay with bovine serum albumin as the standard protein using the Nanodrop 2000c spectrophotometer (v. 1.5). Total proteins were separated by electrophoresis on 10- 12% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE). The protein was then electro-transferred onto activated polyvinyl difluoride (PVDF) membranes (Amersham Hybond P 0.45, GE Healthcare). The membranes were incubated for one hour in a blocking solution (5% dry skimmed milk in PBS, 0.5% Tween 20) at room temperature, and incubated with specific primary antibodies at 4°C overnight with 1:200 to 1:1,000 dilution of polyclonal/monoclonal antibodies against cannabinoid receptor 1 (CB1), cannabinoid receptor 2 (CB2) (all from Abeam, Cambridge, UK) or GPR18 (from LSBio, Seattle, USA) or CDK2, cyclin El, E2F1, ERK1/2, pERKl/2, PFKFB3 (all from Cell Signaling, Danvers, USA) or AKT1, p53, pAKTl/2/3 (all
from Santa Cruz Biotechnology, Dallas, USA), IL-6, IL-8, COX-2, ACE2, TMPRSS2 (Abeam). Blots of the primary antibodies tested were developed with peroxidase- labelled secondary antibodies specific to the primaries. The membranes were washed (5 times of 5 min of washing with PBS-Tween) before and after adding secondary antibodies. The protein bands of interest were detected using an enhanced chemiluminescence (ECL) system by incubating for 5 min in ECL detection reagents (GE Healthcare, Amersham Biosciences) and visualized using the FluorChem HD2 ALC detection system (software v.3.2.2.0805, Cell Biosciences).
DOSAGE FORMS
The compositions of the present invention may be provided in any suitable dosage form. According to some embodiments, the dosage form is an oral dosage form. Oral dosage forms comprise liquids (solutions, suspensions, and emulsions), semi-solids (pastes), and solids (tablets, capsules, powders, granules, premixes, and medicated blocks).
Some examples of oral dosage forms in the art include, W090/04391, which discloses an oral dosage form of omega-3 polyunsaturated acids to overcome the problems of diseases. It is known to supply said acids in soft gelatine capsule shells.
EP 2 240 581 B1 discloses a gelatine capsule for pharmaceutical use with a controlled release of active ingredients and a process for the preparation of said gelatine capsules. During said process xylose is added to the liquid gelatine from which afterwards gelatine capsules are formed. Gelatine capsules manufactured according to the process provide retarded release of active ingredients.
US Patent No. 7,264,824 discloses and oral dosage form for food and food supplements, as well as dietetics comprising polyunsaturated acids in a xylose- hardened gelatine capsule with a retarded release time.
According to some embodiments of the present invention, the compositions described herein may be in a suspension or emulsion.
A suspension is a coarse dispersion of insoluble drug particles, generally with a diameter exceeding 1 pm, in a liquid (usually aqueous) medium. Suspensions are useful for administering insoluble or poorly soluble drugs/components or in situations when the presence of a finely divided form of the material in the GI tract is required. The taste of most drugs is less noticeable in suspension than in solution, due to the
drug being less soluble in suspension. Particle size is an important determinant of the dissolution rate and bioavailability of drugs in suspension. In addition to the excipients described above for solutions, suspensions include surfactants and thickening agents. Surfactants wet the solid particles, thereby ensuring the particles disperse readily throughout the liquid. Thickening agents reduce the rate at which particles settle to the bottom of the container. Some settling is acceptable, provided the sediment can be readily dispersed when the container is shaken. Because hard masses of sediment do not satisfy this criterion, caking of suspensions is not acceptable.
An emulsion is a system consisting of 2 immiscible liquid phases, one of which is dispersed throughout the other in the form of fine droplets; droplet diameter generally ranges from 0.1-100 pm. The 2 phases of an emulsion are known as the dispersed phase and the continuous phase. Emulsions are inherently unstable and are stabilized through the use of an emulsifying agent, which prevents coalescence of the dispersed droplets. Creaming, as occurs with milk, also occurs with pharmaceutical emulsions. However, it is not a serious problem because a uniform dispersion returns upon shaking. Creaming is, nonetheless, undesirable because it is associated with an increased likelihood of the droplets coalescing and the emulsion breaking. Other additives include buffers, antioxidants, and preservatives. Emulsions for oral administration are usually oil (the active ingredient) in water, and facilitate the administration of oily substances such as castor oil or liquid paraffin in a more palatable form.
A paste is a 2-component semi-solid in which drug is dispersed as a powder in an aqueous or fatty base. The particle size of the active ingredient in pastes can be as large as 100 pm. The vehicle containing the drug may be water; a polyhydroxy liquid such as glycerin, propylene glycol, or polyethylene glycol; a vegetable oil; or a mineral oil. Other formulation excipients include thickening agents, co solvents, adsorbents, humectants, and preservatives. The thickening agent may be a naturally occurring material such as acacia or tragacanth, or a synthetic or chemically modified derivative such as xanthum gum or hydroxypropylmethyl cellulose. The degree of cohesiveness, plasticity, and syringeability of pastes is attributed to the thickening agent. It may be necessary to include a cosolvent to increase the solubility of the drug. Syneresis of pastes is a form of instability in which the solid and liquid components of
the formulation separate over time; it is prevented by including an adsorbent such as microcrystalline cellulose. A humectant (eg, glycerin or propylene glycol) is used to prevent the paste that collects at the nozzle of the dispenser from forming a hard crust. Microbial growth in the formulation is inhibited using a preservative. It is critical that pastes have a pleasant taste or are tasteless.
A tablet consists of one or more active ingredients and numerous excipients and may be a conventional tablet that is swallowed whole, a chewable tablet, or a modified-release tablet (more commonly referred to as a modified-release bolus due to its large unit size). Conventional and chewable tablets are used to administer drugs to dogs and cats, whereas modified-release boluses are administered to cattle, sheep, and goats. The physical and chemical stability of tablets is generally better than that of liquid dosage forms. The main disadvantages of tablets are the bioavailability of poorly water-soluble drugs or poorly absorbed drugs, and the local irritation of the GI mucosa that some drugs may cause.
A capsule is an oral dosage form usually made from gelatin and filled with an active ingredient and excipients. Two common capsule types are available: hard gelatin capsules for solid-fill formulations, and soft gelatin capsules for liquid-fill or semi-solid-fill formulations. Soft gelatin capsules are suitable for formulating poorly water-soluble drugs because they afford good drug release and absorption by the GI tract. Gelatin capsules are frequently more expensive than tablets but have some advantages. For example, particle size is rarely altered during capsule manufacture, and capsules mask the taste and odor of the active ingredient and protect photolabile ingredients.
A powder is a formulation in which a drug powder is mixed with other powdered excipients to produce a final product for oral administration. Powders have better chemical stability than liquids and dissolve faster than tablets or capsules because disintegration is not an issue. This translates into faster absorption for those drugs characterized by dissolution rate-limited absorption. Unpleasant tastes can be more pronounced with powders than with other dosage forms and can be a particular concern with in-feed powders, in which it contributes to variable ingestion of the dose. Moreover, sick animals often eat less and are therefore not amenable to treatment with in-feed powder formulations. Drug powders are principally used prophylactically in feed, or formulated as a soluble powder for addition to drinking
water or milk replacer. Powders have also been formulated with emulsifying agents to facilitate their administration as liquid drenches.
A granule is a dosage form consisting of powder particles that have been aggregated to form a larger mass, usually 2-4 mm in diameter. Granulation overcomes segregation of the different particle sizes during storage and/or dose administration, the latter being a potential source of inaccurate dosing. Granules and powders generally behave similarly; however, granules must deaggregate prior to dissolution and absorption.
A premix is a solid dosage form in which an active ingredient, such as a coccidiostat, production enhancer, or nutritional supplement, is formulated with excipients. Premix products are mixed homogeneously with feed at rates (when expressed on an active ingredient basis) that range from a few milligrams to -200 g/ton of food/beverage The density, particle size, and geometry of the premix particles should match as closely as possible those of the feed in which the premix will be incorporated to facilitate uniform mixing. Issues such as instability, electrostatic charge, and hygroscopicity must also be addressed. The excipients present in premix formulations include carriers, liquid binders, diluents, anti-caking agents, and anti dust agents. Carriers, such as wheat middlings, soybean mill run, and rice hulls, bind active ingredients to their surfaces and are important in attaining uniform mixing of the active ingredient. A liquid binding agent, such as a vegetable oil, should be included in the formulation whenever a carrier is used. Diluents increase the bulk of premix formulations, but unlike carriers, do not bind the active ingredients. Examples of diluents include ground limestone, dicalcium phosphate, dextrose, and kaolin. Caking in a premix formulation may be caused by hygroscopic ingredients and is addressed by adding small amounts of anti-caking agents such as calcium silicate, silicon dioxide, and hydrophobic starch. The dust associated with powdered premix formulations can have serious implications for both operator safety and economic losses, and is reduced by including a vegetable oil or light mineral oil in the formulation. An alternate approach to overcoming dust is to granulate the premix formulation.
A medicated block is a compressed feed material that contains an active ingredient, such as a drug, anthelmintic, surfactant (for bloat prevention), or a nutritional supplement, and is commonly packaged in a cardboard box. Ruminants
typically have free access to the medicated block over several days, and variable consumption may be problematic. This concern is addressed by ensuring the active ingredient is nontoxic, stable, palatable, and preferably of low solubility. In addition, excipients in the formulation modulate consumption by altering the palatability and/or the hardness of the medicated block. For example, molasses increases palatability and sodium chloride decreases it. Additionally, the incorporation of a binder such as lignin sulfonate in blocks manufactured by compression or magnesium oxide in blocks manufactured by chemical reaction, increases hardness. The hygroscopic nature of molasses in a formulation may also impact the hardness of medicated blocks and is addressed by using appropriate packaging.
In another embodiment, the composition of the present invention is in a chewable oral dosage form. In another embodiment, the chewable oral dosage form is a chewable tablet. In another embodiment, the chewable tablet of the invention is taken slowly by chewing or sucking in the mouth. In another embodiment, the chewable tablet of the invention enables the dried cannabis extracts contained therein to be orally administered without drinking.
According to some embodiments of the present invention, the composition may comprise any suitable flavor or combination of flavors.
The composition may further comprise other additives, coloring, emulsifiers. The flavors and additives may be of a natural, semi-synthetic, synthetic source or combinations thereof.
In another embodiment of the present invention, the composition further comprises fructose, sorbitol, microcrystalline cellulose, magnesium stearate, or any combination thereof. In another embodiment, the composition further comprises chamomile. In another embodiment, the composition further comprises ginger. In another embodiment, the composition further comprises peppermint. In another embodiment, the composition further comprises anise. In another embodiment, the composition further comprises fennel. In another embodiment, the composition further comprises thyme. In another embodiment, the composition further comprises Arsenicum album. In another embodiment, the composition further comprises Carbo vegetabilis. In another embodiment, the composition further comprises Ignatia, homeopathic ipecac. In another embodiment, the composition further comprises Nux vomica. In another embodiment, the composition further comprises Zingiber
officinale.
In another embodiment, the composition of the present invention is in the form of a chewing gum product. In another embodiment, chewing gum compositions contemplated by the present invention comprise all types of sugar and sugarless chewing gums and chewing gum formulations known to those skilled in the art, including regular and bubble gum types. In another embodiment, chewing gum compositions of the invention comprise a chewing gum base, a modifier, a bulking agent or sweetener, and one or more other additives such as, flavoring agents, colorants and antioxidants. In another embodiment, the modifying agents are used to soften, plasticize and/or compatibilize one or more of the components of the gum base and/or of the formulation as a whole.
In another embodiment, the present invention provides a soft, chewable dosage form which is pliable and chewy, yet dissolves quickly in the mouth, has a long shelf life, contains little moisture which improves stability and decreases the tendency for the dosage form to dry out, does not require cooking or heating as part of the manufacturing process. In another embodiment, the dosage form is used as a matrix for dried cannabis extracts.
In another embodiment, the chewable tablet of the invention comprises a metal salt such as calcium, magnesium, aluminum salt, or any mixture thereof. In another embodiment, the chewable tablet of the invention comprises hydroxyalkyl cellulose. In another embodiment, the chewable tablet of the invention comprises low viscosity hydroxyalkyl cellulose. In another embodiment, the chewable tablet of the invention comprises high viscosity hydroxyalkyl cellulose.
In another embodiment, the chewable tablet of the invention comprises various additives. In another embodiment, the chewable tablet of the invention comprises sweeteners. In another embodiment, the chewable tablet of the invention comprises acidic ingredients. In another embodiment, the chewable tablet of the invention comprises taste correctives. In another embodiment, the chewable tablet of the invention comprises polymeric compounds. In another embodiment, the chewable tablet of the invention comprises essential oils.
In another embodiment, the chewable tablet of the invention is a soft tablet. In another embodiment, the chewable tablet of the invention is made in a state of soft candy. In another embodiment, the chewable tablet of the invention is made in a state
of jelly.
In another embodiment, the chewable tablet of the invention comprises a core comprising the vitamins of the invention. In another embodiment, the chewable tablet of the invention comprises an outer layer wrapping the core which is made up of chewable base such as a gum, a soft candy or a caramel.
In another embodiment, the compositions of the present invention may be provided in any suitable food of a solid, semi- solid or liquid form.
The preparation of pharmaceutical compositions that contain a dried cannabis extract, for example by mixing, granulating, or tablet-forming processes, is well understood in the art. The dried cannabis extracts are often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. For oral administration, the active ingredients of compositions of the present invention are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions.
In another embodiment, additional methods of administering the dried cannabis extracts, or compound(s) isolated therefrom, of the invention comprise injectable dosage forms. In another embodiment, the injectable is administered intraperitoneally. In another embodiment, the injectable is administered intramuscularly. In another embodiment, the injectable is administered intra-dermally. In another embodiment, the injectable is administered intravenously. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the pharmaceutical compositions are administered by intravenous, intra-arterial, or intra-muscular injection of a liquid preparation. Suitable liquid formulations include solutions, suspensions, dispersions, emulsions, oils and the like. In another embodiment, the pharmaceutical compositions are administered intravenously and are thus formulated in a form suitable for intravenous administration. In another embodiment, the pharmaceutical compositions are administered intra-arterially and are thus formulated in a form suitable for intra arterial administration. In another embodiment, the pharmaceutical compositions are administered intra-muscularly and are thus formulated in a form suitable for intra muscular administration.
In another embodiment, additional methods of administering the dried cannabis extracts of the invention comprise dispersions, suspensions or emulsions. In another embodiment, the dispersion, suspension or emulsion is administered orally. In another embodiment, the solution is administered by infusion. In another embodiment, the solution is a solution for inhalation. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the pharmaceutical composition is administered as a suppository, for example a rectal suppository or a urethral suppository. In another embodiment, the pharmaceutical composition is administered by subcutaneous implantation of a pellet. In another embodiment, the pellet provides for controlled release of active compound agent over a period of time. Each possibility represents a separate embodiment of the present invention.
In other embodiments, pharmaceutically acceptable carriers for liquid formulations are aqueous or non-aqueous solutions, suspensions, emulsions or oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Examples of oils are those of animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil, another marine oil, or a lipid from milk or eggs. Each possibility represents a separate embodiment of the present invention.
In another embodiment, parenteral vehicles (for subcutaneous, intravenous, intra-arterial, or intramuscular injection) include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Examples are sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Examples of oils are those of animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil, another marine oil, or a lipid from milk or eggs. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the pharmaceutical compositions provided herein are controlled-release compositions, i.e. compositions in which the active compounds are released over a period of time after administration. Controlled- or sustained-release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils). In another embodiment, the composition is an immediate -release composition, i.e. a composition in which all the active compound is released immediately after administration. Each possibility represents a separate embodiment of the present invention.
In another embodiment, the pharmaceutical composition is delivered in a controlled release system. In another embodiment, the agents are administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In another embodiment, a pump is used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989). In another embodiment, polymeric materials are used; e.g. in microspheres in or an implant. In yet another embodiment, a controlled release system is placed in proximity to the therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984); and Langer R, Science 249: 1527-1533 (1990). Each possibility represents a separate embodiment of the present invention.
The compositions also include, in another embodiment, incorporation of the active materials into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.) Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance. Each possibility represents a separate embodiment of the present invention.
Also included in the present invention are particulate compositions coated with polymers (e.g. poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Each possibility represents a separate embodiment of the present invention.
Also comprehended by the invention are compounds modified by the covalent
attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline. The modified compounds are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et ah, 1981; Newmark et ah, 1982; and Katre et ah, 1987). Such modifications also increase, in another embodiment, the compound's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. In another embodiment, the desired in vivo biological activity is achieved by the administration of such polymer-compound abducts less frequently or in lower doses than with the unmodified compound. Each possibility represents a separate embodiment of the present invention.
The compositions of the present invention may comprise one or more additional components may further include an additional component selected from the group consisting of an anti-static agent, a buffering agent, a bulking agent, a chelating agent, a colorant, a diluent, a dye, an emollient, a fragrance, an occlusive agent, a pH- adjusting agent, a preservative, and a vitamin.
The compositions of the present invention may comprise one or more additional active agents, selected from the group consisting of active herbal extracts, analgesics, anti-allergic agents, anti-aging agents, anti-bacterials, antibiotic agents, anticancer agents, antidandruff agents, antidepressants, anti-dermatitis agents, anti- edemics, antihistamines, anti-helminths, anti-hyperkeratolyte agents, anti inflammatory agents, anti-irritants, anti-microbials, anti-mycotic s, anti-proliferative agents, antioxidants, anti-wrinkle agents, anti-pruritic s, antiseptic agents, antiviral agents, anti-yeast agents, astringents, topical cardiovascular agents, chemotherapeutic agents, corticosteroids, dicarboxylic acids, disinfectants, fungicides, hair growth regulators, hormones, hydroxy acids, immunosuppressants, immunoregulating agents, keratolytic agents, lactams, metals, metal oxides, mitocides, neuropeptides, non steroidal anti-inflammatory agents, oxidizing agents, photodynamic therapy agents, retinoids, sanatives, scabicides, self-tanning agents, skin whitening agents, vasoconstrictors, vasodilators, vitamins, vitamin D derivatives and wound healing agents.
According to some embodiments, the composition may comprise one or more anti-oxidants/radical scavengers. The anti-oxidant/radical scavenger may be selected from butylated hydroxy benzoic acids and their salts, coenzyme Q10, coenzyme A, gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N- diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and its salts, lycine pidolate, arginine pilolate, nordihydroguaiaretic acid, bioflavonoids, curcumin, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts, grape skin/seed extracts, melanin, and rosemary extracts.
In one embodiment, the term “treating” refers to curing a disease. In another embodiment, “treating” refers to preventing a disease. In another embodiment, “treating” refers to reducing the incidence of a disease. In another embodiment,
“treating” refers to ameliorating symptoms of a disease. In another embodiment,
“treating” refers to inducing remission. In another embodiment, “treating” refers to slowing the progression of a disease.
The references cited herein teach many principles that are applicable to the present invention. Therefore, the full contents of these publications are incorporated by reference herein where appropriate for teachings of additional or alternative details, features and/or technical background.
It is to be understood that the invention is not limited in its application to the details set forth in the description contained herein or illustrated in the drawings. The invention is capable of other embodiments and of being practiced and carried out in various ways. Those skilled in the art will readily appreciate that various modifications and changes can be applied to the embodiments of the invention as hereinbefore described without departing from its scope, defined in and by the appended claims.
REFERENCES 1. Zhao, S., et al., Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. Int J Infect Dis, 2020. 92: p. 214- 217. . Li, G., et al., Coronavirus infections and immune responses. J Med Virol, 2020.
3. Channappanavar, R. and S. Perlman, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol, 2017. 39(5): p. 529-539. . Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. 395(10223): p. 497-506.
5. Guo, Y.R., et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res, 2020. 7(1): p. 11.
6. Liu, Q., Y.H. Zhou, and Z.Q. Yang, The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol, 2016.
13(1): p. 3-10. . Tanaka, T., M. Narazaki, and T. Kishimoto, Immunotherapeutic implications ofIL-6 blockade for cytokine storm. Immunotherapy, 2016. 8(8): p. 959-70.
8. Tisoncik, J.R., et al., Into the eye of the cytokine storm. Microbiol Mol Biol Rev, 2012. 76(1): p. 16-32.
Claims
1. An organic extract of at least one plant line, said at least one plant line formed from combining at least one of: a) at least one marijuana strain; and b) at least one hemp strain, wherein said organic extract comprises at least one compound suitable for treating a mammalian oral disease or disorder.
2. An organic extract according to claim 1, wherein said at least one plant line comprises a Cannabis sativa line.
3. An organic extract according to claim 1, wherein said mammalian oral disease or disorder is selected from the group consisting of a viral disease, an oral disease, a lung disease, an intestinal disease and combinations thereof.
4. An organic extract according to claim 1, wherein said extract is effective against corona virus disease.
5. An organic extract according to claim 1, wherein said extract is effective against other virus diseases.
6. An organic extract according to claim 1, wherein said extract is effective against ARDS and other cytokine-induced diseases and disorders.
7. An organic extract according to claim 1, wherein said organic extract is at least 2-20, 3-15, 4-12, 5-10 or 6-9 times as effective as at least one of THC and CBD, administered at the same concentration in treating said disease.
8. A combination therapy, isolated from an organic extract of at least one hybrid line, said at least one hybrid line formed from combining at least one of: a) at least one marijuana strain; and b) at least one hemp strain; and wherein said organic extract comprises a plurality of compounds suitable for treating a mammalian viral disease and disorder.
9. A Cannabis extract for treating and preventing a viral disease or disorder, wherein said extract efficacy can be further increased by adding CBD, CBG, CBN, terpenes or combinations thereof.
10. A Cannabis extract for treating and preventing viral disease or disorder, wherein said extract efficacy can be further increased by adding extracts of turmeric, chamomile, sage, fennel, ginger, rosehip, as well as probiotics or
combinations thereof.
11. A line of Cannabis sativa formed by combining at least one marijuana strain and at least one hemp strain, said line will be deposited at public culture collection, currently under designation numbers #81, #130, #1, #7, #9, #45, #129, #169, #5, #10, #31, #49, #114, #207.
12. A pharmaceutical composition for treating a viral disease or disorder in a mammalian subject, the pharmaceutical composition comprising at least one of: a) an organic extract according to claim 1 ; b) at least one of Cannabigerol (CBG), Cannabinol (CBN) and Cannabidiol (CBD); and c) at least one terpene or terpene alcohol; wherein said pharmaceutical composition is suitable for treating said viral disease or said viral disorder in said mammalian subject.
13. A pharmaceutical composition according to claim 12, wherein said at least one terpene is selected from the group consisting of myrcene, humulene, pinene carophyllene and valencene.
14. A pharmaceutical composition according to claim 12, wherein said terpene alcohol comprises bisabolol.
15. A pharmaceutical composition according to claim 12, wherein said at least one of Cannabigerol (CBG), Cannabinol (CBN) and Cannabidiol (CBD) comprises only Cannabidiol (CBD).
16. A pharmaceutical composition according to claim 15, wherein said viral disease or disorder is caused by a corona virus, a mutant or variant thereof.
17. A pharmaceutical composition according to claim 16, wherein said viral disease is COVID 19.
18. A pharmaceutical composition according to claim 17, wherein said pharmaceutical composition is effective in treating a cytokine storm associated with said COVID 19.
19. A pharmaceutical composition according to claim 12, is suitable for reducing a level of an ACE2 protein in said mammalian subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062994873P | 2020-03-26 | 2020-03-26 | |
US62/994,873 | 2020-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021191888A1 true WO2021191888A1 (en) | 2021-09-30 |
Family
ID=77890013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2021/050265 WO2021191888A1 (en) | 2020-03-26 | 2021-03-10 | Cannabis sativa (hemp and cannabis) products for viral disease prevention and management |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021191888A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022094330A3 (en) * | 2020-10-29 | 2022-07-21 | Nagy Aurangzeb Nafees | Compositions comprising tetrahydrocannabinol for treating acute respiratory failure and/or acute respiratory distress syndrome |
CN115778941A (en) * | 2022-11-18 | 2023-03-14 | 哈尔滨医科大学 | Anti-neocoronavirus combined pharmaceutical composition and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013147965A1 (en) * | 2012-03-28 | 2013-10-03 | Freeman Keith Gerald | Medical compositions, methods of making and using those compositions, and kits including those compositions |
WO2017091764A1 (en) * | 2015-11-24 | 2017-06-01 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
WO2019002926A1 (en) * | 2017-06-27 | 2019-01-03 | Enviro BioMedical Laboratories Inc. | Blended cannabis compounds and methods of making the same |
-
2021
- 2021-03-10 WO PCT/IL2021/050265 patent/WO2021191888A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013147965A1 (en) * | 2012-03-28 | 2013-10-03 | Freeman Keith Gerald | Medical compositions, methods of making and using those compositions, and kits including those compositions |
WO2017091764A1 (en) * | 2015-11-24 | 2017-06-01 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
WO2019002926A1 (en) * | 2017-06-27 | 2019-01-03 | Enviro BioMedical Laboratories Inc. | Blended cannabis compounds and methods of making the same |
Non-Patent Citations (5)
Title |
---|
AURELIUS DATA: "COVID-19 Patients Should Avoid THC. Studies Find Potential Harmful Side Effects of Cannabis on Infected Coronavirus Patients", GLOBENEWSWIRE - NEWS RELEASE, 19 March 2020 (2020-03-19), XP055862927, Retrieved from the Internet <URL:https://www.globenewswire.com/news-release/2020/03/19/2003252/0/en/COVID-19-Patients-Should-Avoid-THC.html> * |
MAROON JOSEPH, BOST JEFF: "Review of the neurological benefits of phytocannabinoids", SURGICAL NEUROLOGY INTERNATIONAL, vol. 9, no. 1, 26 April 2018 (2018-04-26), pages 91, XP055862806, ISSN: 2152-7806, DOI: 10.4103/sni.sni_45_18 * |
ORIO LP ET AL.: "New ACE-Inhibitory Peptides from Hemp Seed (Cannabis sativa L.) Proteins", PROTEINS. J AGRIC FOOD CHEM., vol. 65, no. 48, 17 November 2017 (2017-11-17), pages 10482 - 10488, XP055862929, DOI: 10.1021/acs.jafc.7b04522 * |
PELLATI F ET AL.: "New Methods for the Comprehensive Analysis of Bioactive Compounds in Cannabis sativa L. (hemp", MOLECULES, vol. 23, no. 10, 14 October 2018 (2018-10-14), pages 2639, XP055728231, DOI: 10.3390/molecules23102639 * |
REISS C. S: "Cannabinoids and Viral Infections", PHARMACEUTICALS, vol. 3, no. 6, 9 June 2010 (2010-06-09), Basel, pages 1873 - 1886, XP055765009, DOI: 10.3390/ph3061873 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022094330A3 (en) * | 2020-10-29 | 2022-07-21 | Nagy Aurangzeb Nafees | Compositions comprising tetrahydrocannabinol for treating acute respiratory failure and/or acute respiratory distress syndrome |
CN115778941A (en) * | 2022-11-18 | 2023-03-14 | 哈尔滨医科大学 | Anti-neocoronavirus combined pharmaceutical composition and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090155349A1 (en) | Methods of treating influenza viral infections | |
WO2021191888A1 (en) | Cannabis sativa (hemp and cannabis) products for viral disease prevention and management | |
KR20100136997A (en) | Methods and use of inducing apoptosis in cancer cells | |
WO2006105155A2 (en) | Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms | |
US20180256601A1 (en) | Ursodeoxycholic acid and brain disorders | |
US20140127316A1 (en) | Propolis and caffeic acid phenethyl ester and uses thereof | |
WO2021191864A1 (en) | Food supplements for the prevention of covid-19 | |
US9308270B2 (en) | Pharmaceutical composition on the basis of nanomicelles containing epigallocatechin gallate and a method of administration thereof to treat atopic dermatitis, Crohn's disease, adenomyosis, and hyperplastic diseases of the prostate gland | |
CN115701990A (en) | Medicine/medicament for treating coronavirus infection, retrovirus infection and hepatitis C | |
WO2021124316A1 (en) | High cbd cannabis sativa lines and extracts with anti-inflammatory potencies for oral and gut health | |
Biesalski et al. | Retinyl palmitate supplementation by inhalation of an aerosol improves vitamin A status of preschool children in Gondar (Ethiopia) | |
Chan et al. | α-Tocopherol Reduces Proteinuria, Oxidative Stress, and Expression of Transforming Growth Factor β1 in IgA Nephropathy in the Rat | |
US11541030B2 (en) | Methods for the treatment of inflammation associated with infection | |
JP2014514277A (en) | Soluble selenoglycoprotein compositions and methods of separation, characterization, and administration | |
US20200197462A1 (en) | Novel cannabis lines and extracts for treating skin disorders | |
US20200197463A1 (en) | Novel cannabis lines and extracts with anti-inflammatory potencies | |
US20200197294A1 (en) | Novel cannabis lines and extracts for skin rejuvenation and skin protection | |
EP3079709A1 (en) | Ephedra alata extracts and methods of use thereof | |
NZ537089A (en) | Interleukin 6 production inhibitor | |
WO2023227087A1 (en) | Plectranthus amboinicus extract for use in inhibiting immune responses | |
TW201919589A (en) | Monoterpene compositions and uses thereof | |
Tsubura et al. | A case of symptomatic inflammatory tongue treated with fucoidan | |
CN115590844B (en) | Application of mesaconic acid in preparation of medicine for preventing or treating metabolic syndrome | |
CN115501236B (en) | Application of enogestrel acetate in preparation of medicines for reducing lung inflammatory diseases | |
Abdeltawab et al. | Investigating the effect of the nitric oxide donor L-arginine on albendazole efficacy in Trichinella spiralis-induced myositis and myocarditis in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21774142 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21774142 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03/07/2023) |